US20210382038A1 - Method for identifying modulators of notch signaling - Google Patents
Method for identifying modulators of notch signaling Download PDFInfo
- Publication number
- US20210382038A1 US20210382038A1 US17/354,521 US202117354521A US2021382038A1 US 20210382038 A1 US20210382038 A1 US 20210382038A1 US 202117354521 A US202117354521 A US 202117354521A US 2021382038 A1 US2021382038 A1 US 2021382038A1
- Authority
- US
- United States
- Prior art keywords
- tert
- pyridin
- amine
- butylphenoxy
- aromatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010070047 Notch Receptors Proteins 0.000 title description 164
- 102000005650 Notch Receptors Human genes 0.000 title description 163
- 230000011664 signaling Effects 0.000 title description 89
- 238000000034 method Methods 0.000 title description 57
- 125000003118 aryl group Chemical group 0.000 claims description 179
- 150000001875 compounds Chemical class 0.000 claims description 110
- -1 4-substituted phenyl Chemical group 0.000 claims description 87
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 69
- 125000002541 furyl group Chemical group 0.000 claims description 58
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 58
- 125000005032 thiofuranyl group Chemical group S1C(=CC=C1)* 0.000 claims description 58
- 125000002883 imidazolyl group Chemical group 0.000 claims description 56
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 55
- 150000002390 heteroarenes Chemical class 0.000 claims description 38
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 37
- 125000001624 naphthyl group Chemical group 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 30
- DHHKPEUQJIEKOA-UHFFFAOYSA-N tert-butyl 2-[6-(nitromethyl)-6-bicyclo[3.2.0]hept-3-enyl]acetate Chemical group C1C=CC2C(CC(=O)OC(C)(C)C)(C[N+]([O-])=O)CC21 DHHKPEUQJIEKOA-UHFFFAOYSA-N 0.000 claims description 19
- 239000002246 antineoplastic agent Substances 0.000 claims description 14
- 229940127089 cytotoxic agent Drugs 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 229960003087 tioguanine Drugs 0.000 claims description 8
- LJKWNYNPDQDKSX-UHFFFAOYSA-N 4-(4-cyclohexylphenoxy)aniline Chemical compound C1=CC(N)=CC=C1OC1=CC=C(C2CCCCC2)C=C1 LJKWNYNPDQDKSX-UHFFFAOYSA-N 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 claims description 4
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 4
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 claims description 4
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims description 4
- CNRDZNZBESGLIV-UHFFFAOYSA-N 4-(4-cyclohexylphenoxy)-3-fluoroaniline Chemical compound FC1=CC(N)=CC=C1OC1=CC=C(C2CCCCC2)C=C1 CNRDZNZBESGLIV-UHFFFAOYSA-N 0.000 claims description 4
- WHNSSOAQKWYDIK-UHFFFAOYSA-N 6-(4-cyclohexylphenoxy)pyridin-3-amine Chemical compound N1=CC(N)=CC=C1OC1=CC=C(C2CCCCC2)C=C1 WHNSSOAQKWYDIK-UHFFFAOYSA-N 0.000 claims description 4
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 4
- 108010006654 Bleomycin Proteins 0.000 claims description 4
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 4
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 4
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 4
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 4
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 claims description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 4
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 4
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 4
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims description 4
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 4
- 229930192392 Mitomycin Natural products 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 4
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims description 4
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 claims description 4
- 229960000473 altretamine Drugs 0.000 claims description 4
- 229960001561 bleomycin Drugs 0.000 claims description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
- 229960002092 busulfan Drugs 0.000 claims description 4
- 229960004117 capecitabine Drugs 0.000 claims description 4
- 229960004562 carboplatin Drugs 0.000 claims description 4
- 229960005243 carmustine Drugs 0.000 claims description 4
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 4
- 229960004630 chlorambucil Drugs 0.000 claims description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
- 229960004316 cisplatin Drugs 0.000 claims description 4
- 229960002436 cladribine Drugs 0.000 claims description 4
- 229950006799 crisantaspase Drugs 0.000 claims description 4
- 229960004397 cyclophosphamide Drugs 0.000 claims description 4
- 229960000684 cytarabine Drugs 0.000 claims description 4
- 229960003901 dacarbazine Drugs 0.000 claims description 4
- 229960000975 daunorubicin Drugs 0.000 claims description 4
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 229960001904 epirubicin Drugs 0.000 claims description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 4
- 229960005420 etoposide Drugs 0.000 claims description 4
- 229960000390 fludarabine Drugs 0.000 claims description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 4
- 229960002949 fluorouracil Drugs 0.000 claims description 4
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 4
- 229960005277 gemcitabine Drugs 0.000 claims description 4
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 229960000908 idarubicin Drugs 0.000 claims description 4
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960001101 ifosfamide Drugs 0.000 claims description 4
- 229960004768 irinotecan Drugs 0.000 claims description 4
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 4
- 229960002247 lomustine Drugs 0.000 claims description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 4
- 229960001924 melphalan Drugs 0.000 claims description 4
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims description 4
- 229960001428 mercaptopurine Drugs 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- 229960004857 mitomycin Drugs 0.000 claims description 4
- 229960001156 mitoxantrone Drugs 0.000 claims description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 4
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 4
- 229960001756 oxaliplatin Drugs 0.000 claims description 4
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 claims description 4
- 229960002340 pentostatin Drugs 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 4
- 229960000624 procarbazine Drugs 0.000 claims description 4
- 229960001052 streptozocin Drugs 0.000 claims description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 claims description 4
- 229960004964 temozolomide Drugs 0.000 claims description 4
- 229960001196 thiotepa Drugs 0.000 claims description 4
- 229960000303 topotecan Drugs 0.000 claims description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 4
- 229960003181 treosulfan Drugs 0.000 claims description 4
- 229960004528 vincristine Drugs 0.000 claims description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims description 4
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims description 4
- 229960004355 vindesine Drugs 0.000 claims description 4
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 claims description 4
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims description 4
- 229960002066 vinorelbine Drugs 0.000 claims description 4
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims description 3
- 229960003048 vinblastine Drugs 0.000 claims description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims description 3
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- WHIWGRCYMQLLAO-UHFFFAOYSA-N 6-(4-tert-butylphenoxy)pyridin-3-amine Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C(N)C=N1 WHIWGRCYMQLLAO-UHFFFAOYSA-N 0.000 abstract description 372
- 206010028980 Neoplasm Diseases 0.000 abstract description 105
- 230000005913 Notch signaling pathway Effects 0.000 abstract description 26
- 239000003112 inhibitor Substances 0.000 abstract description 14
- 210000004027 cell Anatomy 0.000 description 241
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 156
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 140
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 111
- 238000011282 treatment Methods 0.000 description 91
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 83
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 71
- 230000004913 activation Effects 0.000 description 62
- 238000001994 activation Methods 0.000 description 62
- 230000037361 pathway Effects 0.000 description 58
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 56
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 56
- 201000011510 cancer Diseases 0.000 description 53
- 241000699670 Mus sp. Species 0.000 description 50
- 238000003556 assay Methods 0.000 description 43
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 description 41
- 238000011977 dual antiplatelet therapy Methods 0.000 description 41
- 239000011541 reaction mixture Substances 0.000 description 41
- 235000019439 ethyl acetate Nutrition 0.000 description 40
- 206010006187 Breast cancer Diseases 0.000 description 39
- 239000012043 crude product Substances 0.000 description 37
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 36
- 102000001759 Notch1 Receptor Human genes 0.000 description 35
- 108010029755 Notch1 Receptor Proteins 0.000 description 35
- 229910052681 coesite Inorganic materials 0.000 description 35
- 229910052906 cristobalite Inorganic materials 0.000 description 35
- 238000003818 flash chromatography Methods 0.000 description 35
- 239000000377 silicon dioxide Substances 0.000 description 35
- 229910052682 stishovite Inorganic materials 0.000 description 35
- 229910052905 tridymite Inorganic materials 0.000 description 35
- 238000005160 1H NMR spectroscopy Methods 0.000 description 34
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 33
- 230000001404 mediated effect Effects 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 32
- 230000005764 inhibitory process Effects 0.000 description 28
- 239000007787 solid Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 27
- 208000026310 Breast neoplasm Diseases 0.000 description 25
- 108060001084 Luciferase Proteins 0.000 description 25
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 24
- 101001005664 Homo sapiens Mastermind-like protein 1 Proteins 0.000 description 23
- 102100025129 Mastermind-like protein 1 Human genes 0.000 description 23
- 239000003921 oil Substances 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 23
- 239000005089 Luciferase Substances 0.000 description 22
- 238000000684 flow cytometry Methods 0.000 description 20
- 239000003540 gamma secretase inhibitor Substances 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 125000004398 2-methyl-2-butyl group Chemical group CC(C)(CC)* 0.000 description 18
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 18
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 18
- 230000018109 developmental process Effects 0.000 description 18
- 238000000605 extraction Methods 0.000 description 18
- 229910000027 potassium carbonate Inorganic materials 0.000 description 18
- 239000000725 suspension Substances 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 102000001756 Notch2 Receptor Human genes 0.000 description 17
- 108010029751 Notch2 Receptor Proteins 0.000 description 17
- 238000011161 development Methods 0.000 description 17
- 101150092640 HES1 gene Proteins 0.000 description 16
- 230000001419 dependent effect Effects 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 230000012010 growth Effects 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 229940125373 Gamma-Secretase Inhibitor Drugs 0.000 description 14
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 14
- 208000032839 leukemia Diseases 0.000 description 14
- 239000003446 ligand Substances 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 230000011712 cell development Effects 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 13
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 230000003828 downregulation Effects 0.000 description 12
- 229910052736 halogen Inorganic materials 0.000 description 12
- 150000002367 halogens Chemical class 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 11
- 230000002018 overexpression Effects 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 0 C1=CC=C(CC2=CC=CC=C2)C=C1.CCC.[1*]C([2*])([3*])C[4*] Chemical compound C1=CC=C(CC2=CC=CC=C2)C=C1.CCC.[1*]C([2*])([3*])C[4*] 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000022131 cell cycle Effects 0.000 description 10
- 238000013537 high throughput screening Methods 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 230000002062 proliferating effect Effects 0.000 description 10
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- BAZVFQBTJPBRTJ-UHFFFAOYSA-N 2-chloro-5-nitropyridine Chemical compound [O-][N+](=O)C1=CC=C(Cl)N=C1 BAZVFQBTJPBRTJ-UHFFFAOYSA-N 0.000 description 9
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 9
- 210000002175 goblet cell Anatomy 0.000 description 9
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 229910001868 water Inorganic materials 0.000 description 9
- 238000001262 western blot Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- CUYKNJBYIJFRCU-UHFFFAOYSA-N 3-aminopyridine Chemical compound NC1=CC=CN=C1 CUYKNJBYIJFRCU-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 102000013814 Wnt Human genes 0.000 description 8
- 108050003627 Wnt Proteins 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 230000004069 differentiation Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- 238000001959 radiotherapy Methods 0.000 description 8
- XFZZDIHCNHYESF-UHFFFAOYSA-N 7-amino-1-bromo-4-phenyl-5,7,8,9-tetrahydrobenzo[7]annulen-6-one Chemical compound C=12CC(=O)C(N)CCC2=C(Br)C=CC=1C1=CC=CC=C1 XFZZDIHCNHYESF-UHFFFAOYSA-N 0.000 description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 7
- 241000242739 Renilla Species 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 7
- 210000003098 myoblast Anatomy 0.000 description 7
- 210000004940 nucleus Anatomy 0.000 description 7
- 201000002528 pancreatic cancer Diseases 0.000 description 7
- 208000008443 pancreatic carcinoma Diseases 0.000 description 7
- 229950010131 puromycin Drugs 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 6
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 6
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- 208000034951 Genetic Translocation Diseases 0.000 description 6
- 206010054949 Metaplasia Diseases 0.000 description 6
- 102000001760 Notch3 Receptor Human genes 0.000 description 6
- 108010029756 Notch3 Receptor Proteins 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000000389 T-cell leukemia Diseases 0.000 description 6
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000015689 metaplastic ossification Effects 0.000 description 6
- 229920002866 paraformaldehyde Polymers 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 241000027355 Ferocactus setispinus Species 0.000 description 5
- 230000006370 G0 arrest Effects 0.000 description 5
- 230000037057 G1 phase arrest Effects 0.000 description 5
- 101000851434 Homo sapiens Tumor necrosis factor ligand superfamily member 13B Proteins 0.000 description 5
- 241000713666 Lentivirus Species 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 5
- 101150073096 NRAS gene Proteins 0.000 description 5
- 102100036922 Tumor necrosis factor ligand superfamily member 13B Human genes 0.000 description 5
- 238000002679 ablation Methods 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000013613 expression plasmid Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000010859 live-cell imaging Methods 0.000 description 5
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 5
- 238000012423 maintenance Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 210000001541 thymus gland Anatomy 0.000 description 5
- RUBQQRMAWLSCCJ-UHFFFAOYSA-N 1,2-difluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(F)=C1 RUBQQRMAWLSCCJ-UHFFFAOYSA-N 0.000 description 4
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 4
- GVSIFRRVTNAEBL-UHFFFAOYSA-N 2-(4-tert-butylphenoxy)-5-nitropyridine Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C([N+]([O-])=O)C=N1 GVSIFRRVTNAEBL-UHFFFAOYSA-N 0.000 description 4
- MRZJKJYVUWUMOH-UHFFFAOYSA-N 4-(4-tert-butylphenoxy)-3-fluoroaniline Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C(N)C=C1F MRZJKJYVUWUMOH-UHFFFAOYSA-N 0.000 description 4
- WBBJEKAHJPQRFN-UHFFFAOYSA-N 4-[4-(2-methylbutan-2-yl)phenoxy]aniline Chemical compound C1=CC(C(C)(C)CC)=CC=C1OC1=CC=C(N)C=C1 WBBJEKAHJPQRFN-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 4
- 102100032768 Complement receptor type 2 Human genes 0.000 description 4
- 238000011771 FVB mouse Methods 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 4
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 4
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 4
- 102000005604 Myosin Heavy Chains Human genes 0.000 description 4
- 108010084498 Myosin Heavy Chains Proteins 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 102400000545 Notch 2 intracellular domain Human genes 0.000 description 4
- 101800001731 Notch 2 intracellular domain Proteins 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 241000021375 Xenogenes Species 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000008045 co-localization Effects 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 238000003125 immunofluorescent labeling Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 230000005751 tumor progression Effects 0.000 description 4
- 238000002689 xenotransplantation Methods 0.000 description 4
- QLSWIGRIBOSFMV-UHFFFAOYSA-N 1h-pyrrol-2-amine Chemical compound NC1=CC=CN1 QLSWIGRIBOSFMV-UHFFFAOYSA-N 0.000 description 3
- OYARGYQZCRHSSZ-UHFFFAOYSA-N 2-(3-tert-butylphenoxy)-5-nitropyridine Chemical compound CC(C)(C)C1=CC=CC(OC=2N=CC(=CC=2)[N+]([O-])=O)=C1 OYARGYQZCRHSSZ-UHFFFAOYSA-N 0.000 description 3
- AGTUNKZIRWRULT-UHFFFAOYSA-N 2-[4-(2-methylpentan-2-yl)phenoxy]-5-nitropyridine Chemical compound C1=CC(C(C)(C)CCC)=CC=C1OC1=CC=C([N+]([O-])=O)C=N1 AGTUNKZIRWRULT-UHFFFAOYSA-N 0.000 description 3
- KZMYFIUFUAOZHP-UHFFFAOYSA-N 4-(1-adamantyl)phenol Chemical compound C1=CC(O)=CC=C1C1(C2)CC(C3)CC2CC3C1 KZMYFIUFUAOZHP-UHFFFAOYSA-N 0.000 description 3
- OPMIBQSFIUJNAT-UHFFFAOYSA-N 4-(2-methylpentan-2-yl)phenol Chemical compound CCCC(C)(C)C1=CC=C(O)C=C1 OPMIBQSFIUJNAT-UHFFFAOYSA-N 0.000 description 3
- FHOZTGQNSUZCIN-UHFFFAOYSA-N 4-(4-tert-butylphenoxy)aniline Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C(N)C=C1 FHOZTGQNSUZCIN-UHFFFAOYSA-N 0.000 description 3
- OAHMVZYHIJQTQC-UHFFFAOYSA-N 4-cyclohexylphenol Chemical compound C1=CC(O)=CC=C1C1CCCCC1 OAHMVZYHIJQTQC-UHFFFAOYSA-N 0.000 description 3
- QHPQWRBYOIRBIT-UHFFFAOYSA-N 4-tert-butylphenol Chemical compound CC(C)(C)C1=CC=C(O)C=C1 QHPQWRBYOIRBIT-UHFFFAOYSA-N 0.000 description 3
- NLZGKZNDUWWCOX-UHFFFAOYSA-N 6-(3-tert-butylphenoxy)pyridin-3-amine Chemical compound CC(C)(C)C1=CC=CC(OC=2N=CC(N)=CC=2)=C1 NLZGKZNDUWWCOX-UHFFFAOYSA-N 0.000 description 3
- DTVIDGUIKYZTHO-UHFFFAOYSA-N 6-(4-butylphenoxy)pyridin-3-amine Chemical compound C1=CC(CCCC)=CC=C1OC1=CC=C(N)C=N1 DTVIDGUIKYZTHO-UHFFFAOYSA-N 0.000 description 3
- KSGGMHCBMQYDKO-UHFFFAOYSA-N 6-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]pyridin-3-amine Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OC1=CC=C(N)C=N1 KSGGMHCBMQYDKO-UHFFFAOYSA-N 0.000 description 3
- ZWZPUNQJXSXYDU-UHFFFAOYSA-N 6-[4-(2-methylbutan-2-yl)phenoxy]pyridin-3-amine Chemical compound C1=CC(C(C)(C)CC)=CC=C1OC1=CC=C(N)C=N1 ZWZPUNQJXSXYDU-UHFFFAOYSA-N 0.000 description 3
- XFHPDSPLDRTIJI-UHFFFAOYSA-N 6-[4-(2-methylpentan-2-yl)phenoxy]pyridin-3-amine Chemical compound C1=CC(C(C)(C)CCC)=CC=C1OC1=CC=C(N)C=N1 XFHPDSPLDRTIJI-UHFFFAOYSA-N 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 208000005623 Carcinogenesis Diseases 0.000 description 3
- 101100239628 Danio rerio myca gene Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000010867 Hoechst staining Methods 0.000 description 3
- 102100030234 Homeobox protein cut-like 1 Human genes 0.000 description 3
- 101000726740 Homo sapiens Homeobox protein cut-like 1 Proteins 0.000 description 3
- 101000761460 Homo sapiens Protein CASP Proteins 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000036952 cancer formation Effects 0.000 description 3
- 231100000504 carcinogenesis Toxicity 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000001516 cell proliferation assay Methods 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- UTVVREMVDJTZAC-UHFFFAOYSA-N furan-2-amine Chemical compound NC1=CC=CO1 UTVVREMVDJTZAC-UHFFFAOYSA-N 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 238000003468 luciferase reporter gene assay Methods 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000030648 nucleus localization Effects 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 230000002246 oncogenic effect Effects 0.000 description 3
- NRZWYNLTFLDQQX-UHFFFAOYSA-N p-tert-Amylphenol Chemical compound CCC(C)(C)C1=CC=C(O)C=C1 NRZWYNLTFLDQQX-UHFFFAOYSA-N 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000013538 segmental resection Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- GLQWRXYOTXRDNH-UHFFFAOYSA-N thiophen-2-amine Chemical compound NC1=CC=CS1 GLQWRXYOTXRDNH-UHFFFAOYSA-N 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000011830 transgenic mouse model Methods 0.000 description 3
- 230000005747 tumor angiogenesis Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
- LAWSVVSZHKUFTP-UHFFFAOYSA-N 1-(2-methylbutan-2-yl)-4-(4-nitrophenoxy)benzene Chemical compound C1=CC(C(C)(C)CC)=CC=C1OC1=CC=C([N+]([O-])=O)C=C1 LAWSVVSZHKUFTP-UHFFFAOYSA-N 0.000 description 2
- KOILHQSSYCVDGB-UHFFFAOYSA-N 1-(4-cyclohexylphenoxy)-2-fluoro-4-nitrobenzene Chemical compound FC1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(C2CCCCC2)C=C1 KOILHQSSYCVDGB-UHFFFAOYSA-N 0.000 description 2
- NODZFNPUKXLUHF-UHFFFAOYSA-N 1-(4-tert-butylphenoxy)-2-fluoro-4-nitrobenzene Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C([N+]([O-])=O)C=C1F NODZFNPUKXLUHF-UHFFFAOYSA-N 0.000 description 2
- YFHWGRVPEWMRLY-UHFFFAOYSA-N 1-cyclohexyl-4-(4-nitrophenoxy)benzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(C2CCCCC2)C=C1 YFHWGRVPEWMRLY-UHFFFAOYSA-N 0.000 description 2
- ZWOYWHYRFBLDEV-UHFFFAOYSA-N 1-tert-butyl-4-(4-nitrophenoxy)benzene Chemical compound C1=CC(C(C)(C)C)=CC=C1OC1=CC=C([N+]([O-])=O)C=C1 ZWOYWHYRFBLDEV-UHFFFAOYSA-N 0.000 description 2
- BADZQXKGLDJKGJ-UHFFFAOYSA-N 2-(4-butylphenoxy)-5-nitropyridine Chemical compound C1=CC(CCCC)=CC=C1OC1=CC=C([N+]([O-])=O)C=N1 BADZQXKGLDJKGJ-UHFFFAOYSA-N 0.000 description 2
- OGKTVQGNKQEOQE-UHFFFAOYSA-N 2-(4-cyclohexylphenoxy)-5-nitropyridine Chemical compound N1=CC([N+](=O)[O-])=CC=C1OC1=CC=C(C2CCCCC2)C=C1 OGKTVQGNKQEOQE-UHFFFAOYSA-N 0.000 description 2
- KQXSSSIOJITHFG-UHFFFAOYSA-N 2-[4-(2-methylbutan-2-yl)phenoxy]-5-nitropyridine Chemical compound C1=CC(C(C)(C)CC)=CC=C1OC1=CC=C([N+]([O-])=O)C=N1 KQXSSSIOJITHFG-UHFFFAOYSA-N 0.000 description 2
- UJAGAYHAHFPAHI-UHFFFAOYSA-N 2-fluoro-1-[4-(2-methylbutan-2-yl)phenoxy]-4-nitrobenzene Chemical compound C1=CC(C(C)(C)CC)=CC=C1OC1=CC=C([N+]([O-])=O)C=C1F UJAGAYHAHFPAHI-UHFFFAOYSA-N 0.000 description 2
- XIAIUQXVBHJSKW-UHFFFAOYSA-N 3-fluoro-4-[4-(2-methylbutan-2-yl)phenoxy]aniline Chemical compound C1=CC(C(C)(C)CC)=CC=C1OC1=CC=C(N)C=C1F XIAIUQXVBHJSKW-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- YQUQWHNMBPIWGK-UHFFFAOYSA-N 4-isopropylphenol Chemical compound CC(C)C1=CC=C(O)C=C1 YQUQWHNMBPIWGK-UHFFFAOYSA-N 0.000 description 2
- FGHNPNBPVJDUTM-UHFFFAOYSA-N 5-nitro-2-(4-propan-2-ylphenoxy)pyridine Chemical compound C1=CC(C(C)C)=CC=C1OC1=CC=C([N+]([O-])=O)C=N1 FGHNPNBPVJDUTM-UHFFFAOYSA-N 0.000 description 2
- LEAICXPXSDBANS-UHFFFAOYSA-N 5-nitro-2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]pyridine Chemical compound C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OC1=CC=C([N+]([O-])=O)C=N1 LEAICXPXSDBANS-UHFFFAOYSA-N 0.000 description 2
- IZMGJPCUJXDZLD-UHFFFAOYSA-N 6-(4-propan-2-ylphenoxy)pyridin-3-amine Chemical compound C1=CC(C(C)C)=CC=C1OC1=CC=C(N)C=N1 IZMGJPCUJXDZLD-UHFFFAOYSA-N 0.000 description 2
- 239000012103 Alexa Fluor 488 Substances 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 101100455978 Arabidopsis thaliana MAM1 gene Proteins 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 2
- 102000015735 Beta-catenin Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- 230000035519 G0 Phase Effects 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 2
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 2
- 108010029741 Notch4 Receptor Proteins 0.000 description 2
- 102000001753 Notch4 Receptor Human genes 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000004243 Tubulin Human genes 0.000 description 2
- 108090000704 Tubulin Proteins 0.000 description 2
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 238000003349 alamar blue assay Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000006552 constitutive activation Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 238000007821 culture assay Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000004077 genetic alteration Effects 0.000 description 2
- 231100000118 genetic alteration Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000005734 heterodimerization reaction Methods 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 150000002484 inorganic compounds Chemical class 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000005865 ionizing radiation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000012139 lysis buffer Substances 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 210000003826 marginal zone b cell Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 230000007718 nuclear exclusion Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 150000002894 organic compounds Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011127 radiochemotherapy Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000011255 standard chemotherapy Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000005748 tumor development Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
- 239000012130 whole-cell lysate Substances 0.000 description 2
- 239000008096 xylene Substances 0.000 description 2
- BQJCRHHNABKAKU-UHFFFAOYSA-N (-)-morphine Chemical compound C12C=CC(O)C3OC4=C5C32CCN(C)C1CC5=CC=C4O BQJCRHHNABKAKU-UHFFFAOYSA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- JRMGHBVACUJCRP-BTJKTKAUSA-N (z)-but-2-enedioic acid;4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline Chemical compound OC(=O)\C=C/C(O)=O.COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 JRMGHBVACUJCRP-BTJKTKAUSA-N 0.000 description 1
- GFBLPULLSAPXDC-UHFFFAOYSA-N 1-(4-hydroxyphenyl)butan-1-one Chemical compound CCCC(=O)C1=CC=C(O)C=C1 GFBLPULLSAPXDC-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- AQICASXNQRZXAT-UHFFFAOYSA-N 2-(4-tert-butylphenoxy)-1H-pyridin-2-amine Chemical class CC(C)(C)C(C=C1)=CC=C1OC1(N)NC=CC=C1 AQICASXNQRZXAT-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- HLTDBMHJSBSAOM-UHFFFAOYSA-N 2-nitropyridine Chemical class [O-][N+](=O)C1=CC=CC=N1 HLTDBMHJSBSAOM-UHFFFAOYSA-N 0.000 description 1
- CYEKUDPFXBLGHH-UHFFFAOYSA-N 3-tert-Butylphenol Chemical compound CC(C)(C)C1=CC=CC(O)=C1 CYEKUDPFXBLGHH-UHFFFAOYSA-N 0.000 description 1
- BPSFDLNXDUBTKE-UHFFFAOYSA-N 4-(4-propan-2-ylphenoxy)aniline Chemical compound C1=CC(C(C)C)=CC=C1OC1=CC=C(N)C=C1 BPSFDLNXDUBTKE-UHFFFAOYSA-N 0.000 description 1
- CYYZDBDROVLTJU-UHFFFAOYSA-N 4-n-Butylphenol Chemical compound CCCCC1=CC=C(O)C=C1 CYYZDBDROVLTJU-UHFFFAOYSA-N 0.000 description 1
- ISAVYTVYFVQUDY-UHFFFAOYSA-N 4-tert-Octylphenol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 ISAVYTVYFVQUDY-UHFFFAOYSA-N 0.000 description 1
- NKMJZJDVLMDPGO-UHFFFAOYSA-N 5,8-dihydroxy-2-(2-phenylethyl)chromen-4-one Chemical compound OC1=CC=C(O)C(C(C=2)=O)=C1OC=2CCC1=CC=CC=C1 NKMJZJDVLMDPGO-UHFFFAOYSA-N 0.000 description 1
- 102000036664 ADAM10 Human genes 0.000 description 1
- 108091007504 ADAM10 Proteins 0.000 description 1
- 102000043279 ADAM17 Human genes 0.000 description 1
- 108091007505 ADAM17 Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- CZZYITDELCSZES-UHFFFAOYSA-N C1=CC=C(CC2=CC=CC=C2)C=C1 Chemical compound C1=CC=C(CC2=CC=CC=C2)C=C1 CZZYITDELCSZES-UHFFFAOYSA-N 0.000 description 1
- HWMKDLUTAIWEBN-UHFFFAOYSA-N CC(C)(C)C1(C=CC=CC1)OC(C=C1)=CC=C1N Chemical compound CC(C)(C)C1(C=CC=CC1)OC(C=C1)=CC=C1N HWMKDLUTAIWEBN-UHFFFAOYSA-N 0.000 description 1
- VNXFQSCBGOMKPV-UHFFFAOYSA-N CC(C)(C)C1=CC(OC2=NC=C(N)C=C2)=CC=C1.CC1=CC=C(OC2=CC=C(C(C)(C)C)C=C2)C(F)=C1.CC1=CC=C(OC2=CC=C(C3CCCCC3)C=C2)C(F)=C1.CC1=CC=C(OC2=CC=C(C3CCCCC3)C=C2)C=C1.CCC(C)(C)C1=CC=C(OC2=CC=C(C)C=C2)C=C1.CCC(C)(C)C1=CC=C(OC2=NC=C(C)C=C2)C=C1.CCCCC1=CC=C(OC2=NC=C(C)C=C2)C=C1.NC1=CN=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 Chemical compound CC(C)(C)C1=CC(OC2=NC=C(N)C=C2)=CC=C1.CC1=CC=C(OC2=CC=C(C(C)(C)C)C=C2)C(F)=C1.CC1=CC=C(OC2=CC=C(C3CCCCC3)C=C2)C(F)=C1.CC1=CC=C(OC2=CC=C(C3CCCCC3)C=C2)C=C1.CCC(C)(C)C1=CC=C(OC2=CC=C(C)C=C2)C=C1.CCC(C)(C)C1=CC=C(OC2=NC=C(C)C=C2)C=C1.CCCCC1=CC=C(OC2=NC=C(C)C=C2)C=C1.NC1=CN=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 VNXFQSCBGOMKPV-UHFFFAOYSA-N 0.000 description 1
- OBIJEDGTMPPMBD-UHFFFAOYSA-N CC(C)(C)CC(C)(C)C1=CC=C(OC2=NC=C(N)C=C2)C=C1.CC1=CC=C(OC2=CC=C(C(C)(C)C)C=C2)C=C1.CC1=CC=C(OC2=CC=C(C(C)C)C=C2)C=C1.CC1=CN=C(OC2=CC=C(C3CCCCC3)C=C2)C=C1.CCC(C)(C)C1=CC=C(OC2=NC=C(C)C=C2F)C=C1.CCCC(C)(C)C1=CC=C(OC2=NC=C(C)C=C2)C=C1.NC1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C(F)=C1.NC1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OC2=NC=C(N)C=C2)C=C1.CC1=CC=C(OC2=CC=C(C(C)(C)C)C=C2)C=C1.CC1=CC=C(OC2=CC=C(C(C)C)C=C2)C=C1.CC1=CN=C(OC2=CC=C(C3CCCCC3)C=C2)C=C1.CCC(C)(C)C1=CC=C(OC2=NC=C(C)C=C2F)C=C1.CCCC(C)(C)C1=CC=C(OC2=NC=C(C)C=C2)C=C1.NC1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C(F)=C1.NC1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 OBIJEDGTMPPMBD-UHFFFAOYSA-N 0.000 description 1
- OVVJEJJWRVYKQK-UHFFFAOYSA-N CC1=CC=C(OC2=CC=C(C3CCCCC3)C=C2)C(F)=C1 Chemical compound CC1=CC=C(OC2=CC=C(C3CCCCC3)C=C2)C(F)=C1 OVVJEJJWRVYKQK-UHFFFAOYSA-N 0.000 description 1
- HBMYPVLGWPQIIS-UHFFFAOYSA-N CC1=CN=C(OC2=CC=C(C3CCCCC3)C=C2)C=C1 Chemical compound CC1=CN=C(OC2=CC=C(C3CCCCC3)C=C2)C=C1 HBMYPVLGWPQIIS-UHFFFAOYSA-N 0.000 description 1
- 101100074187 Caenorhabditis elegans lag-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000004139 Choroid Plexus Neoplasms Diseases 0.000 description 1
- 208000037156 Choroid plexus tumor Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 102100028138 F-box/WD repeat-containing protein 7 Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 102000003893 Histone acetyltransferases Human genes 0.000 description 1
- 108090000246 Histone acetyltransferases Proteins 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 1
- 101001060231 Homo sapiens F-box/WD repeat-containing protein 7 Proteins 0.000 description 1
- 101001005667 Homo sapiens Mastermind-like protein 2 Proteins 0.000 description 1
- 101001005668 Homo sapiens Mastermind-like protein 3 Proteins 0.000 description 1
- 101000978766 Homo sapiens Neurogenic locus notch homolog protein 1 Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000049556 Jagged-1 Human genes 0.000 description 1
- 108700003486 Jagged-1 Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101710189714 Major cell-binding factor Proteins 0.000 description 1
- 102100025130 Mastermind-like protein 2 Human genes 0.000 description 1
- 102100025134 Mastermind-like protein 3 Human genes 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101100294417 Mus musculus Notch1 gene Proteins 0.000 description 1
- LYHTZIQKDWQBEI-UHFFFAOYSA-N NC1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C(F)=C1 Chemical compound NC1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C(F)=C1 LYHTZIQKDWQBEI-UHFFFAOYSA-N 0.000 description 1
- FNSQIHBVWREKLJ-UHFFFAOYSA-N NC1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 Chemical compound NC1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 FNSQIHBVWREKLJ-UHFFFAOYSA-N 0.000 description 1
- CJLVDDOLNUSZCN-UHFFFAOYSA-N NC1=CN=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 Chemical compound NC1=CN=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 CJLVDDOLNUSZCN-UHFFFAOYSA-N 0.000 description 1
- 101150103623 NOTCH3 gene Proteins 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- CORPXCFTJPDKOW-UHFFFAOYSA-N O=[N+]([O-])C1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C(F)=C1 Chemical compound O=[N+]([O-])C1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C(F)=C1 CORPXCFTJPDKOW-UHFFFAOYSA-N 0.000 description 1
- SMTYQXUIHOCNBQ-UHFFFAOYSA-N O=[N+]([O-])C1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 Chemical compound O=[N+]([O-])C1=CC=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 SMTYQXUIHOCNBQ-UHFFFAOYSA-N 0.000 description 1
- UCZSIOWBTWSKPT-UHFFFAOYSA-N O=[N+]([O-])C1=CN=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 Chemical compound O=[N+]([O-])C1=CN=C(OC2=CC=C(C34CC5CC(CC(C5)C3)C4)C=C2)C=C1 UCZSIOWBTWSKPT-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000016588 Rosa centifolia Nutrition 0.000 description 1
- 244000052585 Rosa centifolia Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 231100000230 acceptable toxicity Toxicity 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000037844 advanced solid tumor Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000008568 cell cell communication Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-M cholate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-M 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000000375 direct analysis in real time Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000012063 dual-affinity re-targeting Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000009786 epithelial differentiation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 1
- 229960005073 erlotinib hydrochloride Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 102000045609 human NOTCH1 Human genes 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000004609 intestinal homeostasis Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 201000011649 lymphoblastic lymphoma Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000023247 mammary gland development Effects 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 150000002828 nitro derivatives Chemical class 0.000 description 1
- 150000005181 nitrobenzenes Chemical class 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000012988 ovarian serous adenocarcinoma Diseases 0.000 description 1
- 201000003709 ovarian serous carcinoma Diseases 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000009038 pharmacological inhibition Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- NTGBUUXKGAZMSE-UHFFFAOYSA-N phenyl n-[4-[4-(4-methoxyphenyl)piperazin-1-yl]phenyl]carbamate Chemical compound C1=CC(OC)=CC=C1N1CCN(C=2C=CC(NC(=O)OC=3C=CC=CC=3)=CC=2)CC1 NTGBUUXKGAZMSE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 231100000205 reproductive and developmental toxicity Toxicity 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
- 229940075554 sorbate Drugs 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 108091006108 transcriptional coactivators Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960004449 vismodegib Drugs 0.000 description 1
- BPQMGSKTAYIVFO-UHFFFAOYSA-N vismodegib Chemical compound ClC1=CC(S(=O)(=O)C)=CC=C1C(=O)NC1=CC=C(Cl)C(C=2N=CC=CC=2)=C1 BPQMGSKTAYIVFO-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000003245 working effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/27—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups
- C07C205/35—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/36—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system
- C07C205/38—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by etherified hydroxy groups having nitro groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton to carbon atoms of the same non-condensed six-membered aromatic ring or to carbon atoms of six-membered aromatic rings being part of the same condensed ring system the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. nitrodiphenyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/90—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- C07D213/643—2-Phenoxypyridines; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/75—Fibrin; Fibrinogen
Definitions
- the present invention relates to the use of inhibitors of Notch signalling pathway in particular 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (CAS number 218457-67-1) and its derivatives, in the treatment and/or prevention of cancers.
- I3 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine
- the Notch signalling pathway represents a critical component in the molecular circuits that control cell fate during development, cell survival and cell proliferation (Shih IeM, Wang T L in Cancer Res 2007;67(5):1879-82). Aberrant activation of this pathway contributes to tumorigenesis.
- the Notch family members are being revealed as oncogenes in an ever-increasing number of cancers.
- the role of Notch in human cancer has been highlighted recently by the presence of activating mutations and amplification of Notch genes in human cancer and by the demonstration that genes in the Notch signalling pathway could be potential therapeutic targets. It has become clear that one of the major therapeutic targets in the Notch pathway are the Notch receptors, in which ⁇ -secretase inhibitors prevent the generation of the oncogenic (intracellular) domain of Notch molecules and suppress the Notch activity.
- Notch inhibitors Although significant progress has been made in dissecting the complex workings of this signalling pathway, there are verge limited options available for Notch inhibitors.
- the pioneering class of Notch inhibitors is already in clinical trials for few cancer types, such as ⁇ -secretase inhibitors MK0752 of Merck Sharp & Dohme Corp. MK0752, and RO4929097 (Roche), a synthetic small molecule, inhibits the Notch signalling pathway, which may result in induction of growth arrest and apoptosis in tumor cells in which the Notch signalling pathway is overactivated.
- ⁇ -secretase inhibitors to block Notch signaling, as currently on the market or uner investigation, is their wide range of additional targets such as amyloid precursor protein as well as non-selectivity in blocking Notch signalling via all four ligands (Notch 1, 2,3 and 4). Due to their ability to block Notch signalling via all four receptors ⁇ -secretase inhibitors are known to cause goblet cell metaplasia in the intestine. In addition, some of the hematological malignancies and solid tumors harbor mutations in the Notch receptors (such as chromosomal translocation) resulting in constitutive expression of dominant active form of NICD independent of cleavage by ⁇ -secretase complex. Therefore these tumors fail to respond to ⁇ -secretase inhibitors treatment.
- the present invention concerns an 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of Formula I
- a further object of the present invention is to provide a pharmaceutical composition
- a pharmaceutical composition comprising pharmaceutical composition comprising 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of Formula I, or one of its derivatives having Notch signalling pathway inhibition properties, or pharmaceutically acceptable salts, solvates, tautomers, isomers thereof, and a pharmaceutically acceptable carrier.
- pharmaceutical composition comprising 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of Formula I, or one of its derivatives having Notch signalling pathway inhibition properties, or pharmaceutically acceptable salts, solvates, tautomers, isomers thereof, and a pharmaceutically acceptable carrier.
- the invention also contemplates a kit comprising one or more doses of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), or one of its derivatives having Notch signalling pathway inhibition properties, for use in a method for treatment and/or prevention of cancer, optionally with reagents and/or instructions for use.
- kit comprising one or more doses of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), or one of its derivatives having Notch signalling pathway inhibition properties, for use in a method for treatment and/or prevention of cancer, optionally with reagents and/or instructions for use.
- a further object of the invention is to provide the use of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of Formula I or one of its derivatives having Notch signalling pathway inhibition properties, for inhibiting in vitro or in vitro the Notch signalling pathway in cells.
- Another object of the invention is to provide a method of treating a subject for Notch dependent cancer.
- FIGS. 1A-1D show 6-(4-'Pert-Butylphenoxy)Pyridin-3-Amine (I3) (CAS number 218457-67-1) blocks NICD mediated Notch signalling activation.
- FIG. 1A shows N1-HeLa cells co-transfected with pcDNA3.Notch1 expression plasmid, pGL4.26-12 ⁇ CSL luciferase and SV40 renilla plasmids.
- DL4- and N1-HeLa cells were cocultured in a 96 well plate in 1:1 ratio (20,000: 20,000 cells/well) and treated with DMSO or with 2. 5 and 10 ⁇ M of I3 and DAPT for 24 hours.
- the Notch pathway activation was measured by quantifying Notch signalling driven luciferase reporter assay.
- Treatment of DL4:N1 coculture assay with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT causes a concentration dependent decrease in Notch signalling activation.
- FIG. 1B shows HeLa cells transfected with NICD and treated with DMSO or with 2, 5, 10, 20 and 40 ⁇ M of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3).
- As a control co-cultured cells were also treated with 5, 10, 20 and 40 ⁇ M of DAPT.
- the pathway activation was measured using Notch driven luciferase reporter assay.
- FIG. 1C shows DL4:N1 and DL4:N2 coculture assay treated with I3 and DAPT (each 10 ⁇ M) for 24 hours.
- FIG. 1D shows 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) inhibits pathway activation via intracellular domains of Notch1 (NICD) and Notch2 (N2-ICD).
- FIG. 2 shows 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) mediated inhibition of Notch signalling can be rescued with increasing concentration of MAML1.
- HeLa cells were co-transfected 800 ng of NICD+3 ⁇ g of pCDNA3.1 or 800 ng of NICD+1 ⁇ g of MAML1-FLAG or 800 ng of NICD+3 ⁇ g of MAML1-FLAG expression vectors.
- pGL4.26-12 ⁇ CSL luciferase plasmid was also introduced into the cells.
- SV40 renilla was used as an internal control.
- FIGS. 3A-3E show 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) inhibits Notch signalling and downregulates its target genes in human cancer cell lines.
- FIG. 3A shows RPMI 8402 cells treated with DMSO, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT (10 ⁇ M) for 24 hours and analyzed for the expression of Notch target genes, Hes1, cMyc and Dtxl by qRT-PCR. Data normalized to HPRT as a house-keeping gene.
- FIG. 3B shows whole cell lysate from 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treated cells was analyzed by Western blot. Using antibodies against NICD (Val1744), Hes1 and cMyc, the protein levels of NICD and Notch target genes were determined.
- FIGS. 3C-3D show the human T-ALL cell lines HPB ALL and KOPTK1 treated with DMSO or 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) for 24 hours. Western blot analyses were performed using NICD (Val1744) and Hes1 specific antibodes. Tubulin served as a loading control.
- FIG. 4 shows 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) induces a proliferative block in human cancer cells.
- Human T-ALL cell lines RPMI 8402 and KOPTK1, and pancreatic cancer cell line PANC1 as well as nRas driven melanoma cells were seeded in a 96 well plate and treated with 10 ⁇ M concentration of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT for several days. Their growth inhibitory effects were compared with cells treated with equal amount of DMSO.
- FIGS. 5A-5E show 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) blocks NICD dependent growth of human cancer cells.
- FIG. 5A shows DND41-Parental and DND41-NICD cells were treated with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT for 24 hours.
- Western blot analyses were carried out for Hes1 protein using Hes1 specific antibodies. Both DAPT and 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) caused a downregulation of Hes1 in DND41-Parental cells.
- DND41-NICD cells showed a downregulation of Hes1 only when treated with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3).
- FIG. 5B shows five thousand DND41-Parental cells were seeded and treated with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT in a 96 well plate. Growth kinetics of the parental cell line was followed over 5 days using Alamar blue readout. Treatment of DND41-Parental cell line with both 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT caused a proliferation arrest. Simarly, FIG.
- FIG. 5C shows DND4I-NICD cells treated with DMSO, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT and their growth kinetics were monitored using Alamar blue readout over 5 days.
- the treatment of DND41-NICD cells with DAPT did not have a significant impact on their proliferation, while 6-(4-Tell-Butylphenoxy)Pyridin-3-Amine (I3) treatment induced a proliferation arrest.
- FIG. 5D shows human breast cancer cell line HCC1187 harbors a SEC22B-Notch2 chromosomal translocation, thus leading to an expression of constitutively active form of NICD independent of cleavage by the ⁇ -secretase complex.
- FIGS. 6A-6D show 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) induces G0/G1 cell cycle arrest and apoptosis in human T cell acute lymphoblastic leukemia cell lines and human breast cancer cell line HCC1187.
- FIG. 6A shows human leukemic cell lines (RPIMI8402, CUTL1, KOPTK1, TALL1 and HPBALL) were treated with I3 (10 ⁇ M). Percentage of Annexin V positive (apoptotic) cell population was measured using flow cytometry.
- FIG. 1 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine
- FIG. 6B shows cell cycle analyses: RPMI8402, KOPTK1 and TALL1 cell lines were treated with I3 (10 ⁇ M) and stained with Ki67 and Hoechst stain to determine cell cycle status.
- the cell cycle analyses suggest that I3 treatment causes 20-30% increase in cells arrested in G0/G1 phase of the cell cycle.
- FIG. 6C shows HCC1187 cells were treated with DMSO or 10 ⁇ M of I3 and percentage of apoptotic population was measured using Annexin V stain.
- FIG. 6D shows I3 treated HCC1187 cells analyzed for cell cycle status. Ki67 and Hoechst stain revealed that I3 induces G0/G1 arrest in HCC1187 cells.
- FIGS. 7A-7C show 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) mimics genetic loss of Notch2 signalling phenotype in the spleen. Loss of Notch signalling in the spleen leads to a reduction in Marginal Zone B cells (MZB) cells in the spleen.
- FIG. 7A shows schematics of the experimental plan.
- MZB cells within the B cell compartment were detected using antibodies against CD23 and CD21 cell surface markers.
- the treatment of mice with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) causes a significant reduction in the percentage of MZB cells in the spleen.
- FIG. 7C shows that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment causes a reduction in the absolute numbers of MZB cells in the spleen when compared to vehicle treated animals.
- FIGS. 8A-8B show 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment increases latency of leukemia development in mice.
- FIG. 8A shows NOD/SCID ⁇ c ⁇ / ⁇ mice were injected with 1 ⁇ 10 6 HPB ALL (luciferase expressing) cells. On day 15, leukemic cells were established in the bone marrow. Mice were treated with oil or 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) for every day, Mice were imaged on day 27 using Caliper IVIS (Xenogen) live imaging system. Red and blue colour indicates the intensity of luciferase signal and correlates with the number of leukemic cells.
- FIG. 8A shows NOD/SCID ⁇ c ⁇ / ⁇ mice were injected with 1 ⁇ 10 6 HPB ALL (luciferase expressing) cells. On day 15, leukemic cells were established in the bone marrow. Mice were treated
- 5B shows 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment blocks RPMI 8402 leukemic cell growth in xenotransplantation assay.
- FIGS. 9A-9B show 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment blocks MMTV-ErbB2 mouse mammary tumors.
- FIG. 9A shows Hes1 protein expression levels in MMTV-ErbB2 mammary tumors and normal age matched mammary glands (M.G) were compared using Anti-Hes1 antibody. Western blot analyses showed a very high expression of Hes1 protein in MMTV-ErbB2 mammary tumors. Tubulin served as a loading control.
- FIG. 9A shows Hes1 protein expression levels in MMTV-ErbB2 mammary tumors and normal age matched mammary glands (M.G) were compared using Anti-Hes1 antibody.
- Western blot analyses showed a very high expression of Hes1 protein in MMTV-ErbB2 mammary tumors.
- Tubulin served as a loading control.
- FIG. 10 shows Notch inhibitory activity of chemical derivatives of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3).
- Different chemical derivatives of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) were tested in DL4-N1 coculture assay and Notch activity levels were measured using Notch driven luciferase reporter gene.
- I3-A, I3-B, I3-C, I3-E, I3-G, I3-H, I3-M and I3-N exhibit anti-Notch activity comparable to 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), while derivatives I3-F and I3-I appear to have enhanced activity.
- the term “comprise/comprising” is generally used in the sense of include/including, that is to say permitting the presence of one or more features or components.
- the terms “comprise” and “comprising” also encompass the more restricted ones “consist” and “consisting”.
- the term “compound(s) of the invention” or “compound(s) according to the invention” used throughout the description refers to the compound 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (CAS number 218457-67-1), derivatives of said I3, salts or solvates of the compound I3 or of the derivatives, and to isomers, including enantiomers, stereoisomers, rotamers, tautomers and racemates of the compound I3, chemical modified I3 compounds and derivatives of said I3 compounds.
- I3 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine
- the terms “subject” is well-recognized in the art, and, refers to a mammal, including dog, cat, rat, mouse, monkey, cow, horse, goat, sheep, pig, camel, and, most preferably, a human.
- the subject is a subject in need of treatment or a subject with a disease or disorder, such as cancer.
- the subject can be a normal subject or a subject who has already undergone a treatment against cancer.
- the term does not denote a particular age or sex. Thus, adult, children and newborn subjects, whether male or female, are intended to be covered.
- cancer refers to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
- cancer refers preferably to solid tumors, such as brain, breast, prostate, colorectum, kidney, lung, sarcoma, or melanoma and liquid tumors, affecting the blood, such as leukemia.
- cancers are Notch dependent cancers selected from the group comprising T cell-Acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), Mantle cell lymphoma, breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumors, tumor angiogenesis, colorectal cancer.
- T-ALL T cell-Acute lymphoblastic leukemia
- CML chronic myeloid leukemia
- CLL chronic lymphocytic leukemia
- Mantle cell lymphoma breast cancer
- pancreatic cancer prostate cancer
- melanoma brain tumors
- tumor angiogenesis colorectal cancer
- colorectal cancer colorectal cancer.
- the Notch dependent cancer is resistant to ⁇ -secretase inhibitor treatment.
- Examples of ⁇ -secretase inhibitor treatment comprise 1) Gamma secretase inhibitor RO4929097 and Cediranib Maleate in treating patients with advanced solid tumors (NCT01131234), 2) Gamma-Secretase Inhibitor RO04929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia (NCT01088763), 3) Study of MK-0752 in combination with Tamoxifen or Letrozole to treat early stage breast cancer (NCT00756717), 4) GDC-0449 and RO4929097 in treating patients with Advances or metastatic sarcoma (NCT01154452) 5) RO4929097 and Erlotinib Hydrochloride in treating patients with stage IV or recurrent Non-Small Cell Lung Cancer (NCT01193881), 6) Bicalutamide and RO4929097 in treating patients with previously treated prostate cancer (NCT01200810), 7) RO49
- Notch signalling pathway is evolutionarily conserved and the basic molecular players in this pathway are ligands (Delta and Jagged), Notch receptors, and the transcription factors (Shih IeM, Wang TL in Cancer Res 2007;67(5): 1879-82).
- Notch is a transmembrane heterodimeric receptor and there are four distinct members (Notch1, Notch2, Notch3 and Notch4) in humans and rodents.
- Notch-ICD Notch receptor
- ⁇ -secretase also called tumor necrosis factor- ⁇ -converting enzyme
- ⁇ -secretase also called tumor necrosis factor- ⁇ -converting enzyme
- ⁇ -secretase also called tumor necrosis factor- ⁇ -converting enzyme
- CBF1 suppressor of hairless, Lag-1
- molecular genetic alterations such as chromosomal translocation, point mutations, and chromosomal amplification at the Notch receptor loci, are the known mechanisms for constitutive activation of Notch pathway. Despite the different mechanisms, they all result in increased levels of intracellular Notch-IC.
- T-ALL T-cell acute lymphoblastic leukemia
- Notch1 signalling is essential for normal development of T-cell progenitors
- constitutive activation of Notch1 signalling due to molecular genetic alterations is associated with T-ALL.
- Notch3 gene amplification was found to occur in about 19% of tumors, and overexpression of Notch3 was found in more than half of the ovarian serous carcinomas.
- Notch signalling activation has been shown in the development of breast cancer.
- constitutively active Notch4 expression causes mammary tumors in mice and Notch1-activating mutations contribute to the development of T-ALL.
- overexpression of activated Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mouse breast tumors.
- Notch signalling activation has also been implicated in lung and bone metastasis of breast cancer cells. Overexpression of Notch3 is sufficient to induce choroid plexus tumor formation in a mouse model, suggesting a role of Notch3 in the development of certain types of brain tumors.
- HTS High-Through put Screening
- Applicants have established a coculture assay to induce a ligand-receptor mediated activation of the pathway.
- the coculture assay was established using Notch ligand DL4 and Notch 1 receptor specifically, because DL4-N1 ligand-receptor mediated pathway activation plays an important role in pathophysiological conditions such as tumor angiogenesis and the role of Notch1 receptor in inducing T cell leukemia. Since this assay depends on the expression and interaction between DL4 ligand and. Notch1 receptor, it provides an opportunity to interrogate ligand-receptor interactions-induced Notch signalling in a controlled manner.
- this assay into a 96 well plate and 384 well plate format helped Applicants to adapt this assay to conduct HTS.
- the use of this coculture assay to screen siRNA or small molecule libraries can lead to the identification of proteins or chemical compounds that are able to modulate Notch signalling at different steps along the pathway.
- a HTS using siRNA or small molecule libraries can yield modulators of the pathway able to act in the signal sending or signal receiving cells.
- Small molecule or protein mediated alterations in the recycling or trafficking of the ligands and receptors to the plasma membrane can potentially block the Notch pathway and could be studied using this assay.
- this assay can also help identify proteins or chemical entities able to block ligand-receptor interactions, ADAM10/17 mediated S2 cleavage or ⁇ -secretase catalyzed S3 cleavage of the Notch receptor, nuclear translocation of the active form of Notch or entities able to block transcriptional activation complex.
- Notch-independent renilla system as an internal control allowed Applicants to eliminate cytotoxic chemical compounds, thereby limiting the rate of false positive hits.
- this cell-based assay also helped to circumvent issues related to the cell permeability of the chemical compounds for further hit validation.
- I3 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine
- the present invention relates to 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of Formula I
- the present invention also encompasses chemical modifications of the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (CAS number: 218457-67-1) to prolong their circulating lifetimes.
- Non-limiting examples of methods for transiently, or reversibly, pegylating drugs, including polypeptide-based drugs, are provided in U.S. Pat. Nos. 4,935,465 (issued in Jun. 19, 1990) and 6,342,244 (issued Jan. 29, 2002); and in U.S. published applications number US2006/0074024.
- PEG-based reagents for example, published applications WO2005047366. US2005171328, and those listed on the NEKTAR PEG Reagent Catalog® 2005-2006 (Nektar Therapeutics, San Carlos, Calif).
- the present invention further encompasses chemical derivatives of said I3 having Notch signalling pathway inhibition properties.
- Applicants have shown that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and its derivatives target Notch signalling at the transcriptional activation complex in the nucleus, human tumors resistant to ⁇ -secretase inhibitors due to above mentioned mutations are expected to respond to 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) appears to selectively target Notch signalling thus limiting its off-target toxic effects.
- X is O and position 3 (or pain) is NH2.
- the derivative having Notch signalling pathway inhibition properties is selected from the non-limiting group comprising
- n is an integer selected from 1 to 4.
- n is an integer selected from 1 to 4.
- R1, R2, R3, R4 are each independently selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH 2 ) n CH 3 alkenyl, alkynyl; the subscript n is an integer independently selected front 1 to 15;
- n is an integer selected from 1 to 4.
- n is an integer selected from 1 to 3;
- heteroaromatic is a aminopyrrole, aminofurane, aminothiofurane, or a pyrimidine:
- n is an integer independently selected from 1 to 15;
- heteroaromatic is an aminopyrrole, aminofurane, aminothiofurane, or a pyrimidine
- the invention also relates to salts or solvates of the compound I3, chemical modified I3 compounds and derivatives of said I3 compounds of the invention.
- these salts and/or solvates are pharmaceutically acceptable.
- pharmaceutically acceptable salts are produced from acidic inorganic or organic compounds, or alkaline inorganic or organic compounds.
- pharmaceutically acceptable salt refers to a salt that retains the biological effectiveness of the free acids and bases of a specified compound and that is not biologically or otherwise undesirable.
- isomers including enantiomers, stereoisomers, rotamers, tautomers and racemates of the compound I3, chemical modified I3 compounds and derivatives of said I3 compounds of the invention are contemplated as being part of this invention.
- the invention includes stereoisomers in optically pure form and in admixture, including racemic mixtures. Isomers can be prepared using conventional techniques, either by reacting optically pure or optically enriched starting materials or by separating isomers of compounds of the present invention.
- Racemates refers to a mixture of enantiomers.
- Stereoisomer or “stereoisomers” refer to compounds that differ in the chirality of one or more stereocentres. Stereoisomers include enantiomers and diastereomers.
- the compound I3, chemical modified I3 compounds and derivatives of said I3 compounds of this invention may exist in stereoisomeric form if they possess one or more asymmetric centres or a double bond with asymmetric substitution and, therefore, can be produced as individual stereoisomers or as mixtures. Unless otherwise indicated, the description is intended to include individual stereoisomers as well as mixtures.
- the methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in Chapter 4 of Advanced Organic Chemistry, 4th ed., J. March, John Wiley and Sons, New York, 1992).
- Tautomer refers to alternate forms of a compound that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryl groups containing a ring atom attached to both a ring —NH— moiety and a ring ⁇ N-moiety such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.
- a suitable counterion will be derived from an organic or inorganic acid.
- Such counterions include halide (such as chloride, bromide, fluoride, iodide), sulfate, phosphate, acetate, succinate, citrate, lactate, maleate, fumarate, palmitate, cholate, glutamate, glutarate, tartrate, stearate, salicylate, methanesulfonate, benzenesulfonate, sorbate, picrate, benzoate, cinnamate, and the like.
- a suitable counterion will be selected from sodium, ammonium, barium, calcium, copper, iron, lithium, potassium and zinc, and the like.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was identified as a potential Notch inhibitor.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was found to block NICD mediated pathway activation ( FIGS. 1A-D ).
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) is able to block proliferation of NICD overexpressing leukemic cell lines which are resistant to DAPT (a- ⁇ -secretase inhibitor, N-[N-(3,5-difluorophenacetyl-Lalanyl)]-(S)-phenylglycine t-butyl ester) ( FIGS. 5A-E ).
- the Notch inhibitory potential of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was further confirmed by the downregulation of Notch target genes in human T-ALL cell lines ( FIGS.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) can induce differentiation of C2C12 cells into MHC expressing multinucleated myotubes further validated the anti-Notch role of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (data not shown).
- the Notch pathway inhibition caused by 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) can be rescued by the overexpression of MAML1 above certain levels.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was able to block the signalling with 800 ng of NICD and 1 ⁇ g of MAML1 was transiently introduced into the cells, however when the amount of MAML1 was increased to 3 ⁇ g, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was no longer able to block the pathway activation ( FIG. 2 ).
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) may interfere with the Notch transcriptional activation complex thereby inhibiting the signalling activation.
- CBP/p300 histone acetyltransferase HAT is recruited to the complex leading to its autoacetylation and acetylation of histone 3 and 4.
- mice treated with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) were expected to develop goblet cell metaplasia.
- treatment of mice with 25 mg/kg of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) for 7 days (more than a month in case of xenotransplants) did not perturb intestinal homeostasis and without any indication of goblet cell accumulation (data not shown). This unexpected outcome could be due to two reasons.
- Notch signalling plays an important role in the regulation of hematopoietic system. For instance, DL4-Notch1 signalling is essential for T cell development in the thymus. Notch2 and MAML1 mediated pathway activation is critical for Marginal Zone B (MZB) cells development in the spleen.
- MZB Marginal Zone B
- C57Bl6 mice were treated with 25 mg/kg of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) for 7 days and analyzed on day 8.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) Anti-cancer activity of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was investigated in transplant models for human diseases, namely T-cell leukemia and breast cancer.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) has demonstrated a remarkable ability to slow down the progression and metastasis of very aggressive form of leukemic cell lines ( FIGS. 8A-B ).
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment has led to a block in tumor progression in the mice ( FIGS. 9A-B ).
- the chemical compound 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) has shown ability to block NICD mediated signalling Therefore this compound is useful in cancers where Notch driven tumors are resistant to ⁇ -secretase inhibitor treatment.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of formula I, or one of its derivatives having Notch signalling pathway inhibition properties as described herein, or pharmaceutically acceptable salts, solvates, tautomers, isomers thereof, and a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier As to the appropriate carriers, reference may be made to the standard literature describing these, e.g. to chapter 25.2 of Vol. 5 of “Comprehensive Medicinal Chemistry”, Pergamon Press 1990, and to “Lexikon der Hilfsstoffe für Pharmazie, Kosmetik and angrenzende füre”, by H. P. Fiedler, Editio Cantor, 2002.
- pharmaceutically acceptable carrier means a carrier or excipient that is useful in preparing a pharmaceutical composition that is generally safe, and possesses acceptable toxicities. Acceptable carriers include those that are acceptable for veterinary use as well as human pharmaceutical use.
- pharmaceutically acceptable carrier as used in the specification and claims includes both one and more than one such carrier.
- the pharmaceutical composition of the present invention further comprises one or more additional active agents selected among the non limiting group comprising chemotherapeutic agents for treating cancer.
- chemotherapeutic agents may be selected among the group comprising, for example, Altretamine, Bleomycin, Busulphan, Capecitabine, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Crisantaspase, Cyclophosphamid, Cytarabine, dacarbazine, Daunorubicin, Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Idarubicin, Ifosfamide, Irinotecan, Lomustine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitoxantrone, Oxaliplatin, Pentostatin, Procarbazine, Streptozocin, Taco, Temozolomide, Tioguanine/Thiogu
- the compounds of the invention namely the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and derivatives thereof, that are used in the treatment and/or prevention of cancers can be incorporated into a variety of formulations and medicaments for therapeutic administration. More particularly, one or more compound(s) as provided herein can be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable carriers, and can be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, pills, powders, granules, dragees, gels, slurries, ointments, solutions, suppositories, injections, inhalants and aerosols.
- administration of the compounds can be achieved in various ways, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intracranial and/or intratracheal administration.
- the compound can be administered in a local rather than systemic manner, in a depot or sustained release formulation.
- the compounds can be formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated as elixirs or solutions for convenient oral administration, or administered by the intramuscular or intravenous routes.
- the compounds can be administered transdermally, and can be formulated as sustained release dosage firms and the like.
- the compounds can be administered alone, in combination with each other, or they can be used in combination with other known compounds.
- Suitable formulations for use in the present invention are found in Remington's Pharmaceutical Sciences (Mack Publishing Company (1985) Philadelphia, Pa., 17th ed.), which is incorporated herein by reference. Moreover, for a brief review of methods for drug delivery, see, Langer, Science (1990) 249:1527-1533, which is incorporated herein by reference.
- suitable unit doses for the compounds of the present invention can, for example, preferably contain between 0.1 mg to about 1000 mg, between 1 mg to about 500 mg, and between 1 mg to about 300 mg of the active compound. In another example, the unit dose is between 1 mg to about 100 mg.
- Such unit doses can be administered more than once a day, for example, 2, 3, 4, 5 or 6 times a day, but preferably 1 or 2 times per day, so that the total dosage for a 70 kg human adult is in the range of 0.001 to about 15 mg per kg weight of subject per administration.
- a preferred dosage is 0.01 to about 1.5 mg per kg weight of subject per administration, and such therapy can extend for a number of weeks or months, and in some cases, years. It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs that have previously been administered; and the severity of the particular disease undergoing therapy, as is well understood by those of skill in the area.
- a typical dosage can be one 1 mg to about 100 mg tablet or 1 mg to about 300 mg taken once a day, or, multiple times per day, or one time-release capsule or tablet taken once a day and containing a proportionally higher content of active ingredient.
- the time-release effect can be obtained by capsule materials that dissolve at different pH values, by capsules that release slowly by osmotic pressure, or by any other known means of controlled release. It can be necessary to use dosages outside these ranges in some cases as will be apparent to those skilled in the art.
- the present invention further provides a compound of the invention for use in treating and/or preventing cancers.
- cancers are preferably Notch dependent cancers and are selected from the non limiting group comprising T cell-Acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), Mantle cell lymphoma, breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumors, tumor angiogenesis, and colorectal cancer.
- T-ALL T cell-Acute lymphoblastic leukemia
- CML chronic myeloid leukemia
- CLL chronic lymphocytic leukemia
- Mantle cell lymphoma breast cancer
- pancreatic cancer prostate cancer
- melanoma brain tumors
- tumor angiogenesis tumor angiogenesis
- colorectal cancer colorectal cancer
- the compounds of the present invention (6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), its derivatives) can be also used in the treatment of cancers where Notch dependent cancers are resistant to ⁇ -secretase inhibitor treatment.
- Notch signalling dependent human tumors resistant to ⁇ -secretase inhibitor treatment can be determined by the levels of NICD, Notch target genes as well as by mutation status of Notch receptor and other components of the Notch pathway.
- the present invention also provides a method for treating and/or preventing cancers, said method comprising administering the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), its derivatives, or the pharmaceutical composition of the invention to a subject in need thereof.
- a method for treating and/or preventing cancers comprising administering the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), its derivatives, or the pharmaceutical composition of the invention to a subject in need thereof.
- the present invention provides a method of treatment of a disease associated with an up-regulated Notch signalling pathway activity, said method comprising administrating the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), a derivative thereof, or the pharmaceutical composition of the invention to a subject in need thereof.
- a method of treatment of a disease associated with an up-regulated Notch signalling pathway activity comprising administrating the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), a derivative thereof, or the pharmaceutical composition of the invention to a subject in need thereof.
- the daily dose of compounds of the present invention will necessarily be varied depending upon the host treated, the particular route of administration, and the severity and kind of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient. Further, it is noted that the clinician or treating physician will know how and when to start, interrupt, adjust, or terminate therapy in conjunction with individual patient response.
- a therapeutically effective dose can be estimated initially from cell culture assays, animal models, or microdosing of human subjects.
- Treatment refers to both therapeutic treatment and prophylactic or preventative measures.
- Subjects in need of treatment include those already with the disorder, such as cancer, as well as those in which the disorder, such as cancer, is to be prevented.
- the mammal, preferably human, to he treated herein may have been diagnosed as having the disorder, such as cancer, or may be predisposed or susceptible to the disorder, such as cancer.
- the term “therapeutically effective amount” refers to an amount of a drug effective to treat a disease or disorder in a mammal.
- the therapeutically effective amount of the drug may reduce the number of tumor or cancer cells, reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cells infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer.
- the compounds of the present invention may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic.
- terapéuticaally effective amount is used herein to mean an amount sufficient to prevent, or preferably reduce by at least about 30 percent, preferably by at least 50 percent, preferably by at least 70 percent, preferably by at least 80 percent, preferably by at least 90%, a clinically significant change in the growth or progression or mitotic activity of a target cellular mass, group of cancer cells, or other feature of pathology.
- the compounds of the present invention may be used against cell proliferate diseases in combination (for example either at the same time, or almost at the same time, or one after the other) with conventional treatments such as standard radiotherapy and/or standard chemotherapy.
- standard radiotherapy and chemotherapy can be also the concomitant chemo-radiotherapy.
- the standard radiotherapy and/or chemotherapy can be performed before, simultaneously or after the administration of a therapeutically effective amount of the compound of the present invention, or pharmaceutical compositions containing thereof.
- chemo-radiotherapy is used when these two treatments (chemotherapy and radiotherapy) are given either at the same time, or almost at the same time, for instance one after the other, or on the same day, etc.
- standard radiotherapy refers to the use of ionizing radiation as part of cancer treatment to control malignant cells.
- the ionizing radiation is ⁇ -irradiation. It is also common to combine radiotherapy with surgery, chemotherapy, hormone therapy, or combinations thereof. Most common cancer types can be usually treated with radiotherapy.
- the precise treatment intent (curative, adjuvant, neoadjuvant or palliative) will depend on the tumor type, location, and stage, as well as the general health of the subject in need thereof.
- standard chemotherapy generally refers to a treatment of a cancer using specific chemotherapeutic/chemical agents.
- a chemotherapeutic agent refers to a pharmaceutical agent generally used for treating cancer.
- the chemotherapeutic agents for treating cancer include, for example, Altretamine, Bleomycin, Busulphan, Capecitabine, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Crisantaspase, Cyclophosphamid, Cytarabine, dacarbazine, Daunorubicin, Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Idarubicin, Ifosfamide, Irinotecan, Lomustine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitoxantrone, Oxaliplatin, Pentostatin, Procarbazine, Streptozocin, Taco, Temozolomide, Tio
- chemotherapeutic agent when used in combination with a compound according to the present invention, then this may be used in the form of a medicament containing a combination of these two agents, for simultaneous administration, or they may be used in the form of separate dosage forms, each containing one of the agents, and in the latter case the individual dosage forms may be used e.g. sequentially, i.e. one dosage form with the compound of the invention , followed by a dosage form containing the chemotherapeutic agent (or vice versa).
- This embodiment of two separate dosage forms may be conceived and provided in the form of a kit.
- the compounds of the present invention may be used against cell proliferate diseases, such as cancers, in combination with conventional removal of a tumor bulk, by for example segmental resection (biopsy or gross resection).
- the term “removal of a tumor bulk” refers to any removal, ablation or resection of a tumor bulk from a subject.
- the removal can be chemical, radiation or surgical.
- Preferably said removal is surgical, such as ablation or resection.
- Resection can be “segmental resection” (or segmentectomy), a surgical procedure to remove part of an organ or gland from a subject. It may also be used to remove a tumor and normal tissue around it.
- Debulking agent may be also used to remove tumor bulk.
- the term “debulking agent” includes any molecule (e.g. chemical, biological) or any external/environmental agent (e.g. ⁇ -irradiation) or traditional surgery that would allow killing cancer cells from the tumor bulk (e.g. FL1 0 and FL1 ⁇ cells as mentioned above).
- kits comprising one or more doses of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), or of one of its derivatives having Notch signalling pathway inhibition properties, or the pharmaceutical composition of the present invention for use in a method for treatment and/or prevention of cancers.
- the kit can further comprise one or more doses of a chemotherapeutic agent.
- the kit may also comprise reagents and/or instructions for use.
- the kit comprises a container and a label or package insert on or associated with the container.
- Suitable containers include, for example, bottles, vials, syringes, etc.
- the containers may be formed from a variety of materials such as glass or plastic.
- the container holds the pharmaceutical composition that is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle).
- the label or package insert indicates that the composition is used for treating the condition of choice, such as cancer.
- the present invention also relates to the use of the compounds of the invention for inhibiting in vitro or in vivo the Notch signalling pathway in cells.
- said cells are cancer cells.
- the Notch signalling pathway dependency in cancer cells is determined by any method known in the art.
- this method can consist in an in vitro ⁇ -secretase complex activity assays as described herein.
- This method of treating may further comprise administering at least one conventional cancer treatment.
- the conventional cancer treatment is administered before, simultaneously or after the administration of the therapeutically effective amount of 6-4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of Formula I or one of its derivatives having Notch signalling pathway inhibition properties, or the pharmaceutical composition of the invention.
- the conventional cancer treatment consists in radiotherapy and/or chemotherapy.
- the present invention also relates to the use of the compounds of the invention in a method for provoking apoptosis in a cell, either in vitro or in vivo, by inducing G0/G1 cell cycle arrest.
- Mouse DL4-IRES dsRED cDNA was cloned into a pENTR1 vector (Invitrogen®) and finally shuttled into a destination lentivirus vector using Gateway cloning strategy (Invitrogen).
- a Phosphoglycerate kinase (PGK) promoter drove the expression of DL4 protein.
- DL4-lentiviral particles were produced in 293T cells by cotransfection of DL4-lentivirus vector, Gag/pol expression plasmid and plasmid encoding for viral envelope proteins.
- mouse full length Notch1 cDNA was a cloned in a pCDNA3.1-IRES-puromycin vector.
- Notch1 cDNA was cloned upstream of IRES-puromycin between HindIII and XbaI restriction sites.
- a CMV promoter controlled the expression of Notch1 protein.
- CSL/RBP-jk consensus DNA binding sequences were cloned in a head to tail conformation in the pGL4 luciferase vector (Promega), thus named 12 ⁇ CSL/RBP-jjk luciferase vector.
- 12 ⁇ CSL/RBP-jk consensus DNA binding sequences were cloned into pGL4.26.luciferase vector (Promega).
- SV40 Renilla vector was used (Promega).
- NICD-GFP overexpression studies were performed using pEGFP-C1-NICD expression plasmid.
- the FLAG-CMV2 plasmid expressing MAML1-FLAG was a kind gift from Dr. Lizi Wu, Harvard Medical School, Boston.
- HeLa cell were bought from ATCC (catalog # CCL-2).
- cells were transduced with DL4-lentiviral particles.
- DL4 stable clones were selected using puromycin, High DL4 expressing clones were sorted using antibodies against DL4 with Fluorescence activated cell sorting (FACS).
- FACS Fluorescence activated cell sorting
- N1 stable line cell were transfected with a pCDNA3.1+ (Invitrogen) plasmid containing mouse full length Notch1 under the control of CMV promoter.
- an IRES puromycin cassette was cloned downstream of Notch1 cDNA.
- HeLa cells expressing high levels of Notch1 were enriched by FACS using anti-Notch1 antibodies.
- DL4- and N1-HeLa cells were cultured in DMEM (GIBCO, Invitrogen), 10% FCS and 10 ug/ml of puromycin (Sigma).
- the coculture assay was performed as follows. N1-HeLa cells were cotransfected in 10 cm tissue culture dishes with 16 ⁇ g of pGL4.26.12 ⁇ CSL.luciferase vector/plate, 4 ⁇ g of Notch1 expression plasmid/plate, and 200 ng of SV40 Renilla vector/plate. DL4- and N1-HeLa cells were detached from the plate by using 0.5 mM EDTA (1 ⁇ PBS). The both cell populations were counted and mixed in 1:1 ratio (5,000:5,000 cells/well in a 384 well plate) and dispensed into 384 well plates (white, clear bottom, Corning) using multidrop Combi plate dispenser.
- the assay plates were pre-dispensed (using automated Biomek 3000 liquid handler) with chemical compound libraries (Microsource Maybridge Hitfinder and Prestwick) to give a final concentration of 10 ⁇ M.
- the final assay volume was 22 ⁇ ls.
- Luciferase activity was measured using Luciferase Assay Reagent II and Renilla values were determined by using Stop and Glow reagent (Dual luciferase assay system, Cat # E1980, Promega). Luciferase and renilla readouts were taken using Tecan® F500 (Tecan) multiplate reader. All the liquid handling steps (aspiration of the medium, dispensing of Passive lysis buffer, Luciferase Assay Reagent II and Stop and Glow reagents) were performed using ELF406 liquid handler.
- RNA pellet was dried off of excess of ethanol and resuspended in 40 ⁇ l DPEC water.
- RNA extracted from the cell was used to synthesize cDNA by reverse transcription reaction.
- Reverse transcription was performed using SuperScriptTM RT (Invitrogen).
- RNA concentration was measured using NanoDrop®ND-1000 spectrophotometer (Witec AG) and 500 ng of total RNA was mixed with a 10 mM mix of dNTPs and 100 ng of random primers.
- the reaction mix was incubated at 65° C. for 5 minutes and quickly incubated on ice for 1 minute. Following incubation on ice. 5 ⁇ first strand buffer and 0.1 M DTT were added and mix was incubated for 2 minutes at 25° C.
- 200U of SuperScripTM II RT was added to the reaction mix and incubated at 42° C. for 50 minutes. The reaction was stopped by incubating the reaction mix at 75° C. for 15 minutes.
- membranes were blocked with 5% milk and incubated overnight with primary antibodies at 4° C. Membrane were washed with 1 ⁇ TBST (1 ⁇ TBS+0.5% tween 20) for 5 minutes (3 times) and incubated with HRP-conjugated secondary antibodies for one hour at room temperature. Signal was detected with Super Signal West chemiluminescent substrate (Thermo Scientific, catalog number 34077).
- HeLa cells or C2C12 cells were grown on cover slips. Cells were washed with 1 ⁇ ice-cold PBS, fixed with 4% PFA for 5 minutes at room temperature and permeabilized using 0.3% Triton X-100. Subsequently permeabilized cells were blocked for 20 minutes with 1% BSA for 20 minutes at room temperature. Cells were incubated with appropriate primary antibodies for one at room temperature. Alexa Fluor-488 conjugated secondary antibodies were used to detect primary antibodies. Cells were counterstained with DAPI and mounted in fluorescent mounting media. Fluorescent images were viewed and captured using Zeiss Axioplan microscope at Bioimaging and optics core facility at EPFL.
- C2C12 cells were grown on collagen-coated cover slip in the presence of growth media (10% serum). To induce myoblast differentiation, cells were grown to 100% confluency for 3 days in the presence of differentiation media (2% horse serum) or in the presence of growth media+Notch inhibitors. After 3 days, cells were washed with 1 ⁇ ice-cold PBS and fixed with 4% PFA. Immunofluorescence staining was performed using anti-MHC antibody as explained in the section 2.2.6 (Immunofluorescence staining).
- Fluorescence activated cell sorting (FACS) analyses were performed on CyAnTM ADP instrument platform for flow cytometry at Flow cytometry core facility, EPFL.
- DL4 and Notch1 expression in DL4- and N1-HeLa cells was determined using anti-DL4 and anti-N1 antibodies respectively.
- T cell development in the thymus was investigated using antibodies against CD4, CD8 and TCR ⁇ .
- MZB cell development was monitored using antibodies against B220, CD21 and CD23.
- a single cell suspension was prepared from thymus and spleen. 1 ⁇ 10 6 cells suspended in 50 ⁇ l of staining media (HBSS supplemented with 2% NCS and 25 mM HEPES) and stained with appropriate antibody combinations by incubating on ice for 30 minutes.
- staining media HBSS supplemented with 2% NCS and 25 mM HEPES
- AnnexinV and 7AAD staining were performed. Thymic cells were suspended in 300 ⁇ l of 1 ⁇ AnnexinV binding buffer (BD Biosciences, San Diego, USA) and incubated with 10 ⁇ l of AnnexinV-Cy5 antibody and 10 ⁇ l of 7AAD (BD Biosciences, San Diego, USA). Samples were incubated for 15 minutes at room temperature. FACS was performed with in one hour of antibody staining.
- Flow cytometry analyses were done on live cells by gating on forward scatter (FSC) and side scatter (SSC). Data were analyzed by FlowJo software (Tree Star, Ashland, Oreg.).
- Alamarblue® proliferation assays were performed to determine the growth kinetics of Notch inhibitor treated cells.
- Alamar blue® consists of a cell permeable substrate resazurin. In metabolically active and proliferating cells, resazurin is converted to resorufin due to an intrinsic reducing power of live cells and produces a red fluorescence. Therefore production of resorufin serves as an indicator of the viability of the cell population.
- Proliferation assays were performed by seeding 5000 cells/well in a 96 well plate. Cells were treated with DMSO or Notch inhibitors for different time intervals. Each treatment for every time interval was carried out in 8 replicates. To determine the growth kinetics, 10 ⁇ l of Alamar blue® (Invitrogen) was added to each well and incubated for 4 hours. Alamarblue readout was taken using Tecan F500 (Tecan) multiplate reader.
- Organs were harvested, fixed in 4% paraformaldehyde (PFA) overnight at 4° C. and embedded in paraffin. Tissue sections were dewaxed and hydrated using decreasing concentration of ethanol (100%-70%) and finally in distilled water. Sections were stained with Hemotoxylin for 5 minutes, rinsed in acid alcohol for about 20 seconds and then rinsed in running water for 10 minutes. Sections were then stained with Eosin for 5 minutes, washed in water and dehydrated using increasing concentration of ethanol (70%-100%) and cleared in xylene solution. Sections were the mounted using mounting solution. Haematoxylin and Eosin stained sections were viewed and images were captured using Leica DMI4000 microscope.
- Intestinal tissue was flushed with ice-cold 1 ⁇ PBS, fixed in 4% PFA. Tissues were embedded in paraffin and sectioned to a thickness of 4 microns. Intestinal sections were deparaffinized at 60° C. and hydrated with decreasing concentration of alcohol (100% -70%) and finally washed in distilled water. Alcian blue staining was performed for 30 minutes at room temperature washed in running water and finally counterstained in nuclear fast red solution for 5 minutes. Tissue sections were then washed in running water dehydrated in 100% alcohol and cleared in xylene solution. Mounted sections were then viewed and images were captured using Leica DMI4000 microscope.
- mice were kept and bred at Animal facility, EPFL, Lausanne.
- C57Bl6 mice were used to assess the intestinal toxicity of the chemical compounds
- MMTV-ErbB2/Neu-IRES Cre FVB background mice were obtained from Dr. William J Muller, McGill University, Montreal and genotyped using MMTV-ErbB2/Neu specific primers (Ursini-Siegel et al., 2008).
- NOD/SCID ⁇ c ⁇ / ⁇ mice were bought from The Jackson Laboratory (USA) and were kept and bred at Animal facility, EPFL, Lausanne.
- C57Bl6 mice were intra peritoneal (i.p) injected with oil or 25 mg/kg of I3 or 10 mg/kg of CPA, once a day for 5-7 days. Mice were weighed using a weighing scale on day 0, day 3 and day 5. On day 8, intestinal tissue, spleen and thymus were harvested for analyses.
- the human leukemic cell lines RPMI 8402 and HPB ALL were transduced with a lentivirus containing luciferase gene constitutively expressed downstream of a CMV promoter.
- the human leukemic cell lines RPMI 8204 (0.5 ⁇ 1 ⁇ 10 6 cells) and HPB ALL (1 ⁇ 10 6 ) were suspended in 100 ⁇ l of ice-cold 1 ⁇ PBS and kept on ice until the transplant.
- NOD/SCID ⁇ c ⁇ / ⁇ mice were transplanted with the human leukemic cell lines by intravenous (i.v) injection. Mice were monitored for tumor development using Caliper IVIS (Xenogen) live imaging system.
- the luciferase substrate luciferin (Biosynth, L-8820) was dissolved in 1 ⁇ PBS and was injected (intra peritoneal) into the mice at a concentration of 150 mg/kg of body weight. Mice were imaged 5 minutes after the luciferin injection using Caliper IVIS live imaging system.
- mice were treated with oil or 25 mg/kg of I3 on a daily basis. Images were captured at the end of the experiments.
- MMTV-ErbB2/Neu mammary tumors were harvested from the mice and a single cell suspension was prepared. 1 ⁇ 10 6 primary tumor cells were suspended in 50 ⁇ l of 1 ⁇ PBS and kept on ice. Three weeks old recipient FVB mice were cleared of their endogenous epithelium and tumor cells were injected into the empty fat pad. Tumor development in the recipient mice was monitored and tumor volumes were measured using digital caliper. Tumor volumes were calculated using following formula: 2 ⁇ length ⁇ (width) 2 . Once the tumor reached a volume of about 100 min 3 , recipient mice were treated with oil or 25 mg/kg of I3 on alternate days.
- Applicants In order to identify novel modulators of the Notch pathway, Applicants have established a coculture assay in which DL4 ligand expressing HeLa cells were cultured with Ni HeLa cells, thereby activating the Notch pathway.
- the use of a DL4 and N1 HeLa cell coculture system mimics physiological conditions of cell-cell communication between ligand and receptor expressing cells.
- the in vitro generation of a controlled receptor-ligand assay system allowed Applicants to modify and monitor the Notch signal intensity by ⁇ -secretase inhibitors.
- Applicants have established DL4 and N1 expressing stable HeLa cell lines.
- HeLa cells were transduced with a lentivirus containing DL4 cDNA downstream of the PGK promoter.
- the D4 expressing cell population was enriched by fluorescence activated cell sorting.
- the N1 stable HeLa cell line was established using a plasmid containing the mouse N1 cDNA followed by an IRES Puromycin selection cassette. This system allowed Applicants to select for only Notch1 expressing clones when selected using puromycin.
- the expression levels of DL4 and N1 proteins in the respective cell lines were detected using anti-DL4 and anti-N1 antibodies. Quantification of the protein levels by flow cytometry showed high level expression of DL4 and N1 compared to parental HeLa cells (data not shown).
- DL4 and N1 stable HeLa cells were cocultured in 1:1 ratio in a 6-well plate and grown to continency.
- the cocultured cells were treated with DMSO or DAPT (10 ⁇ M) for 24 hours.
- parental HeLa cells were also cocultured with DL4-HeLa cells and were grown in the presence or absence of DAPT for 24 hours.
- Western blot analyses for the active form of Notch1 (NICD) using VAL1744 antibodies was performed and revealed only modest levels of NICD when parental HeLa cells were cocultured with DL4 HeLa cells (data not shown), accounting for a low level of endogenous Notch1 in HeLa cells.
- DI4:N1 coculture assay in a 6 well plate formal allowed Applicants to assess receptor-ligand interaction mediated Notch signalling activation.
- GSI DAPT
- DL4:N1 coculture assay was established in a 6-well plate.
- HTS high-through put screen
- the assay was scaled-down to a 384 well plate format for screening of chemical compound libraries.
- N1-HeLa cells were transfected with a reporter plasmids and N1 expression vector. Twelve hours later, chemical compounds were dispensed into a 384 well plate along with DMSO and DART as negative and positive controls.
- DL4- and N1-HeLa cells were mixed in a 1:1 ratio (5000: 5000 cells/well) and added to 384 well plates using multidropCombi plate dispenser. Luciferase readout was measured using dual luciferase assay system.
- the DL4:N1 coculture assay system was used to validate the Notch inhibitory activity and determine the IC50 value of the I3 compound.
- the cells in the coculture assay were treated for 24 hours with an increasing concentration of I3 (2-10 ⁇ M).
- the activation of the Notch pathway was measured using a Notch driven luciferase reporter assay.
- I3 blocks Notch signalling in a concentration dependent manner with an IC50 value in the lower ⁇ M range.
- NICD To determine whether over expression of NICD can rescue I3 mediated inhibition of Notch signalling, HeLa cells were co-transfected with a NICD expression plasmid and 12 ⁇ CSL luciferase construct. The transfected cells were treated with an increasing concentration of I3 and DAPT. Surprisingly, treatment of NICD expressing cells with I3 could block pathway activation in a dose-dependent manner, while DAPT had no effect on the signalling activation ( FIG. 1B ). This data suggests that I3 mediated inhibition of the Notch pathway is due to its activity downstream of the S3 cleavage event.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) blocks Notch signalling by acting downstream of S3 cleavage event.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment could impair nuclear localization of the NICD.
- a second possible mechanism of inhibition could be targeting of one or more individual components of the transcriptional activation complex in the nucleus.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) has an impact on nuclear transport of NICD
- HeLa cell were transfected with a NICD-CGP fusion construct and treated with DMSO and 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3). This allowed Applicants to follow transport of fusion protein within the cell.
- the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) mediated pathway inhibition was determined by Notch driven luciferase measurement (data not shown).
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) mediated blockage of Notch signalling does not involve nuclear exclusion of NICD
- HeLa cells were co-transfected with 800 ng of NICD-GFP plasmid, 1 ⁇ g of MAML1-FLAG expression vector and grown on cover slips.
- the transfected HeLa cells were treated with DMSO or 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (10 ⁇ M) for 24 hours.
- the ability of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) to block Notch activation at this concentration of NICD and MAML1 was verified by Notch driven luciferase measurement (data not shown).
- the cells were fixed with 4% PFA, blocked with 1% BSA and stained with antibodies against FLAG tagged MANTL1 and CSL-RBP-jk.
- NICD-GFP fusion protein was visualized by tracing the GFP protein.
- NICD-GFP protein When expressed alone, NICD-GFP protein was localized in the nucleus in a diffused manner and 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment did not alter its nuclear localization. However overexpression of NICD-GFP and MAML1 led to co-localization of both proteins into sub-nuclear compartments (possibly nuclear bodies). The 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment of the cells did not perturb the translocation and co-localization of NICD-GFP and MANUA into sub-nuclear compartment (data not shown).
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) Applicants speculated that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) might be targeting one of the components of the transcriptional activation complex.
- the over expression of this target protein may titrate out 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) compound and thus rescue 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) induced pathway inhibition.
- HeLa cells were co-transfected with 800 ng of NICD-GFP plasmid and with an increasing amount (0, 1 and 3 ⁇ g) of MAML1-FLAG expression vector.
- the Notch pathway activation was measured by introducing 12 ⁇ CSL luciferase plasmid.
- FIG. 2 in HeLa cells transfected with NICD alone or NICD+1 ⁇ g of MAML1, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment can block Notch signalling in a concentration dependent manner.
- T-ALL cell lines RPM 8402, HPBALL, KOPTK1 and pancreatic cancer cell line PANC1 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (l3) were treated with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (l3) for 24 hours.
- the effect on Notch signalling was determined by measuring the expression levels of Notch target genes.
- RAJI cell lines with no known Notch imitations were used as a control (data not shown).
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT treatment induced a significant proliferation block in T-ALL cell lines RPMI 8402, KOPTK1 and pancreatic cancer line PANC1.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) significantly inhibited the growth of nRas driven melanoma cell lines ( FIG. 4 ).
- neither DAPT nor 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) had any effect on the proliferation of Notch-independent RAJI cells (data not shown).
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) can block NICD mediated activation of the Notch pathway ( FIGS. 1A-D ).
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) can also induce a proliferation block in NICD overexpressing cells
- the human T-ALL cell line DND41 DND41-Parental
- a NICD expressing lentivirus to generate DND41-NICD cell line.
- DND41-parental cell line with DAPT and 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) led to a downregulation of Hes1 when compared to DMSO treated cells.
- DND41-NICD cells were treated with DMSO, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT, only 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), but not DAPT treatment caused a downregulation of Hes1 ( FIG. 5A ).
- HCC1187 human breast cancer cell lines was treated with this compound.
- HCC1187 cell line harbors a SECC22B-Notch2 chromosomal translocation, thus generating constitutively active form of N2-ICD ( FIG. 5D ).
- HCC1187 cell lines do not respond to ⁇ -secretase inhibitors such as DAPT.
- FIG. 5E while DAPT treatment did not inhibit proliferation of HCC1187 cell lines, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment significantly induced a proliferation block in these cell line.
- inhibition of Notch signalling using ⁇ -secretase inhibitors has been shown to induce G0/G1 cell cycle arrest in human TALL cell lines.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment induces significant apoptosis in RPMI8402, CUTL1, KOPTK1, TALL1 and HPB ALL.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine induces apoptosis in human breast cancer cell line HCC1187 ( FIG. 6C ).
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) induces an arrest in the G0/G1 phase of the cell cycle, a phenotype normally observed due to inhibition of Notch signalling.
- C2C12 myoblast differentiation was used as a functional assay.
- the Notch pathway activation in C2C12 myoblasts retains them in an undifferentiated state, while abrogation of Notch signalling induces their differentiation.
- C2C12 myoblasts were treated with DMSO, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT and grown to 100% confluency for 3 days. After three days, cells were fixed and stained with antibodies against Myosin Heavy Chain (MHC) protein. Cell nuclei were counterstained with DAPI.
- MHC Myosin Heavy Chain
- C2C12 myoblasts grown in the presence of 10% serum (growth medium) maintain their undifferentiated state, while the cells treated with DAPT and 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) started to differentiate into multinucleated MHC positive myotubes (data not shown).
- a plasmid encoding for ⁇ -catenin was co-transfected into HeLa cells.
- the co-transfected cells were incubated in the presence or absence of the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) chemical compound.
- Transient introduction of ⁇ -catenin leads to an upregulation of Wnt signalling as measured by ⁇ -catenin-TCF/LEF driven luciferase activity.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment of cells with activated Wnt signalling does not block the Wnt pathway activation (data not shown).
- Hedgehog signalling was activated in HeLa cells by introducing the Gli1 transcription factor and pathway activation was monitored using a promoter sequence containing Gli1 binding sites driving the luciferase expression.
- the treatment of these cells with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) did not inhibit the Hedgehog signalling cascade (data not shown).
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) chemical compound may not impair other developmental pathways and might be specific for Notch signalling inhibition.
- it still needs to be determined whether the resistance of Wnt and Hedgehog signalling towards 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) is cell type specific or whether it is a general phenomenon.
- Notch signalling regulates homeostasis of several organs during development.
- Notch1 mediated pathway activation is essential for T cell development in the thymus (Radtke et al., 1999).
- the Notch1 driven T cell development does not appear to be dependent on MAML1, as the loss of MAML1 did not perturb T cell development in the mice. This could be due to a compensatory mechanism by MAML2 and MAML3 family members for the loss of MAML1 in the spleen.
- Notch2 driven signalling exclusively via MAML1 is required for MZB cell development. Genetic ablation loss of Notch2 and MAML1 cause a block in the development of MZB cells (Wu et al., 2007, Saito et al., 2003,).
- Notch signalling via both Notch1 and Notch2 is essential for the maintenance of the crypt compartment.
- mice were intra peritoneally (i.p) injected with 25 mg/kg of 6-(4-Ten-Butylphenoxy)Pyridin-3-Amine (I3) for 7 consecutive days. On day S. animals were sacrificed and intestinal tissues were fixed and embedded in paraffin.
- mice were injected for 5 consecutive days with 25 mg/kg of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and the changes in body mass were recorded.
- the treatment of mice with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) did not cause a loss in the body weight.
- 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) mediated block in MZB cell development mimics loss of Notch2 and MAML1 phenotype, however, it is still need to be seen, whether 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) exert its Notch inhibitory effect only via MAML1 or it could block Notch signalling via other MAML family members as well.
- Notch signalling due to activating mutations in different components of the pathway are known to cause more than 50% of the human T cell acute lymphoblastic leukemias. Therefore, Applicants decided to investigate the anti-cancer activity of the chemical compound 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) in Notch driven human T cell leukemia in vivo. To achieve this goal, xenotransplant models of human leukemia were established using NOD/SCID ⁇ c ⁇ / ⁇ mice. Human T-ALL cell lines HPB ALL and RPMI 8402 were used for this purpose.
- the HPB ALL cell line harbours a L1575P mutation in the heterodimerization domain and an insertion in the PEST domain of the Notch) receptor, thereby constitutively activating the Notch1 signalling.
- RPMI 8402 cells exhibit ligand independent Notch signalling activation due to an insertion at 1584 a.a residue in the heterodimerization domain and also an inactivating mutation (R465H) in the E3 ligase FBW7. Both these cells line were found to respond to 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment in in vitro culture assays in terms of proliferation and/or downregulation of the Notch target genes.
- I3 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine
- RPMI 8402 and HPB ALL cell lines were shown to develop leukemia in a xenotransplantation assay, they were transduced with a lentivirus constitutively expressing luciferase gene. This allowed Applicants to visualize and monitor the leukemia progression in the mice using the Caliper IVIS (Xenogen) live imaging detection system.
- Caliper IVIS Xenogen live imaging detection system.
- I3 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine
- mice were monitored for leukemia development by detecting luciferase expressing leukemic cells. Once the disease was established around day 15, the mice were split into two groups. One group was treated with oil as a control and the second group was treated with 25 mg/kg of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) on a daily basis. As shown in FIG. 8A , the mice treated with oil develop leukemia with 100% penetrance while leukemia in the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treated mice did not progress at the same rate as in the oil treated group ( FIG. 8A ).
- NOD/SCID ⁇ c ⁇ / ⁇ mice were transplanted with 5 ⁇ 10 5 RPMI 8402 cells and treated with oil or 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) following the establishment of the disease.
- animals treated with oil developed leukemia while 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treated mice were free of the disease.
- I3 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine
- MMTV-ErbB2 mouse mammary tumors One of the characteristics of MMTV-ErbB2 mouse mammary tumors is the presence of predominantly luminal epithelial cell types. Notch signalling is known to drive luminal cell differentiation from mouse mammary stem cells. Therefore Applicants hypothesized that the activation of the Notch pathway in MMTV-ErbB2 mammary tumors may contribute towards tumorigenesis in part by favouring luminal epithelial cell differentiation. To this end, Applicants investigated the levels of Notch signalling activation in MMTV-ErbB2-IRES-Cre mammary tumors by measuring the levels of Hes1 by Western blotting. As shown in FIG.
- MMTV-ErbB2 driven mammary tumors express very high levels of Hes1 protein compared to age matched normal mammary glands.
- MMTV-ErbB2 mammary tumors were harvested from FVB mice carrying the MMTV-ErbB2 transgene. A single cell suspension was prepared and 5 ⁇ 10 5 tumor cells were injected into an empty fat pad of a recipient FVB mouse.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
Abstract
Description
- This application is a continuation of co-pending U.S. application Ser. No. 16/363,336, filed Mar. 25, 2019, now allowed, which is a continuation of U.S. application Ser. No. 15/017,986, now U.S. Pat. No. 10,274,481, issued Apr. 30, 2019, which is a continuation of U.S. application Ser. No. 14/366,917, now U.S. Pat. No. 9,296,682, issued Mar. 29, 2016, which is the National Stage of International Application No, PCT/IB2012/057622, filed Dec. 21, 2012, which claims the benefit of European Patent Application No. 11010130.0, filed Dec. 21, 2011, each of which is hereby incorporated by reference in its entirety.
- The present invention relates to the use of inhibitors of Notch signalling pathway in particular 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (CAS number 218457-67-1) and its derivatives, in the treatment and/or prevention of cancers.
- The Notch signalling pathway represents a critical component in the molecular circuits that control cell fate during development, cell survival and cell proliferation (Shih IeM, Wang T L in Cancer Res 2007;67(5):1879-82). Aberrant activation of this pathway contributes to tumorigenesis. The Notch family members are being revealed as oncogenes in an ever-increasing number of cancers. The role of Notch in human cancer has been highlighted recently by the presence of activating mutations and amplification of Notch genes in human cancer and by the demonstration that genes in the Notch signalling pathway could be potential therapeutic targets. It has become clear that one of the major therapeutic targets in the Notch pathway are the Notch receptors, in which γ-secretase inhibitors prevent the generation of the oncogenic (intracellular) domain of Notch molecules and suppress the Notch activity.
- Though significant progress has been made in dissecting the complex workings of this signalling pathway, there are verge limited options available for Notch inhibitors. However, the pioneering class of Notch inhibitors is already in clinical trials for few cancer types, such as γ-secretase inhibitors MK0752 of Merck Sharp & Dohme Corp. MK0752, and RO4929097 (Roche), a synthetic small molecule, inhibits the Notch signalling pathway, which may result in induction of growth arrest and apoptosis in tumor cells in which the Notch signalling pathway is overactivated.
- One of the drawbacks of use of γ-secretase inhibitors to block Notch signaling, as currently on the market or uner investigation, is their wide range of additional targets such as amyloid precursor protein as well as non-selectivity in blocking Notch signalling via all four ligands (Notch 1, 2,3 and 4). Due to their ability to block Notch signalling via all four receptors γ-secretase inhibitors are known to cause goblet cell metaplasia in the intestine. In addition, some of the hematological malignancies and solid tumors harbor mutations in the Notch receptors (such as chromosomal translocation) resulting in constitutive expression of dominant active form of NICD independent of cleavage by γ-secretase complex. Therefore these tumors fail to respond to γ-secretase inhibitors treatment.
- Therefore, there is still a need to identify and develop further specific and selective inhibitors of Notch signalling pathway useful for treating and/or preventing cancers.
- The present invention concerns an 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of Formula I
- or one of its derivatives having Notch signalling pathway inhibition properties, salts, solvates, tautomers, isomers thereof for use in the treatment and/or prevention of a cancer.
- A further object of the present invention is to provide a pharmaceutical composition comprising pharmaceutical composition comprising 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of Formula I, or one of its derivatives having Notch signalling pathway inhibition properties, or pharmaceutically acceptable salts, solvates, tautomers, isomers thereof, and a pharmaceutically acceptable carrier.
- The invention also contemplates a kit comprising one or more doses of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), or one of its derivatives having Notch signalling pathway inhibition properties, for use in a method for treatment and/or prevention of cancer, optionally with reagents and/or instructions for use.
- A further object of the invention is to provide the use of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of Formula I or one of its derivatives having Notch signalling pathway inhibition properties, for inhibiting in vitro or in vitro the Notch signalling pathway in cells.
- Another object of the invention is to provide a method of treating a subject for Notch dependent cancer.
-
FIGS. 1A-1D show 6-(4-'Pert-Butylphenoxy)Pyridin-3-Amine (I3) (CAS number 218457-67-1) blocks NICD mediated Notch signalling activation.FIG. 1A shows N1-HeLa cells co-transfected with pcDNA3.Notch1 expression plasmid, pGL4.26-12×CSL luciferase and SV40 renilla plasmids. DL4- and N1-HeLa cells were cocultured in a 96 well plate in 1:1 ratio (20,000: 20,000 cells/well) and treated with DMSO or with 2. 5 and 10 μM of I3 and DAPT for 24 hours. The Notch pathway activation was measured by quantifying Notch signalling driven luciferase reporter assay. Treatment of DL4:N1 coculture assay with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT causes a concentration dependent decrease in Notch signalling activation.FIG. 1B shows HeLa cells transfected with NICD and treated with DMSO or with 2, 5, 10, 20 and 40 μM of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3). As a control co-cultured cells were also treated with 5, 10, 20 and 40 μM of DAPT. The pathway activation was measured using Notch driven luciferase reporter assay. 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment of NICD expressing cells led to an attenuation of the signalling , while DAPT treatment had no effect on Notch signalling activation mediated by NICD.FIG. 1C shows DL4:N1 and DL4:N2 coculture assay treated with I3 and DAPT (each 10 μM) for 24 hours. The effect of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT on DL4-N1 and DL4-N2 driven pathway activation was measured by Notch driven luciferase activity. Both I3 and DAPT treatment block Notch1 and Notch2 induced pathway activation.FIG. 1D shows 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) inhibits pathway activation via intracellular domains of Notch1 (NICD) and Notch2 (N2-ICD). -
FIG. 2 shows 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) mediated inhibition of Notch signalling can be rescued with increasing concentration of MAML1. HeLa cells were co-transfected 800 ng of NICD+3 μg of pCDNA3.1 or 800 ng of NICD+1 μg of MAML1-FLAG or 800 ng of NICD+3 μg of MAML1-FLAG expression vectors. To measure Notch pathway activation, pGL4.26-12×CSL luciferase plasmid was also introduced into the cells. SV40 renilla was used as an internal control. Cells transfected with different combinations and amounts of plasmid were treated with DMSO or increasing concentration of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (1, 2.5, 5 and 10 μM) for 24 hours. 12×CSL driven luciferase activity was measured using dual luciferase assay system. In the absence of MAML1, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) could block Notch signalling activations, but Notch inhibitory effect of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was diminished with increasing amount of MAML1. -
FIGS. 3A-3E show 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) inhibits Notch signalling and downregulates its target genes in human cancer cell lines.FIG. 3A showsRPMI 8402 cells treated with DMSO, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT (10 μM) for 24 hours and analyzed for the expression of Notch target genes, Hes1, cMyc and Dtxl by qRT-PCR. Data normalized to HPRT as a house-keeping gene.FIG. 3B shows whole cell lysate from 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treated cells was analyzed by Western blot. Using antibodies against NICD (Val1744), Hes1 and cMyc, the protein levels of NICD and Notch target genes were determined.FIGS. 3C-3D show the human T-ALL cell lines HPB ALL and KOPTK1 treated with DMSO or 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) for 24 hours. Western blot analyses were performed using NICD (Val1744) and Hes1 specific antibodes. Tubulin served as a loading control.FIG. 3E shows whole cell lysate from DMSO, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treated PANC1 cells (pancreatic cancer cell line) analyzed by Western blot. Hes1 protein levels were determined using Hes1 specific antibodies. Statistical analyses were done using student's two-tailed t.test. *=p value<0.05. -
FIG. 4 shows 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) induces a proliferative block in human cancer cells. Human T-ALLcell lines RPMI 8402 and KOPTK1, and pancreatic cancer cell line PANC1 as well as nRas driven melanoma cells were seeded in a 96 well plate and treated with 10 μM concentration of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT for several days. Their growth inhibitory effects were compared with cells treated with equal amount of DMSO. Using Alamar blue assay, the growth kinetics ofRPMI 8402 and KOPTK1 were followed for upto 6 days, while PANC1 and nRas melanoma cells were monitored for 4 days. 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment ofRP1141 8402, KOPTK1. PANC1 and nRas melanoma cells caused a significant reduction in their growth potential. Statistical analyses were done using student's t.test. *=p value<0.05. ns=not significant. -
FIGS. 5A-5E show 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) blocks NICD dependent growth of human cancer cells.FIG. 5A shows DND41-Parental and DND41-NICD cells were treated with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT for 24 hours. Western blot analyses were carried out for Hes1 protein using Hes1 specific antibodies. Both DAPT and 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) caused a downregulation of Hes1 in DND41-Parental cells. DND41-NICD cells showed a downregulation of Hes1 only when treated with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3).FIG. 5B shows five thousand DND41-Parental cells were seeded and treated with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT in a 96 well plate. Growth kinetics of the parental cell line was followed over 5 days using Alamar blue readout. Treatment of DND41-Parental cell line with both 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT caused a proliferation arrest. Simarly,FIG. 5C shows DND4I-NICD cells treated with DMSO, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT and their growth kinetics were monitored using Alamar blue readout over 5 days. The treatment of DND41-NICD cells with DAPT did not have a significant impact on their proliferation, while 6-(4-Tell-Butylphenoxy)Pyridin-3-Amine (I3) treatment induced a proliferation arrest.FIG. 5D shows human breast cancer cell line HCC1187 harbors a SEC22B-Notch2 chromosomal translocation, thus leading to an expression of constitutively active form of NICD independent of cleavage by the γ-secretase complex. This mutation renders this cell line insensitive to γ-secretase inhibitor treatment,FIG. 5E shows two thousand HCC1187 cells were seeded per well in a 96 well plate. The cells were treated with DMSO, γ-secretase inhibitor DAPT and I3 for 6 days. Alamar blue readout was taken atday 0,day 2,day 4 andday 6. Eight replicates were used for each treatment and time point. The treatment of HCC1187 human breast cancer cell line with γ-secretase inhibitor DAPT did not alter the growth kinetics when compared to DMSO treated counterparts, while I3 treatment caused statistically significant inhibition of cell proliferation. P values were calculated using Student's t.test. *=p value<0.05. ns=not significant. -
FIGS. 6A-6D show 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) induces G0/G1 cell cycle arrest and apoptosis in human T cell acute lymphoblastic leukemia cell lines and human breast cancer cell line HCC1187.FIG. 6A shows human leukemic cell lines (RPIMI8402, CUTL1, KOPTK1, TALL1 and HPBALL) were treated with I3 (10 μM). Percentage of Annexin V positive (apoptotic) cell population was measured using flow cytometry.FIG. 6B shows cell cycle analyses: RPMI8402, KOPTK1 and TALL1 cell lines were treated with I3 (10 μM) and stained with Ki67 and Hoechst stain to determine cell cycle status. The cell cycle analyses suggest that I3 treatment causes 20-30% increase in cells arrested in G0/G1 phase of the cell cycle.FIG. 6C shows HCC1187 cells were treated with DMSO or 10 μM of I3 and percentage of apoptotic population was measured using Annexin V stain.FIG. 6D shows I3 treated HCC1187 cells analyzed for cell cycle status. Ki67 and Hoechst stain revealed that I3 induces G0/G1 arrest in HCC1187 cells. -
FIGS. 7A-7C show 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) mimics genetic loss of Notch2 signalling phenotype in the spleen. Loss of Notch signalling in the spleen leads to a reduction in Marginal Zone B cells (MZB) cells in the spleen.FIG. 7A shows schematics of the experimental plan.FIG. 7B shows Mice (n=2) were treated with oil or 25 mg/kg of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) for 7 consecutive days. Spleens were analyzed onday 8. Using B220 specific antibodies, B cells in the spleen were identified. MZB cells within the B cell compartment were detected using antibodies against CD23 and CD21 cell surface markers. The treatment of mice with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) causes a significant reduction in the percentage of MZB cells in the spleen.FIG. 7C shows that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment causes a reduction in the absolute numbers of MZB cells in the spleen when compared to vehicle treated animals. -
FIGS. 8A-8B show 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment increases latency of leukemia development in mice.FIG. 8A shows NOD/SCID γc−/− mice were injected with 1×106 HPB ALL (luciferase expressing) cells. Onday 15, leukemic cells were established in the bone marrow. Mice were treated with oil or 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) for every day, Mice were imaged onday 27 using Caliper IVIS (Xenogen) live imaging system. Red and blue colour indicates the intensity of luciferase signal and correlates with the number of leukemic cells.FIG. 5B shows 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment blocksRPMI 8402 leukemic cell growth in xenotransplantation assay. NOD/SCID γc−/− mice were transplanted with 5×105 RPMI 8402 (luciferase expressing) cells, Leukemia development was followed using Caliper IVIS (Xenogen) live imaging system. Onday 13, a daily treatment was started using oil (n=3) or 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (n=4). Animals were treated for 27 days (end point of the experiment). -
FIGS. 9A-9B show 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment blocks MMTV-ErbB2 mouse mammary tumors.FIG. 9A shows Hes1 protein expression levels in MMTV-ErbB2 mammary tumors and normal age matched mammary glands (M.G) were compared using Anti-Hes1 antibody. Western blot analyses showed a very high expression of Hes1 protein in MMTV-ErbB2 mammary tumors. Tubulin served as a loading control.FIG. 9B shows a single cell suspension of MMTV-ErbB2 mammary tumor was prepared and 1×106 cells were injected into the cleared fat pad of recipient FVB mice, Tumor formation was monitored on a regular basis. Once the tumor developed to a volume of 100-300 mm3′ mice were treated with oil (n=2) or 25 mg/kg of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (n=2). Tumor volume was measured every 6-7 days. Mice treated with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) exhibited a slow tumor progression compared to oil treated mice. -
FIG. 10 shows Notch inhibitory activity of chemical derivatives of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3). Different chemical derivatives of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) were tested in DL4-N1 coculture assay and Notch activity levels were measured using Notch driven luciferase reporter gene. Derivatives I3-A, I3-B, I3-C, I3-E, I3-G, I3-H, I3-M and I3-N exhibit anti-Notch activity comparable to 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), while derivatives I3-F and I3-I appear to have enhanced activity. - Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. The publications and applications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.
- In the case of conflict, the present specification, including definitions, will control. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in art to which the subject matter herein belongs. As used herein, the following definitions are supplied in order to facilitate the understanding of the present invention.
- As used herein, the term “comprise/comprising” is generally used in the sense of include/including, that is to say permitting the presence of one or more features or components. The terms “comprise” and “comprising” also encompass the more restricted ones “consist” and “consisting”.
- As used in the specification and claims, the singular form “a”, “an” and “the” include plural references unless the context clearly dictates otherwise.
- For the reading, the term “compound(s) of the invention” or “compound(s) according to the invention” used throughout the description refers to the compound 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (CAS number 218457-67-1), derivatives of said I3, salts or solvates of the compound I3 or of the derivatives, and to isomers, including enantiomers, stereoisomers, rotamers, tautomers and racemates of the compound I3, chemical modified I3 compounds and derivatives of said I3 compounds.
- As used herein the terms “subject” is well-recognized in the art, and, refers to a mammal, including dog, cat, rat, mouse, monkey, cow, horse, goat, sheep, pig, camel, and, most preferably, a human. In some embodiments, the subject is a subject in need of treatment or a subject with a disease or disorder, such as cancer. However, in other embodiments, the subject can be a normal subject or a subject who has already undergone a treatment against cancer. The term does not denote a particular age or sex. Thus, adult, children and newborn subjects, whether male or female, are intended to be covered.
- The terms “cancer”, “cancer cells”, “cell proliferative diseases” and “cell proliferative disorders” as used herein refer to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth. According to the present invention, cancer refers preferably to solid tumors, such as brain, breast, prostate, colorectum, kidney, lung, sarcoma, or melanoma and liquid tumors, affecting the blood, such as leukemia. More preferably according to the present invention, cancers are Notch dependent cancers selected from the group comprising T cell-Acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), Mantle cell lymphoma, breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumors, tumor angiogenesis, colorectal cancer. Alternatively, the Notch dependent cancer is resistant to γ-secretase inhibitor treatment. Examples of γ-secretase inhibitor treatment comprise 1) Gamma secretase inhibitor RO4929097 and Cediranib Maleate in treating patients with advanced solid tumors (NCT01131234), 2) Gamma-Secretase Inhibitor RO04929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia (NCT01088763), 3) Study of MK-0752 in combination with Tamoxifen or Letrozole to treat early stage breast cancer (NCT00756717), 4) GDC-0449 and RO4929097 in treating patients with Advances or metastatic sarcoma (NCT01154452) 5) RO4929097 and Erlotinib Hydrochloride in treating patients with stage IV or recurrent Non-Small Cell Lung Cancer (NCT01193881), 6) Bicalutamide and RO4929097 in treating patients with previously treated prostate cancer (NCT01200810), 7) RO4929097 in treating patients with recurrent invasive Gliomas (NCT01269411), 8) A Notch signaling pathway inhibitor for patients with T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL) (NCT00100152) and 9) RO4929097 in treating patients with metastatic colorectal cancer (NCT01116687).
- The Notch signalling pathway is evolutionarily conserved and the basic molecular players in this pathway are ligands (Delta and Jagged), Notch receptors, and the transcription factors (Shih IeM, Wang TL in Cancer Res 2007;67(5): 1879-82). Notch is a transmembrane heterodimeric receptor and there are four distinct members (Notch1, Notch2, Notch3 and Notch4) in humans and rodents. In a physiologic condition, binding of the Notch ligand to its receptor initiates Notch signalling by releasing the intracellular domain of the Notch receptor (Notch-ICD) through a cascade of proteolytic cleavages by both α-secretase (also called tumor necrosis factor-α-converting enzyme) and γ-secretase. The released intracellular Notch-ICD then translocates into the nucleus where it modulates gene expression primarily by binding to a ubiquitous transcription factor. CBF1, suppressor of hairless, Lag-1 (CSL). This binding recruits transcription activators to the CSL complex and converts it from a transcriptional repressor into an activator, which turns on several downstream effectors. The physiologic functions of Notch signalling are multifaceted, including maintenance of stem cells, specification of cell fate, and regulation of differentiation in development as well as in oncogenesis.
- In cancers, molecular genetic alterations, such as chromosomal translocation, point mutations, and chromosomal amplification at the Notch receptor loci, are the known mechanisms for constitutive activation of Notch pathway. Despite the different mechanisms, they all result in increased levels of intracellular Notch-IC. The oncogenic potential of Notch was first discovered in human T-cell acute lymphoblastic leukemia (T-ALL). While Notch1 signalling is essential for normal development of T-cell progenitors, constitutive activation of Notch1 signalling due to molecular genetic alterations is associated with T-ALL. For example, interstitial deletions of the extracellular portion of human Notch1 due to (7;9) chromosomal translocation are associated with ˜1% of T-ALL cases and activating point mutations of Notch1are present in about 50% of T-ALL cases, Formation of T-cell leukemia/lymphoma was observed in a Notch-ICD transgenic mouse model, which indicates a causal role of Notch activation in T-ALL development. In non-small cell lung cancer, chromosomal translocation (15;19) has been identified in a subset of tumors, and the translocation is thought to elevate Notch3 transcription in tumors. In ovarian cancer, Notch3 gene amplification was found to occur in about 19% of tumors, and overexpression of Notch3 was found in more than half of the ovarian serous carcinomas. Similarly, Notch signalling activation has been shown in the development of breast cancer. In animal models, constitutively active Notch4 expression causes mammary tumors in mice and Notch1-activating mutations contribute to the development of T-ALL. A recent study further shows that overexpression of activated Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mouse breast tumors. Notch signalling activation has also been implicated in lung and bone metastasis of breast cancer cells. Overexpression of Notch3 is sufficient to induce choroid plexus tumor formation in a mouse model, suggesting a role of Notch3 in the development of certain types of brain tumors.
- With the aim of conducting a High-Through put Screening (HTS) to identify novel modulators (inhibitors) of Notch signalling, Applicants have established a coculture assay to induce a ligand-receptor mediated activation of the pathway. The coculture assay was established using Notch ligand DL4 and
Notch 1 receptor specifically, because DL4-N1 ligand-receptor mediated pathway activation plays an important role in pathophysiological conditions such as tumor angiogenesis and the role of Notch1 receptor in inducing T cell leukemia. Since this assay depends on the expression and interaction between DL4 ligand and. Notch1 receptor, it provides an opportunity to interrogate ligand-receptor interactions-induced Notch signalling in a controlled manner. The miniaturization of this assay into a 96 well plate and 384 well plate format helped Applicants to adapt this assay to conduct HTS. The use of this coculture assay to screen siRNA or small molecule libraries can lead to the identification of proteins or chemical compounds that are able to modulate Notch signalling at different steps along the pathway. For example, a HTS using siRNA or small molecule libraries can yield modulators of the pathway able to act in the signal sending or signal receiving cells. Small molecule or protein mediated alterations in the recycling or trafficking of the ligands and receptors to the plasma membrane can potentially block the Notch pathway and could be studied using this assay. In addition, this assay can also help identify proteins or chemical entities able to block ligand-receptor interactions, ADAM10/17 mediated S2 cleavage or γ-secretase catalyzed S3 cleavage of the Notch receptor, nuclear translocation of the active form of Notch or entities able to block transcriptional activation complex. - Applicants have also been able to screen three different chemical compound libraries (Microsource NIMDS, Prestwick and Maybridge Hit finder) that have led to the identification of several chemicals, which are able to block Notch signalling at different levels along the pathway.
- The use of the Notch-independent renilla system as an internal control allowed Applicants to eliminate cytotoxic chemical compounds, thereby limiting the rate of false positive hits. In addition, this cell-based assay also helped to circumvent issues related to the cell permeability of the chemical compounds for further hit validation.
- The development of DL4:N1 coculture assay system laid the foundation for a HTS campaign. This assay provided a robust and sensitive readout system to identify novel modulators (inhibitors) of the Notch pathway.
- Applicants identified several chemical compounds for their ability to block the Notch pathway activation. Among those, they identified the compound 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (CAS number 218457-67-1) for its ability to block the Notch pathway activation.
- Thus, the present invention relates to 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of Formula I
- for use in the treatment and/or prevention of a cancer.
- The present invention also encompasses chemical modifications of the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (CAS number: 218457-67-1) to prolong their circulating lifetimes. Non-limiting examples of methods for transiently, or reversibly, pegylating drugs, including polypeptide-based drugs, are provided in U.S. Pat. Nos. 4,935,465 (issued in Jun. 19, 1990) and 6,342,244 (issued Jan. 29, 2002); and in U.S. published applications number US2006/0074024. One skilled in the art would typically find more details about PEG-based reagents in, for example, published applications WO2005047366. US2005171328, and those listed on the NEKTAR PEG Reagent Catalog® 2005-2006 (Nektar Therapeutics, San Carlos, Calif).
- The present invention further encompasses chemical derivatives of said I3 having Notch signalling pathway inhibition properties. Applicants have shown that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and its derivatives target Notch signalling at the transcriptional activation complex in the nucleus, human tumors resistant to γ-secretase inhibitors due to above mentioned mutations are expected to respond to 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment. In addition, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) appears to selectively target Notch signalling thus limiting its off-target toxic effects.
- These derivatives all share the follow common structure:
- Preferably, in said derivatives X is O and position 3 (or pain) is NH2.
- Most preferably, the derivative having Notch signalling pathway inhibition properties is selected from the non-limiting group comprising
- wherein m is an integer selected from 1 to 4;
- W is selected from H and halogens; the halogen is selected from F—, Cl—, Br— or
- R1, R2, R3, R4 are each independently selected from the group consisting in H, phenyl, 2-,3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH3)nCH3 alkenyl, alkynyl; the subscript n is an integer independently selected from 1 to 15;
- X is O, S, CR5R6, NR7, NHCOR8, or NHSO2R9; where R5, R6, R7, R8, R9 are each independently selected from the group consisting in selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, or (CH2)nCH3, the subscript n is an integer independently selected from 1 to 15:
- Y is N or CH:
- Z is H, NO2, OH, NR10R11 where R10 and R11 are each independently selected from the group consisting in H and (CH2)nCH3, NHCOR12 where R12 is selected from the group consisting of (CH2)nCH3, aromatic and heteroaromatics such as phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, COOR13 where R13 is selected from the group consisting of H, (CH2)nCH3, aromatic and heteroaromatics such as phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, NHSO2R14 where R14 is selected from the group consisting of phenyl, 2-, 3- or 4, substituted phenyl, naphthyl, heteroaromatics such as pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, (CH2)nCH3; the subscript n is an integer independently selected from 1 to 15;
- wherein in is an integer selected from 1 to 4;
- W is selected from H and halogens; the halogen is selected from F—, Cl—, Br— or I—;
- R4, R15 are each independently selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3 alkenyl, alkynyl; the subscript n is an integer independently selected from 1 to 15;
- X is O, S, CR5R6, NR7, NHCOR8 or NHSO2R9; R5, R6 and R7 are each independently selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3; R8 and R9 are each independently selected from the group consisting in phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, or heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, (CH2)nCH3; the subscript n is an integer independently selected from 1 to 15;
- Y is N or CH;
- Z is FL, NO2, OH, NR10R11 where R10 and R11 are each independently selected from the group consisting in H, (CH2)nCH3, NHCOR12 where R12 is (CH2)nCH3, aromatic and heteroaromatics selected from the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, COOR13 where R13 is H, (CH2)nCH3, aromatic and heteroaromatics selected from the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, NHSO2R14 where R14 is phenyl, 2-, 3- or 4, substituted phenyl, naphthyl, heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, (CH2)nCH3, the subscript n is an integer independently selected from 1 to 15;
- wherein in is an integer selected from 1 to 4;
- W is selected from H and halogens; the halogen is selected from F—, Cl—, Br— or I—;
- R4 is H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3 alkenyl, alkynyl, the subscript n is an integer independently selected from 1 to 15;
- X is O, S, CR5R6, NR7, NHCOR8 or NHSO2R9; R5, R6 and R7 are each independently selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3; R8 and R9 are each independently selected from the group consisting in phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, or heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, (CH2)nCH3; the subscript n is an integer independently selected from 1 to 15;
- Y is N or CH;
- Z is H, NO2, OH, NR10R11 where R10 and R11 are each independently selected from the go up consisting in H, (CH2)nCH3, NHCOR12 where R12 is (CH2)nCH5, aromatic and heteroaromatics selected from the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, COOR13 where R13 is H, (CH2)nCH3, aromatic and heteroaromatics selected from the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, NHSO2R14 where R14 is phenyl, 2-, 3- or 4, substituted phenyl, naphthyl, heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, (CH2)nCH3, the subscript n an integer independently selected from 1 to 15;
- wherein m is an integer selected from 1 to 4;
- W is selected from H and halogens; the halogen is selected from F—, Cl—, Br— or I—,
- R1, R2, R3, R4 are each independently selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3 alkenyl, alkynyl; the subscript n is an integer independently selected
front 1 to 15; - X is O, S, CR5R6, NR7, NHCOR8 or NHSO2R9; R5, R6 and R7 are each independently selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3; R8 and R9 are each independently selected from the group consisting in phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, (CH2)nCH3; the subscript n is an integer independently selected from 1 to 15;
- Z is H, NO2, OH, NR10R11 where R10 and R11 are each independently selected from the group consisting in H, (CH2)nCH3, NHCOR12 where R12 is (CH2)nCH3, aromatic and heteroaromatics selected form the group comprising phenyl, naphthyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, COOR13 where R13 is H, (CH2)nCH3, aromatic and heteroaromatics selected from the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, NHSO2R14 with R14 is phenyl, 2-, 3- or 4, substituted phenyl, naphthyl, heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, (CH2)nCH3; the subscript n is an integer independently selected from 1 to 15;
- wherein m is an integer selected from 1 to 4;
- W is selected from and halogens; the halogen is selected from F—, Cl—, Br— or
- R4, R15 are each independently selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3 alkenyl, alkynyl; the subscript n is an integer independently selected from 0 to 15;
- X is O, S, CR5R6, NR7, NHCOR8 or NHSO2R9; R5, R6 and R7 are each independently selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3; R8 and R9 are each independently selected from the group consisting in phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, or heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, (CH2)nCH3, the subscript n is an integer independently selected from 0 to 15;
- Z is H, NO2, OH, NR10R11 where R10 and R11 are each independently selected from the group consisting in H, (CH2)nCH3, NHCOR12 where R12 is (CH2)nCH3, aromatic and heteroaromatics selected form the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, COOR13 where R13 is H, (CH2)nCH3, aromatic and heteroaromatics selected from the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, NHSO2R14 with R14 is phenyl, 2-, 3- or 4, substituted phenyl, naphthyl, heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, (CH2)nCH3; the subscript n is an integer independently selected from 0 to 15;
- wherein m is an integer selected from 1 to 3;
- W is selected from H and halogens; the halogen is selected from F—, Cl—, Br— or I—;
- R4 is H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3 alkenyl, alkynyl; the subscript n is an integer independently selected from 0 to 15;
- X is O, S, CR5R6, NR7, NHCOR8 or NHSO2R9; R5, R6 and R7 are each independently selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3; R8 and R9 are each independently selected from the group consisting in phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, or heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, (CH2)nCH3; the subscript n is an integer independently selected from 0 to 15;
- Z is H, NO2, OH, NR10R11 where R10 and R11 are each independently selected from the group consisting in H, (CH2)nCH3, NHCOR12 where R12 is (CH2)nCH3, aromatic and heteroaromatics selected form the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, COOR13 where R13 is H, (CH2)nCH3, aromatic and heteroaromatics selected from the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, NHSO2R14 with R14 is phenyl, 2-,
3or 4, substituted phenyl, naphthyl, heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, (CH2)nCH3; the subscript n is an integer independently selected from 0 to 15; - wherein the heteroaromatic is a aminopyrrole, aminofurane, aminothiofurane, or a pyrimidine:
- R1, R2, R3, R4 are each independently selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3 alkenyl, alkynyl; the subscript n is an integer independently selected from 0 to 15:
- X is O, S, CR5R6, NR7, NHCORS, or NHSO2R9; where R5, R6, R7, R8, R9 are each independently selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, imidazolyl, benzyl, isoPropyl, tertButyl, or (CH2)nCH3 , the subscript n is an integer independently selected from 0 to 15;
- Z is H, NO2, OH, NR10R11 where R10 and R11 are each independently selected from the group consisting in H, (CH2)nCH3, NHCOR12 where R12 is (CH2)nCH3, aromatic and heteroaromatics selected form the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, COOR13 where R13 is H, (CH2)nCH3, aromatic and heteroaromatics selected from the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, NHSO2R14 with R14 is phenyl, 2-, 3 or 4, substituted phenyl, naphthyl, heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, (CH2)nCH3; the subscript n is an integer independently selected from 0 to 15;
- wherein the subscript n is an integer independently selected from 1 to 15;
-
- the heteroaromatic is an aminopyrrole, aminofurane, aminothiofurane, or a pyrimidine;
- R4, R15 are each independently selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3 alkenyl, alkynyl; the subscript n is an integer independently selected from 0 to 15;
- X is O, S, CR5R6, NR7, NHCOR8 or NHSO2R9; R5, R6 and R7 are each independently selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3; R8 and R9 are each independently selected from the group consisting in phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, or heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, imidazolyl, benzyl, (CH2)nCH3, the subscript n is an integer independently selected from 0 to 15;
- Z is H, NO2, OH, NR10R11 where R10 and R11 are each independently selected from the group consisting in H, (CH2)nCH3, NHCOR12 where R12 is (CH2)nCH3, aromatic and heteroaromatics selected form the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, COOR13 where R13 is H, (CH2)nCH3, aromatic and heteroaromatics selected from the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, NHSO2R14 with R14 is phenyl, 2-, 3- or 4, substituted phenyl, naphthyl, heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, (CH2)nCH3; the subscript n is an integer independently selected from 0 to 15;
- wherein the heteroaromatic is an aminopyrrole, aminofurane, aminothiofurane, or a pyrimidine;
- R4 is H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3 alkenyl, alkynyl; the subscript n is an integer independently selected from 0 to 15;
- X is O, S, CR5R6, NR7, NHCOR8 or NHSO2R9; R5, R6 and R7 are each independently selected from the group consisting in H, phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, isoPropyl, tertButyl, (CH2)nCH3; R8 and R9 are each independently selected from the group consisting in phenyl, 2-, 3- or 4-substituted phenyl, 2- or 3-naphthyl, or heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, benzyl, (CH2)nCH3, the subscript n is an integer independently selected from 0 to 15;
- Z is H, NO2, OH, NR10R11 where R10 and R11 are each independently selected from the group consisting in H, (CH2)nCH3, NHCOR12 where R12 is (CH2)nCH3, aromatic and heteroaromatics selected form the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, COOR13 where R13 is H, (CH2)nCH3, aromatic and heteroaromatics selected from the group comprising phenyl, naphthyl, pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl, NHSO2R14 with R14 is phenyl, 2-, 3- or 4, substituted phenyl, naphthyl, heteroaromatics selected from the group comprising pyrrolyl, furanyl, thiofuranyl, pyrimidinyl, imidazolyl benzyl, (CH2)nCH3; the subscript n is an integer independently selected from 0 to 15;
Even more preferably, the derivative having Notch signalling pathway inhibition properties is selected from the group consisting in - The invention also relates to salts or solvates of the compound I3, chemical modified I3 compounds and derivatives of said I3 compounds of the invention. Preferably, these salts and/or solvates are pharmaceutically acceptable. According to the present invention, pharmaceutically acceptable salts are produced from acidic inorganic or organic compounds, or alkaline inorganic or organic compounds. As used herein, the phrase “pharmaceutically acceptable salt” refers to a salt that retains the biological effectiveness of the free acids and bases of a specified compound and that is not biologically or otherwise undesirable.
- Unless specified otherwise, it is further understood that all isomers, including enantiomers, stereoisomers, rotamers, tautomers and racemates of the compound I3, chemical modified I3 compounds and derivatives of said I3 compounds of the invention are contemplated as being part of this invention. The invention includes stereoisomers in optically pure form and in admixture, including racemic mixtures. Isomers can be prepared using conventional techniques, either by reacting optically pure or optically enriched starting materials or by separating isomers of compounds of the present invention.
- “Racemates” refers to a mixture of enantiomers.
- “Stereoisomer” or “stereoisomers” refer to compounds that differ in the chirality of one or more stereocentres. Stereoisomers include enantiomers and diastereomers. The compound I3, chemical modified I3 compounds and derivatives of said I3 compounds of this invention may exist in stereoisomeric form if they possess one or more asymmetric centres or a double bond with asymmetric substitution and, therefore, can be produced as individual stereoisomers or as mixtures. Unless otherwise indicated, the description is intended to include individual stereoisomers as well as mixtures. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (see discussion in
Chapter 4 of Advanced Organic Chemistry, 4th ed., J. March, John Wiley and Sons, New York, 1992). - “Tautomer” refers to alternate forms of a compound that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or the tautomeric forms of heteroaryl groups containing a ring atom attached to both a ring —NH— moiety and a ring ═N-moiety such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.
- A skilled person will know that, if compound I3, chemical modified I3 compounds and derivatives of said I3 compounds of the invention contain charged group, a suitable counterion will be derived from an organic or inorganic acid. Such counterions include halide (such as chloride, bromide, fluoride, iodide), sulfate, phosphate, acetate, succinate, citrate, lactate, maleate, fumarate, palmitate, cholate, glutamate, glutarate, tartrate, stearate, salicylate, methanesulfonate, benzenesulfonate, sorbate, picrate, benzoate, cinnamate, and the like. If the polar moiety is a negatively charged group, a suitable counterion will be selected from sodium, ammonium, barium, calcium, copper, iron, lithium, potassium and zinc, and the like.
- Surprisingly, the chemical compound 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was identified as a potential Notch inhibitor. Interestingly, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was found to block NICD mediated pathway activation (
FIGS. 1A-D ). Because of its ability to attenuate NICD mediated Notch activation, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) is able to block proliferation of NICD overexpressing leukemic cell lines which are resistant to DAPT (a-γ-secretase inhibitor, N-[N-(3,5-difluorophenacetyl-Lalanyl)]-(S)-phenylglycine t-butyl ester) (FIGS. 5A-E ). The Notch inhibitory potential of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was further confirmed by the downregulation of Notch target genes in human T-ALL cell lines (FIGS. 3A-E ) and Affymetrix geneChip array (data not shown). The fact that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) can induce differentiation of C2C12 cells into MHC expressing multinucleated myotubes further validated the anti-Notch role of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (data not shown). The Notch pathway inhibition caused by 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) can be rescued by the overexpression of MAML1 above certain levels. For example, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was able to block the signalling with 800 ng of NICD and 1 μg of MAML1 was transiently introduced into the cells, however when the amount of MAML1 was increased to 3 μg, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was no longer able to block the pathway activation (FIG. 2 ). These data suggest that, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) may interfere with the Notch transcriptional activation complex thereby inhibiting the signalling activation. Microscopic studies by introduction of MAML at levels where 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) could still block the pathway activation showed that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment does not impede co-localization of NICD, MAML1 and CSL/RBP-jk in the sub-nuclear compartments (data not shown). Without being bound to theory, one of the possible mechanisms of action of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) could be to disrupt the recruitment of transcriptional coactivators to the core CSL/RBP-jk-NICD-MAML1 complex. Therefore, the status of additional coactivators involved in the formation of functional transcriptional activation complex still needs to be determined. Under physiological conditions, following the formation of CSL/RBP-jk-NICD-MAML1 complex, CBP/p300 histone acetyltransferase (HAT) is recruited to the complex leading to its autoacetylation and acetylation ofhistone - 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), as well as derivatives thereof, were further investigated in an in vivo context to determine their Notch inhibitory as well as toxic side effects in the mice. Notch signalling is essential for the maintenance of normal homoeostasis in the intestine. Genetic ablation or pharmacological inhibition of Notch1 and Notch2 signalling in the intestine leads to goblet cell metaplasia in the intestine. Since, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) has been observed to block Notch1 and Notch2 mediated signalling, mice treated with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) were expected to develop goblet cell metaplasia. Surprisingly, treatment of mice with 25 mg/kg of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) for 7 days (more than a month in case of xenotransplants) did not perturb intestinal homeostasis and without any indication of goblet cell accumulation (data not shown). This unexpected outcome could be due to two reasons. One possible explanation could be that the concentration of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (25 mg/kg) used is not sufficient to block Notch pathway activation in the intestine. However, a second more plausible explanation could be the differences in the composition of transcriptional activation complexes downstream of Notch1 and Notch2 signalling. Due to these possible differences, Notch1 and Notch2 mediated signalling may have different sensitivities against 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment,
- Notch signalling plays an important role in the regulation of hematopoietic system. For instance, DL4-Notch1 signalling is essential for T cell development in the thymus. Notch2 and MAML1 mediated pathway activation is critical for Marginal Zone B (MZB) cells development in the spleen. To address whether 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) can impair Notch dependent MZB cell development in the spleen, C57Bl6 mice were treated with 25 mg/kg of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) for 7 days and analyzed on
day 8. Flow cytometry analyses using antibodies against B220, CD21 and CD23 revealed that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment causes a reduction the percentage and absolute numbers of MZB cells in the spleen (FIGS. 7A-C ). - Anti-cancer activity of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was investigated in transplant models for human diseases, namely T-cell leukemia and breast cancer. In these studies, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) has demonstrated a remarkable ability to slow down the progression and metastasis of very aggressive form of leukemic cell lines (
FIGS. 8A-B ). In addition, in a preliminary study using breast cancer as a model of solid tumors, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment has led to a block in tumor progression in the mice (FIGS. 9A-B ). - The chemical compound 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) has shown ability to block NICD mediated signalling Therefore this compound is useful in cancers where Notch driven tumors are resistant to γ-secretase inhibitor treatment.
- The present invention also provides a pharmaceutical composition comprising 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of formula I, or one of its derivatives having Notch signalling pathway inhibition properties as described herein, or pharmaceutically acceptable salts, solvates, tautomers, isomers thereof, and a pharmaceutically acceptable carrier. As to the appropriate carriers, reference may be made to the standard literature describing these, e.g. to chapter 25.2 of Vol. 5 of “Comprehensive Medicinal Chemistry”, Pergamon Press 1990, and to “Lexikon der Hilfsstoffe für Pharmazie, Kosmetik and angrenzende Gebiete”, by H. P. Fiedler, Editio Cantor, 2002. The term “pharmaceutically acceptable carrier” means a carrier or excipient that is useful in preparing a pharmaceutical composition that is generally safe, and possesses acceptable toxicities. Acceptable carriers include those that are acceptable for veterinary use as well as human pharmaceutical use. A “pharmaceutically acceptable carrier” as used in the specification and claims includes both one and more than one such carrier.
- Optionally, the pharmaceutical composition of the present invention further comprises one or more additional active agents selected among the non limiting group comprising chemotherapeutic agents for treating cancer. Such chemotherapeutic agents may be selected among the group comprising, for example, Altretamine, Bleomycin, Busulphan, Capecitabine, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Crisantaspase, Cyclophosphamid, Cytarabine, Dacarbazine, Daunorubicin, Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Idarubicin, Ifosfamide, Irinotecan, Lomustine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitoxantrone, Oxaliplatin, Pentostatin, Procarbazine, Streptozocin, Taco, Temozolomide, Tioguanine/Thioguanine, Thiotepa, Topotecan, Treosulfan, Vincristine, Vindesine and Vinorelbine.
- The compounds of the invention, namely the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and derivatives thereof, that are used in the treatment and/or prevention of cancers can be incorporated into a variety of formulations and medicaments for therapeutic administration. More particularly, one or more compound(s) as provided herein can be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable carriers, and can be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, pills, powders, granules, dragees, gels, slurries, ointments, solutions, suppositories, injections, inhalants and aerosols. As such, administration of the compounds can be achieved in various ways, including oral, buccal, rectal, parenteral, intraperitoneal, intradermal, transdermal, intracranial and/or intratracheal administration. Moreover, the compound can be administered in a local rather than systemic manner, in a depot or sustained release formulation. The compounds can be formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated as elixirs or solutions for convenient oral administration, or administered by the intramuscular or intravenous routes. The compounds can be administered transdermally, and can be formulated as sustained release dosage firms and the like. The compounds can be administered alone, in combination with each other, or they can be used in combination with other known compounds. Suitable formulations for use in the present invention are found in Remington's Pharmaceutical Sciences (Mack Publishing Company (1985) Philadelphia, Pa., 17th ed.), which is incorporated herein by reference. Moreover, for a brief review of methods for drug delivery, see, Langer, Science (1990) 249:1527-1533, which is incorporated herein by reference.
- The amount of a compound as provided herein that can be combined with a carrier material to produce a single dosage form will vary depending upon the disease treated, the subject in need thereof, and the particular mode of administration. However, as a general guide, suitable unit doses for the compounds of the present invention can, for example, preferably contain between 0.1 mg to about 1000 mg, between 1 mg to about 500 mg, and between 1 mg to about 300 mg of the active compound. In another example, the unit dose is between 1 mg to about 100 mg. Such unit doses can be administered more than once a day, for example, 2, 3, 4, 5 or 6 times a day, but preferably 1 or 2 times per day, so that the total dosage for a 70 kg human adult is in the range of 0.001 to about 15 mg per kg weight of subject per administration. A preferred dosage is 0.01 to about 1.5 mg per kg weight of subject per administration, and such therapy can extend for a number of weeks or months, and in some cases, years. It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs that have previously been administered; and the severity of the particular disease undergoing therapy, as is well understood by those of skill in the area. A typical dosage can be one 1 mg to about 100 mg tablet or 1 mg to about 300 mg taken once a day, or, multiple times per day, or one time-release capsule or tablet taken once a day and containing a proportionally higher content of active ingredient. The time-release effect can be obtained by capsule materials that dissolve at different pH values, by capsules that release slowly by osmotic pressure, or by any other known means of controlled release. It can be necessary to use dosages outside these ranges in some cases as will be apparent to those skilled in the art.
- The present invention further provides a compound of the invention for use in treating and/or preventing cancers.
- As used herein, cancers are preferably Notch dependent cancers and are selected from the non limiting group comprising T cell-Acute lymphoblastic leukemia (T-ALL), chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), Mantle cell lymphoma, breast cancer, pancreatic cancer, prostate cancer, melanoma, brain tumors, tumor angiogenesis, and colorectal cancer.
- Preferably, the compounds of the present invention (6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), its derivatives) can be also used in the treatment of cancers where Notch dependent cancers are resistant to γ-secretase inhibitor treatment. Notch signalling dependent human tumors resistant to γ-secretase inhibitor treatment can be determined by the levels of NICD, Notch target genes as well as by mutation status of Notch receptor and other components of the Notch pathway.
- The present invention also provides a method for treating and/or preventing cancers, said method comprising administering the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), its derivatives, or the pharmaceutical composition of the invention to a subject in need thereof.
- In another embodiment, the present invention provides a method of treatment of a disease associated with an up-regulated Notch signalling pathway activity, said method comprising administrating the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), a derivative thereof, or the pharmaceutical composition of the invention to a subject in need thereof.
- The daily dose of compounds of the present invention will necessarily be varied depending upon the host treated, the particular route of administration, and the severity and kind of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient. Further, it is noted that the clinician or treating physician will know how and when to start, interrupt, adjust, or terminate therapy in conjunction with individual patient response.
- For any compound used in the method of the present invention, a therapeutically effective dose can be estimated initially from cell culture assays, animal models, or microdosing of human subjects.
- “Treatment” as used herein, refers to both therapeutic treatment and prophylactic or preventative measures. Subjects in need of treatment include those already with the disorder, such as cancer, as well as those in which the disorder, such as cancer, is to be prevented. Hence, the mammal, preferably human, to he treated herein may have been diagnosed as having the disorder, such as cancer, or may be predisposed or susceptible to the disorder, such as cancer.
- The term “therapeutically effective amount” refers to an amount of a drug effective to treat a disease or disorder in a mammal. In the case of cancer, the therapeutically effective amount of the drug may reduce the number of tumor or cancer cells, reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cells infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer. To the extent the compounds of the present invention may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic. The phrase “therapeutically effective amount” is used herein to mean an amount sufficient to prevent, or preferably reduce by at least about 30 percent, preferably by at least 50 percent, preferably by at least 70 percent, preferably by at least 80 percent, preferably by at least 90%, a clinically significant change in the growth or progression or mitotic activity of a target cellular mass, group of cancer cells, or other feature of pathology.
- Optionally the compounds of the present invention may be used against cell proliferate diseases in combination (for example either at the same time, or almost at the same time, or one after the other) with conventional treatments such as standard radiotherapy and/or standard chemotherapy. The standard radiotherapy and chemotherapy can be also the concomitant chemo-radiotherapy.
- Therefore, optionally, the standard radiotherapy and/or chemotherapy can be performed before, simultaneously or after the administration of a therapeutically effective amount of the compound of the present invention, or pharmaceutical compositions containing thereof.
- The term “concomitant chemo-radiotherapy” is used when these two treatments (chemotherapy and radiotherapy) are given either at the same time, or almost at the same time, for instance one after the other, or on the same day, etc.
- The term “standard radiotherapy” refers to the use of ionizing radiation as part of cancer treatment to control malignant cells. Preferably the ionizing radiation is γ-irradiation. It is also common to combine radiotherapy with surgery, chemotherapy, hormone therapy, or combinations thereof. Most common cancer types can be usually treated with radiotherapy. The precise treatment intent (curative, adjuvant, neoadjuvant or palliative) will depend on the tumor type, location, and stage, as well as the general health of the subject in need thereof.
- The term “standard chemotherapy”generally refers to a treatment of a cancer using specific chemotherapeutic/chemical agents. A chemotherapeutic agent refers to a pharmaceutical agent generally used for treating cancer. The chemotherapeutic agents for treating cancer include, for example, Altretamine, Bleomycin, Busulphan, Capecitabine, Carboplatin, Carmustine, Chlorambucil, Cisplatin, Cladribine, Crisantaspase, Cyclophosphamid, Cytarabine, Dacarbazine, Daunorubicin, Doxorubicin, Epirubicin, Etoposide, Fludarabine, Fluorouracil, Gemcitabine, Idarubicin, Ifosfamide, Irinotecan, Lomustine, Melphalan, Mercaptopurine, Methotrexate, Mitomycin, Mitoxantrone, Oxaliplatin, Pentostatin, Procarbazine, Streptozocin, Taco, Temozolomide, Tioguanine/Thioguanine, Thiotepa, Topotecan, Treosulfan, Vinblastine, Vincristine, Vindesine or Vinorelbine.
- When a chemotherapeutic agent is used in combination with a compound according to the present invention, then this may be used in the form of a medicament containing a combination of these two agents, for simultaneous administration, or they may be used in the form of separate dosage forms, each containing one of the agents, and in the latter case the individual dosage forms may be used e.g. sequentially, i.e. one dosage form with the compound of the invention , followed by a dosage form containing the chemotherapeutic agent (or vice versa). This embodiment of two separate dosage forms may be conceived and provided in the form of a kit.
- Also optionally the compounds of the present invention may be used against cell proliferate diseases, such as cancers, in combination with conventional removal of a tumor bulk, by for example segmental resection (biopsy or gross resection).
- The term “removal of a tumor bulk” refers to any removal, ablation or resection of a tumor bulk from a subject. The removal can be chemical, radiation or surgical. Preferably said removal is surgical, such as ablation or resection. Resection can be “segmental resection” (or segmentectomy), a surgical procedure to remove part of an organ or gland from a subject. It may also be used to remove a tumor and normal tissue around it. Debulking agent may be also used to remove tumor bulk. The term “debulking agent” includes any molecule (e.g. chemical, biological) or any external/environmental agent (e.g. γ-irradiation) or traditional surgery that would allow killing cancer cells from the tumor bulk (e.g. FL10 and FL1− cells as mentioned above).
- Another object of the present invention is a kit comprising one or more doses of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), or of one of its derivatives having Notch signalling pathway inhibition properties, or the pharmaceutical composition of the present invention for use in a method for treatment and/or prevention of cancers. The kit can further comprise one or more doses of a chemotherapeutic agent. Optionally, the kit may also comprise reagents and/or instructions for use.
- Generally, the kit comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds the pharmaceutical composition that is effective for treating the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The label or package insert indicates that the composition is used for treating the condition of choice, such as cancer.
- The present invention also relates to the use of the compounds of the invention for inhibiting in vitro or in vivo the Notch signalling pathway in cells. Usually, said cells are cancer cells.
- Also envisioned is a method of treating a subject for Notch dependent cancer, comprising
- i) determining in cancer cells obtained from a biological sample of said subject whether the cancer is Notch signalling pathway dependent, ii) and treating said subject based upon whether the cancer is Notch dependent cancer by administering a therapeutically effective amount of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of Formula I or one of its derivatives having Notch signalling pathway inhibition properties, or a pharmaceutical composition of the invention.
- Usually, the Notch signalling pathway dependency in cancer cells is determined by any method known in the art. As an example, this method can consist in an in vitro γ-secretase complex activity assays as described herein.
- This method of treating may further comprise administering at least one conventional cancer treatment. The conventional cancer treatment is administered before, simultaneously or after the administration of the therapeutically effective amount of 6-4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) of Formula I or one of its derivatives having Notch signalling pathway inhibition properties, or the pharmaceutical composition of the invention. Usually, the conventional cancer treatment consists in radiotherapy and/or chemotherapy.
- The present invention also relates to the use of the compounds of the invention in a method for provoking apoptosis in a cell, either in vitro or in vivo, by inducing G0/G1 cell cycle arrest.
- Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications without departing from the spirit or essential characteristics thereof. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations or any two or more of said steps or features. The present disclosure is therefore to be considered as in all aspects illustrated and not restrictive, the scope of the invention being indicated by the appended Claims, and all changes which come within the meaning and range of equivalency are intended to be embraced therein.
- Various references are cited throughout this Specification, each of which is incorporated herein by reference in its entirety.
- The foregoing description will be more fully understood with reference to the following Examples. Such Examples, are, however, exemplary of methods of practicing the present invention and are not intended to limit the scope of the invention.
- Mouse DL4-IRES dsRED cDNA was cloned into a pENTR1 vector (Invitrogen®) and finally shuttled into a destination lentivirus vector using Gateway cloning strategy (Invitrogen). A Phosphoglycerate kinase (PGK) promoter drove the expression of DL4 protein. DL4-lentiviral particles were produced in 293T cells by cotransfection of DL4-lentivirus vector, Gag/pol expression plasmid and plasmid encoding for viral envelope proteins. To overexpress Notch1 protein, mouse full length Notch1 cDNA was a cloned in a pCDNA3.1-IRES-puromycin vector. Notch1 cDNA was cloned upstream of IRES-puromycin between HindIII and XbaI restriction sites. A CMV promoter controlled the expression of Notch1 protein.
- To measure the Notch signalling activation. CSL/RBP-jk consensus DNA binding sequences were cloned in a head to tail conformation in the pGL4 luciferase vector (Promega), thus named 12×CSL/RBP-jjk luciferase vector. In order to determine the Notch pathway activation in chemical compound screening assay, 12×CSL/RBP-jk consensus DNA binding sequences were cloned into pGL4.26.luciferase vector (Promega). As an internal control for transfection efficiency, SV40 Renilla vector was used (Promega).
- NICD-GFP overexpression studies were performed using pEGFP-C1-NICD expression plasmid. The FLAG-CMV2 plasmid expressing MAML1-FLAG was a kind gift from Dr. Lizi Wu, Harvard Medical School, Boston.
- In order to generate DL4 and N1 stable cell lines, HeLa cell were bought from ATCC (catalog # CCL-2). To generate DL4 stable lines, cells were transduced with DL4-lentiviral particles. DL4 stable clones were selected using puromycin, High DL4 expressing clones were sorted using antibodies against DL4 with Fluorescence activated cell sorting (FACS). To generate N1 stable line, cell were transfected with a pCDNA3.1+ (Invitrogen) plasmid containing mouse full length Notch1 under the control of CMV promoter. To select for Notch1 expressing clones, an IRES puromycin cassette was cloned downstream of Notch1 cDNA. HeLa cells expressing high levels of Notch1 were enriched by FACS using anti-Notch1 antibodies. DL4- and N1-HeLa cells were cultured in DMEM (GIBCO, Invitrogen), 10% FCS and 10 ug/ml of puromycin (Sigma).
- For chemical library screen, the coculture assay was performed as follows. N1-HeLa cells were cotransfected in 10 cm tissue culture dishes with 16 μg of pGL4.26.12×CSL.luciferase vector/plate, 4 μg of Notch1 expression plasmid/plate, and 200 ng of SV40 Renilla vector/plate. DL4- and N1-HeLa cells were detached from the plate by using 0.5 mM EDTA (1×PBS). The both cell populations were counted and mixed in 1:1 ratio (5,000:5,000 cells/well in a 384 well plate) and dispensed into 384 well plates (white, clear bottom, Corning) using multidrop Combi plate dispenser. The assay plates were pre-dispensed (using
automated Biomek 3000 liquid handler) with chemical compound libraries (Microsource Maybridge Hitfinder and Prestwick) to give a final concentration of 10 μM. The final assay volume was 22 μls. Twenty-four hours later, growth media was aspirated and cells were lysed with 1× Passive lysis buffer for 10 minutes at room temperature. Luciferase activity was measured using Luciferase Assay Reagent II and Renilla values were determined by using Stop and Glow reagent (Dual luciferase assay system, Cat # E1980, Promega). Luciferase and renilla readouts were taken using Tecan® F500 (Tecan) multiplate reader. All the liquid handling steps (aspiration of the medium, dispensing of Passive lysis buffer, Luciferase Assay Reagent II and Stop and Glow reagents) were performed using ELF406 liquid handler. - Data analyses were performed using in-house built analyses software at Biomolecular Screening Facility (BST) at Ecole Polytechnique Federale de Lausanne (EPFL).
- Total RNA was extracted from cells using TRIzol® extraction kit (Invitrogen). Briefly, 1×106 cells were washed with ice-cold 1×PBS and lysed 1 ml of TRIzol® solution for 5 minutes at room temperature to dissociate nucleoprotein complexes. Lysed cells were then treated with 200 μl of chloroform and shaked vigorously for 15-30 seconds and incubated at room temperature for 2-3 minutes. The samples were centrifuged at 14000 rpm using Eppendorf table top centrifuge for 10 minutes at 4° C. Following centrifugation, upper aqueous phase was transferred to new eppendorf tubes. To precipitate total RNA 500 μl of isomyl alcohol was added to the separated aqueous phase and incubated at room temperature for 10 minutes. A RNA pellet was obtained by centrifuging the samples at 4° C. for 10 minutes. RNA pellet obtained was washed with 1 ml ice cold 75% ethanol and spun down at 14000 rpm at 4° C. RNA pellet was dried off of excess of ethanol and resuspended in 40 μl DPEC water.
- cDNA Synthesis:
- Total RNA extracted from the cell was used to synthesize cDNA by reverse transcription reaction. Reverse transcription was performed using SuperScript™ RT (Invitrogen). RNA concentration was measured using NanoDrop®ND-1000 spectrophotometer (Witec AG) and 500 ng of total RNA was mixed with a 10 mM mix of dNTPs and 100 ng of random primers. The reaction mix was incubated at 65° C. for 5 minutes and quickly incubated on ice for 1 minute. Following incubation on ice. 5× first strand buffer and 0.1 M DTT were added and mix was incubated for 2 minutes at 25° C. To start the reverse transcription reaction, 200U of SuperScrip™ II RT was added to the reaction mix and incubated at 42° C. for 50 minutes. The reaction was stopped by incubating the reaction mix at 75° C. for 15 minutes.
- Cells were lysed in RIPA buffer (50 mM Tris.Cl, pH 7.5, 150 mM NaCl, 1% nonidet P-40, 0.5% sodium deoxycholate and 0.1% SDS) for 30 minutes at 4° C. Lysed cells were centrifuged to remove the debris at 14000 rpm at 4° C. Supernatant was transferred to a new eppendorf tube. The protein concentration was determined by Bradford assay using spectrophotometer (
Ultrospec 3000 pro). 40 μg of protein were denatured in 1×SDS gel loading buffer (100 mM Tris.Cl, pH 6.8, 200 mM DTT, 4% SDS, 0.2% bromophenol, 20% glycerol) by heating at 99° C. for 5 minutes. Denatured protein samples were stored on ice until loading on to the acrylamide gel. The samples were run on 8% or 10% acrylamide gel in Tris-glycine electrophoresis buffer (25 mM Tris. 250 mM glycine, 0.1% SDS). Following separation on the acrylamide gel, protein samples were transferred on to PVDF membrane (PEQ lab, catalog number 39-3010) using transfer buffer (39 mM glycine, 48 mM Tris base, 0.037% SDS and 20% methanol). - For immunoblotting, membranes were blocked with 5% milk and incubated overnight with primary antibodies at 4° C. Membrane were washed with 1×TBST (1×TBS+0.5% tween 20) for 5 minutes (3 times) and incubated with HRP-conjugated secondary antibodies for one hour at room temperature. Signal was detected with Super Signal West chemiluminescent substrate (Thermo Scientific, catalog number 34077).
- To perform immunofluorescence staining, HeLa cells or C2C12 cells were grown on cover slips. Cells were washed with 1× ice-cold PBS, fixed with 4% PFA for 5 minutes at room temperature and permeabilized using 0.3% Triton X-100. Subsequently permeabilized cells were blocked for 20 minutes with 1% BSA for 20 minutes at room temperature. Cells were incubated with appropriate primary antibodies for one at room temperature. Alexa Fluor-488 conjugated secondary antibodies were used to detect primary antibodies. Cells were counterstained with DAPI and mounted in fluorescent mounting media. Fluorescent images were viewed and captured using Zeiss Axioplan microscope at Bioimaging and optics core facility at EPFL.
-
TABLE 1 List of the antibodies and working dilutions. Antibodies Application Dilution Source Anti-Val 1744 WB and ChIP 1:1000 Cell Signal, 2421S NICD Anti-Notch1 (C-20) WB 1:1000 Santa Cruz, sc-6014 Anti-RBP-jk IF 1:500 Santa Cruz, sc-28713 Anti-FLAG-M2 IF 1:500 Sigma, F1804 Anti-Hes1 (H-140) WB 1:500 Santa Cruz, sc-25392 Anti-cMyc (9E10) WB 1:500 Abcam, ab11917 Anti-Delta like 4 Flow cytometry 1:100 Produced in-house Anti-Notch1 Flow cytometry 1:50 Produced in-house Anti-Tubulin WB 1:3000 Sigma, Anti-Myosin heavy IF 1:200 Sigma, MY-32 chain HRP-conjugated WB 1:3000 Invitrogen, 611620 anti-goat IgG HRP-conjugated WB 1:3000 GEhealthcare, anti-mouse IgG NA931V HRP-conjugated WB 1:3000 GEhealthcare, anti-rabbit IgG NA934V Alexa Fluor-488 IF 1:1000 Invitrogen secondary Ab Anti-B220-Pacific Flow cytometry 1:400 Produced in-house blue Anti-CD21-FITC Flow cytometry 1:200 eBioscience Anti-CD23-PE Flow cytometry 1:400 BD Pharmingen Anti-TCR β-APC Flow cytometry 1:400 eBioscience eF780 Anti-CD4-FITC Flow cytometry 1:800 Produced in-house Anti-CD8-Alexa Flow cytometry 1:600 Produced in-house 648 Anti-CD71-PE Flow cytometry 1:800 eBioscience Anti-Ter119-APC Flow cytometry 1:200 eBioscience eF780 Anti-Annexin Flow cytometry 1:50 BD Pharmingen V-Cy5 - C2C12 cells were grown on collagen-coated cover slip in the presence of growth media (10% serum). To induce myoblast differentiation, cells were grown to 100% confluency for 3 days in the presence of differentiation media (2% horse serum) or in the presence of growth media+Notch inhibitors. After 3 days, cells were washed with 1× ice-cold PBS and fixed with 4% PFA. Immunofluorescence staining was performed using anti-MHC antibody as explained in the section 2.2.6 (Immunofluorescence staining).
- Fluorescence activated cell sorting (FACS) analyses were performed on CyAn™ ADP instrument platform for flow cytometry at Flow cytometry core facility, EPFL. DL4 and Notch1 expression in DL4- and N1-HeLa cells was determined using anti-DL4 and anti-N1 antibodies respectively. T cell development in the thymus was investigated using antibodies against CD4, CD8 and TCRβ. MZB cell development was monitored using antibodies against B220, CD21 and CD23. In brief, a single cell suspension was prepared from thymus and spleen. 1×106 cells suspended in 50 μl of staining media (HBSS supplemented with 2% NCS and 25 mM HEPES) and stained with appropriate antibody combinations by incubating on ice for 30 minutes.
- To quantitate the percentage of apoptotic cells, AnnexinV and 7AAD staining was performed. Thymic cells were suspended in 300 μl of 1× AnnexinV binding buffer (BD Biosciences, San Diego, USA) and incubated with 10 μl of AnnexinV-Cy5 antibody and 10 μl of 7AAD (BD Biosciences, San Diego, USA). Samples were incubated for 15 minutes at room temperature. FACS was performed with in one hour of antibody staining.
- Flow cytometry analyses were done on live cells by gating on forward scatter (FSC) and side scatter (SSC). Data were analyzed by FlowJo software (Tree Star, Ashland, Oreg.).
- Alamarblue® proliferation assays were performed to determine the growth kinetics of Notch inhibitor treated cells. Alamar blue® consists of a cell permeable substrate resazurin. In metabolically active and proliferating cells, resazurin is converted to resorufin due to an intrinsic reducing power of live cells and produces a red fluorescence. Therefore production of resorufin serves as an indicator of the viability of the cell population.
- Proliferation assays were performed by seeding 5000 cells/well in a 96 well plate. Cells were treated with DMSO or Notch inhibitors for different time intervals. Each treatment for every time interval was carried out in 8 replicates. To determine the growth kinetics, 10 μl of Alamar blue® (Invitrogen) was added to each well and incubated for 4 hours. Alamarblue readout was taken using Tecan F500 (Tecan) multiplate reader.
- Organs were harvested, fixed in 4% paraformaldehyde (PFA) overnight at 4° C. and embedded in paraffin. Tissue sections were dewaxed and hydrated using decreasing concentration of ethanol (100%-70%) and finally in distilled water. Sections were stained with Hemotoxylin for 5 minutes, rinsed in acid alcohol for about 20 seconds and then rinsed in running water for 10 minutes. Sections were then stained with Eosin for 5 minutes, washed in water and dehydrated using increasing concentration of ethanol (70%-100%) and cleared in xylene solution. Sections were the mounted using mounting solution. Haematoxylin and Eosin stained sections were viewed and images were captured using Leica DMI4000 microscope.
- Intestinal tissue was flushed with ice-cold 1×PBS, fixed in 4% PFA. Tissues were embedded in paraffin and sectioned to a thickness of 4 microns. Intestinal sections were deparaffinized at 60° C. and hydrated with decreasing concentration of alcohol (100% -70%) and finally washed in distilled water. Alcian blue staining was performed for 30 minutes at room temperature washed in running water and finally counterstained in nuclear fast red solution for 5 minutes. Tissue sections were then washed in running water dehydrated in 100% alcohol and cleared in xylene solution. Mounted sections were then viewed and images were captured using Leica DMI4000 microscope.
- Mice were kept and bred at Animal facility, EPFL, Lausanne. C57Bl6 mice were used to assess the intestinal toxicity of the chemical compounds, MMTV-ErbB2/Neu-IRES Cre (FVB background) mice were obtained from Dr. William J Muller, McGill University, Montreal and genotyped using MMTV-ErbB2/Neu specific primers (Ursini-Siegel et al., 2008). NOD/SCIDγc−/− mice were bought from The Jackson Laboratory (USA) and were kept and bred at Animal facility, EPFL, Lausanne.
- C57Bl6 mice were intra peritoneal (i.p) injected with oil or 25 mg/kg of I3 or 10 mg/kg of CPA, once a day for 5-7 days. Mice were weighed using a weighing scale on
day 0,day 3 andday 5. Onday 8, intestinal tissue, spleen and thymus were harvested for analyses. - The human leukemic
cell lines RPMI 8402 and HPB ALL were transduced with a lentivirus containing luciferase gene constitutively expressed downstream of a CMV promoter. The human leukemic cell lines RPMI 8204 (0.5−1×106 cells) and HPB ALL (1×106) were suspended in 100 μl of ice-cold 1×PBS and kept on ice until the transplant. NOD/SCIDγc−/− mice were transplanted with the human leukemic cell lines by intravenous (i.v) injection. Mice were monitored for tumor development using Caliper IVIS (Xenogen) live imaging system. Briefly, the luciferase substrate luciferin (Biosynth, L-8820) was dissolved in 1×PBS and was injected (intra peritoneal) into the mice at a concentration of 150 mg/kg of body weight. Mice were imaged 5 minutes after the luciferin injection using Caliper IVIS live imaging system. - At day 13-15, mice were treated with oil or 25 mg/kg of I3 on a daily basis. Images were captured at the end of the experiments.
- Primary MMTV-ErbB2/Neu mammary tumors were harvested from the mice and a single cell suspension was prepared. 1×106 primary tumor cells were suspended in 50 μl of 1×PBS and kept on ice. Three weeks old recipient FVB mice were cleared of their endogenous epithelium and tumor cells were injected into the empty fat pad. Tumor development in the recipient mice was monitored and tumor volumes were measured using digital caliper. Tumor volumes were calculated using following formula: 2×length×(width)2. Once the tumor reached a volume of about 100 min3, recipient mice were treated with oil or 25 mg/kg of I3 on alternate days.
- In order to identify novel modulators of the Notch pathway, Applicants have established a coculture assay in which DL4 ligand expressing HeLa cells were cultured with Ni HeLa cells, thereby activating the Notch pathway. The use of a DL4 and N1 HeLa cell coculture system mimics physiological conditions of cell-cell communication between ligand and receptor expressing cells. The in vitro generation of a controlled receptor-ligand assay system allowed Applicants to modify and monitor the Notch signal intensity by γ-secretase inhibitors.
- To set up a coculture assay, Applicants have established DL4 and N1 expressing stable HeLa cell lines. In brief, HeLa cells were transduced with a lentivirus containing DL4 cDNA downstream of the PGK promoter. The D4 expressing cell population was enriched by fluorescence activated cell sorting. Similarly, the N1 stable HeLa cell line was established using a plasmid containing the mouse N1 cDNA followed by an IRES Puromycin selection cassette. This system allowed Applicants to select for only Notch1 expressing clones when selected using puromycin. The expression levels of DL4 and N1 proteins in the respective cell lines were detected using anti-DL4 and anti-N1 antibodies. Quantification of the protein levels by flow cytometry showed high level expression of DL4 and N1 compared to parental HeLa cells (data not shown).
- To assess the Notch pathway activation potential of the stable cell lines, DL4 and N1 stable HeLa cells (DL4-HeLa and N1-HeLa, respectively) were cocultured in 1:1 ratio in a 6-well plate and grown to continency. The cocultured cells were treated with DMSO or DAPT (10 μM) for 24 hours. For comparison, parental HeLa cells were also cocultured with DL4-HeLa cells and were grown in the presence or absence of DAPT for 24 hours. Western blot analyses for the active form of Notch1 (NICD) using VAL1744 antibodies was performed and revealed only modest levels of NICD when parental HeLa cells were cocultured with DL4 HeLa cells (data not shown), accounting for a low level of endogenous Notch1 in HeLa cells. On the other hand, in the absence of ligand (DL4-HeLa cells) or in the presence of GSI (DAPT) NICD levels were not detected, indicating a loss of Notch signalling (data not shown). However, cocultures of DL4- and N1-HeLa cells revealed significantly higher levels of NICD, which can be blocked by DAPT treatment (data not shown). Transient introduction of
full length Notch 1 cDNA into N1-HeLa cells further enhanced the robustness of the coculture assay as indicated by the increased levels of NICD protein (data not shown). Inhibiting the N1 cleavage with DAPT can abrogate the increase in Notch signalling activity (data not shown). These results confirmed that high levels of the Notch pathway activation could be achieved in the DL4:N1 coculture assay that responds to GSI inhibition. - The establishment of DI4:N1 coculture assay in a 6 well plate formal allowed Applicants to assess receptor-ligand interaction mediated Notch signalling activation. GSI (DAPT) treatment of the coculture system can block receptor-ligand interaction driven Notch signalling.
- Initially, DL4:N1 coculture assay was established in a 6-well plate. In order to set up a high-through put screen (HTS), the assay system was further optimized to robustly work in a 384 well plate format.
- The assay was scaled-down to a 384 well plate format for screening of chemical compound libraries. In order to accomplish this, N1-HeLa cells were transfected with a reporter plasmids and N1 expression vector. Twelve hours later, chemical compounds were dispensed into a 384 well plate along with DMSO and DART as negative and positive controls. DL4- and N1-HeLa cells were mixed in a 1:1 ratio (5000: 5000 cells/well) and added to 384 well plates using multidropCombi plate dispenser. Luciferase readout was measured using dual luciferase assay system. To optimize and determine the reproducibility of the assay, half of the plate was treated with DMSO (192 wells) and the second half was treated with 10 μM DAPT (192 wells). DAPT treatment led to a 10-fold downregulation of Notch signalling activation. The Z′ value for this assay was higher than 0.5. A Z′ value of >0.5 confirms the reliability and reproducibility of the assays for a HTS campaign.
- To validate the Notch inhibitory activity and determine the IC50 value of the I3 compound, the DL4:N1 coculture assay system was used. The cells in the coculture assay were treated for 24 hours with an increasing concentration of I3 (2-10 μM). The activation of the Notch pathway was measured using a Notch driven luciferase reporter assay. As shown in
FIG. 1A , I3 blocks Notch signalling in a concentration dependent manner with an IC50 value in the lower μM range. - To determine whether over expression of NICD can rescue I3 mediated inhibition of Notch signalling, HeLa cells were co-transfected with a NICD expression plasmid and 12×CSL luciferase construct. The transfected cells were treated with an increasing concentration of I3 and DAPT. Surprisingly, treatment of NICD expressing cells with I3 could block pathway activation in a dose-dependent manner, while DAPT had no effect on the signalling activation (
FIG. 1B ). This data suggests that I3 mediated inhibition of the Notch pathway is due to its activity downstream of the S3 cleavage event. - Next Applicants investigated whether I3 could block pathway activation via other Notch receptors or is it specific to Notch1 signalling. To address this, a coculture assay was used where Notch signalling was activated via DL4:N1 or DL4:N2 ligand receptor pairs. The treatment of cells in these two coculture assays with I3 caused an inhibition of Notch signalling via both DL4:N1 and DL4:N2 ligand-receptor pairs (
FIG. 1C ). Similarly, I3 could also block pathway activation by Notch1-intracellular domain (NICD) and Notch2-intracellular domain (N2-ICD), suggesting that I3 is not specific for NICD mediated activation (FIG. 1D ). - In vitro data from NICD transfected HeLa cells suggested that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) blocks Notch signalling by acting downstream of S3 cleavage event. This raises several possibilities about the mechanism of action of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3). For example, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment could impair nuclear localization of the NICD. A second possible mechanism of inhibition could be targeting of one or more individual components of the transcriptional activation complex in the nucleus. To test whether 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) has an impact on nuclear transport of NICD, HeLa cell were transfected with a NICD-CGP fusion construct and treated with DMSO and 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3). This allowed Applicants to follow transport of fusion protein within the cell. In parallel, the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) mediated pathway inhibition was determined by Notch driven luciferase measurement (data not shown). Microscopic studies showed that in DMSO treated cells NICD-CFP fusion protein translocate to the nucleus, which was not perturbed upon 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment (data not shown). This data rule out nuclear exclusion of NICD as a mechanism of action of I6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3).
- As 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) mediated blockage of Notch signalling does not involve nuclear exclusion of NICD, Applicants addressed whether 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) blocks interaction and thereby sub-nuclear localization of NICD, MAML1 and CSL-RBP-jk (all parts of the core transcriptional activation complex). To resolve this, HeLa cells were co-transfected with 800 ng of NICD-GFP plasmid, 1 μg of MAML1-FLAG expression vector and grown on cover slips. The transfected HeLa cells were treated with DMSO or 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) (10 μM) for 24 hours. The ability of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) to block Notch activation at this concentration of NICD and MAML1 was verified by Notch driven luciferase measurement (data not shown). Following treatment, the cells were fixed with 4% PFA, blocked with 1% BSA and stained with antibodies against FLAG tagged MANTL1 and CSL-RBP-jk. NICD-GFP fusion protein was visualized by tracing the GFP protein. When expressed alone, NICD-GFP protein was localized in the nucleus in a diffused manner and 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment did not alter its nuclear localization. However overexpression of NICD-GFP and MAML1 led to co-localization of both proteins into sub-nuclear compartments (possibly nuclear bodies). The 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment of the cells did not perturb the translocation and co-localization of NICD-GFP and MANUA into sub-nuclear compartment (data not shown).
- Similarly, the location of CSL/RBP-jk was investigated using antibodies specific against this protein. As shown in
FIG. 22C , MAML1-FLAG and CSL/RBP-jk co-localized in sub-nuclear compartments and 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment did not perturb their distribution in the nucleus (data not shown). This data suggest that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment does not perturb co-localization of components of the Notch transcriptional activation complex in the nucleus. However, whether it blocks interaction between various components of the complex still need to be investigated. - To further investigate the mechanism of action of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), Applicants speculated that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) might be targeting one of the components of the transcriptional activation complex. The over expression of this target protein may titrate out 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) compound and thus rescue 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) induced pathway inhibition. To address this question, HeLa cells were co-transfected with 800 ng of NICD-GFP plasmid and with an increasing amount (0, 1 and 3 μg) of MAML1-FLAG expression vector. The Notch pathway activation was measured by introducing 12×CSL luciferase plasmid. As shown in
FIG. 2 , in HeLa cells transfected with NICD alone or NICD+1 μg of MAML1, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment can block Notch signalling in a concentration dependent manner. However, when the amount of MAML1 plasmid was increased to 3 μg, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment was no longer able to inhibit the activation of Notch signalling (FIG. 2 ). Therefore, over expression of MAML1 above a certain threshold could rescue 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) mediated inhibition of the Notch pathway. This data suggest that MAML1 itself might be the target of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) compound. An increase in the concentration of MANUA may be able to titrate out the inhibitor and thus rendering it incapable of blocking the signalling cascade. - 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) Treatment Decreases Notch Signalling in Human Cancer Cell Lines:
- Aberrant activation of Notch signalling plays an important role in tumor initiation and/or maintenance of human cancers. To determine whether 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment can block Notch signalling in human cancer cells, various cancer cell lines (T-ALL
cell lines RPM 8402, HPBALL, KOPTK1 and pancreatic cancer cell line PANC1) were treated with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (l3) for 24 hours. The effect on Notch signalling was determined by measuring the expression levels of Notch target genes. 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment of human cancer cell lines (RPMI 8402, HPBALL, KOPTK1 and PANC1) for 24 hours and subsequent analyses of Notch target genes by qRT-PCR or Western blot analyses showed that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) induced a statistically significant downregulation of Notch target genes such as Hes1, cMyc and Dtx1 at the mRNA as well as at the protein levels (FIGS. 3A-E ). The downregulation of Notch target genes correlates with reduced levels of NICD (FIG. 3B , C and D). - As treatment of the human T-ALL cell lines and PANC I pancreatic cancer cell line with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) induced a downregulation of Notch signalling, Applicants questioned whether this inhibition of the pathway translates into growth arrest in cancer cells. To this end,
RPMI 8402, KOPTK1, PANC1 and nRas driven melanoma cell lines were grown in the presence or absence of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) for several days and their proliferative index was measured using the Alamar blue assay. In addition, B-lymphocyte. RAJI cell lines with no known Notch imitations were used as a control (data not shown). As shown inFIG. 4 , 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT treatment induced a significant proliferation block in T-ALLcell lines RPMI 8402, KOPTK1 and pancreatic cancer line PANC1. Similarly, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) significantly inhibited the growth of nRas driven melanoma cell lines (FIG. 4 ). However neither DAPT nor 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) had any effect on the proliferation of Notch-independent RAJI cells (data not shown). - 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) can block NICD mediated activation of the Notch pathway (
FIGS. 1A-D ). To determine whether 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) can also induce a proliferation block in NICD overexpressing cells, the human T-ALL cell line DND41 (DND41-Parental) was transduced with a NICD expressing lentivirus to generate DND41-NICD cell line. These two cell lines were treated with DMSO, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT. The treatment of DND41-parental cell line with DAPT and 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) led to a downregulation of Hes1 when compared to DMSO treated cells. However, when DND41-NICD cells were treated with DMSO, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT, only 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3), but not DAPT treatment caused a downregulation of Hes1 (FIG. 5A ). In addition, these two cell lines were also monitored over several days for anti-proliferative effects of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT. It was observed that while both 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT treatment caused a significant proliferative block in the DND41-Parental cell line (FIG. 5B ), only 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was able to induce a growth arrest in DND41-NICD cells (FIG. 5C ). This data further strengthen the notion that the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) compound can block NICD mediated pathway activation and proliferation in human cancer cells. - To further strengthen the notion that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) can block NICD mediated pathway activation and proliferation of human cancer cells, HCC1187 human breast cancer cell lines was treated with this compound. HCC1187 cell line harbors a SECC22B-Notch2 chromosomal translocation, thus generating constitutively active form of N2-ICD (
FIG. 5D ). Due to this mutation, HCC1187 cell lines do not respond to γ-secretase inhibitors such as DAPT. As shown isFIG. 5E , while DAPT treatment did not inhibit proliferation of HCC1187 cell lines, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment significantly induced a proliferation block in these cell line. - As shown in
FIGS. 4 and 5 , 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment of human leukemic cell lines and human breast cancer cell lines negatively regulate proliferation. This 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) mediated proliferative arrest could be due to induction of apoptosis or cell cycle arrest during different phases of cell cycle. In addition, inhibition of Notch signalling using γ-secretase inhibitors has been shown to induce G0/G1 cell cycle arrest in human TALL cell lines. Therefore to further elucidate the mechanisms responsible for 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) mediated proliferative arrest cell cycle and apoptosis analyses were carried out. Human TALL cell lines (RPMI8402, KOPTK1, TALL1, CUTL1 and HPB ALL) and human breast cancer cell line HCC1187 were treated with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3)or DMSO for 2 days or 7 days. To investigate cell death, Annexin V staining was performed and proportion of apoptotic (AnnexinV positive) cell population was determined by flow cytometry analyses after 7 days of treatment. As shown inFIG. 6A , 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment induces significant apoptosis in RPMI8402, CUTL1, KOPTK1, TALL1 and HPB ALL. Similarly, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine induces apoptosis in human breast cancer cell line HCC1187 (FIG. 6C ). - In addition to induction of apoptosis, the proliferative arrest observed in 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treated human leukemic cell lines and breast cancer cell line also appears to be due to cell cycle arrest in G0/G4 phase of the cell cycle. Leukemic cell lines (RPMI8402, KOPTK1 and TALL1) and breast cancer cell lines were treated with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) for 48 hours and cell cycle status was determined using Ki67 and Hoechst stain. As shown in
FIG. 6B and 6D , 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) induces an arrest in the G0/G1 phase of the cell cycle, a phenotype normally observed due to inhibition of Notch signalling. - To further confirm the Notch inhibitory potential of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) in different systems, C2C12 myoblast differentiation was used as a functional assay. The Notch pathway activation in C2C12 myoblasts retains them in an undifferentiated state, while abrogation of Notch signalling induces their differentiation. C2C12 myoblasts were treated with DMSO, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and DAPT and grown to 100% confluency for 3 days. After three days, cells were fixed and stained with antibodies against Myosin Heavy Chain (MHC) protein. Cell nuclei were counterstained with DAPI. C2C12 myoblasts grown in the presence of 10% serum (growth medium) maintain their undifferentiated state, while the cells treated with DAPT and 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) started to differentiate into multinucleated MHC positive myotubes (data not shown).
- One of the concerns about the activity of the chemical compound 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) is its specificity towards the Notch signalling pathway. In order to test whether 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) could also block other developmental pathways, Applicants have tested its ability to block the Wnt and Hedgehog signalling pathways. In summary, to measure Wnt signalling, HeLa cells were transfected with a plasmid containing a promoter consisting of TCF/LEF binding sites and thereby driving the expression of a luciferase gene (TOP-luciferase). To activate the Wnt pathway, a plasmid encoding for β-catenin was co-transfected into HeLa cells. The co-transfected cells were incubated in the presence or absence of the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) chemical compound. Transient introduction of β-catenin leads to an upregulation of Wnt signalling as measured by β-catenin-TCF/LEF driven luciferase activity. Importantly, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment of cells with activated Wnt signalling does not block the Wnt pathway activation (data not shown).
- Using a similar strategy, Hedgehog signalling was activated in HeLa cells by introducing the Gli1 transcription factor and pathway activation was monitored using a promoter sequence containing Gli1 binding sites driving the luciferase expression. The treatment of these cells with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) did not inhibit the Hedgehog signalling cascade (data not shown). Taken together these data suggest that the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) chemical compound may not impair other developmental pathways and might be specific for Notch signalling inhibition. However it still needs to be determined whether the resistance of Wnt and Hedgehog signalling towards 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) is cell type specific or whether it is a general phenomenon.
- Notch signalling regulates homeostasis of several organs during development. For example, Notch1 mediated pathway activation is essential for T cell development in the thymus (Radtke et al., 1999). However, the Notch1 driven T cell development does not appear to be dependent on MAML1, as the loss of MAML1 did not perturb T cell development in the mice. This could be due to a compensatory mechanism by MAML2 and MAML3 family members for the loss of MAML1 in the spleen. Notch2 driven signalling exclusively via MAML1 is required for MZB cell development. Genetic ablation loss of Notch2 and MAML1 cause a block in the development of MZB cells (Wu et al., 2007, Saito et al., 2003,). In addition, Notch signalling via both Notch1 and Notch2 is essential for the maintenance of the crypt compartment. A compound genetic ablation of Notch1 and Notch2 in the intestine leads to goblet cell metaplasia. Applicants therefore, investigated whether 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) could impair above-mentioned Notch-dependent developmental processes.
- In in vitro culture assays, chemical compound 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) was able to block Notch1 and Notch2 mediated pathway activation. Therefore, Applicants hypothesized that treatment of mice with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) may lead to a goblet cell metaplasia of the intestine. To test this hypothesis, mice were intra peritoneally (i.p) injected with 25 mg/kg of 6-(4-Ten-Butylphenoxy)Pyridin-3-Amine (I3) for 7 consecutive days. On day S. animals were sacrificed and intestinal tissues were fixed and embedded in paraffin. Histological analyses were carried out using Alcian blue to stain for goblet cells. Surprisingly, despite its ability to block both Notch1 and Notch2 mediated pathway activation in in vitro cultures, the intestinal tissue of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treated mice was completely normal with intact architecture and no indication of goblet cell metaplasia (data not shown). Similarly, the effect of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) on body weight changes was also monitored. Mice were injected for 5 consecutive days with 25 mg/kg of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) and the changes in body mass were recorded. The treatment of mice with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) did not cause a loss in the body weight.
- Applicants hypothesized that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) mediated inhibition of Notch2 signalling should lead to a block in MZB cell development in the spleen. MZB cell development was assessed by flow cytometry staining of splenocytes with antibodies directed against B220, CD21 and CD23. As shown in
FIG. 7B treatment of mice with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) leads to a reduction in the percentage of MZB cell population in the spleen. In addition, the loss of MZB cell population in the spleen also reflects in the absolute number of MZB cells (FIG. 7C ). - Therefore, 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) mediated block in MZB cell development mimics loss of Notch2 and MAML1 phenotype, However, it is still need to be seen, whether 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) exert its Notch inhibitory effect only via MAML1 or it could block Notch signalling via other MAML family members as well.
- Activation of Notch signalling due to activating mutations in different components of the pathway are known to cause more than 50% of the human T cell acute lymphoblastic leukemias. Therefore, Applicants decided to investigate the anti-cancer activity of the chemical compound 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) in Notch driven human T cell leukemia in vivo. To achieve this goal, xenotransplant models of human leukemia were established using NOD/SCID γc−/− mice. Human T-ALL cell lines HPB ALL and
RPMI 8402 were used for this purpose. The HPB ALL cell line harbours a L1575P mutation in the heterodimerization domain and an insertion in the PEST domain of the Notch) receptor, thereby constitutively activating the Notch1 signalling. Similarly,RPMI 8402 cells exhibit ligand independent Notch signalling activation due to an insertion at 1584 a.a residue in the heterodimerization domain and also an inactivating mutation (R465H) in the E3 ligase FBW7. Both these cells line were found to respond to 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment in in vitro culture assays in terms of proliferation and/or downregulation of the Notch target genes. To determine whether these cell lines establish leukemia in a xenotransplant setting, one million cells from each line were intra venously (i.v) injected into NOD/SCIDγc−/− mice. The animals developed leukemia with 100% penetrance and die within 4 weeks after transplantation. - Once
RPMI 8402 and HPB ALL cell lines were shown to develop leukemia in a xenotransplantation assay, they were transduced with a lentivirus constitutively expressing luciferase gene. This allowed Applicants to visualize and monitor the leukemia progression in the mice using the Caliper IVIS (Xenogen) live imaging detection system. In order to determine the anti-cancer efficacy of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) in established tumors, a maintenance experiment was performed. One million HPB ALL cells were injected (i.v) into NOD/SCID γc−/− mice. Mice were monitored for leukemia development by detecting luciferase expressing leukemic cells. Once the disease was established aroundday 15, the mice were split into two groups. One group was treated with oil as a control and the second group was treated with 25 mg/kg of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) on a daily basis. As shown inFIG. 8A , the mice treated with oil develop leukemia with 100% penetrance while leukemia in the 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treated mice did not progress at the same rate as in the oil treated group (FIG. 8A ). - Similarly in a preliminary experiment, NOD/SCID γc−/− mice were transplanted with 5×105
RPMI 8402 cells and treated with oil or 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) following the establishment of the disease. As shown inFIG. 8B , animals treated with oil, developed leukemia while 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treated mice were free of the disease. Furthermore, histological analyses revealed that in oil treated mice, leukemic cells progressed to infiltrate the liver, but 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treated mice did not develop any metastatic lesions in the liver (data not shown). Since these animals were treated with the chemical compound 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) for 27 days, the intestinal tissue was analyzed to detect any toxicity in the gut. Alcian blue staining of intestinal tissue did not reveal any abnormality in the goblet cell numbers and intestinal architecture (data not shown). - Taken together Applicants' data from xenotransplantation model for human leukemia suggest that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) has the ability to slow down disease progression of an already established leukemia. Because of its ability to impact tumor progression, I3 may be a suitable candidate for further development as an anti-cancer agent.
- In human breast cancer, high levels of Notch1 and Jagged1 proteins correlated with a poor survival of breast cancer patients. In addition, activation of Notch signalling in human breast cancer also facilitates bone and lung metastasis. Therefore in order to determine anti-cancer potential of chemical compound 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) in breast cancer, a mouse model of breast cancer was investigated. The mouse mammary tumor virus (MMTV) driven overexpression of ErbB2 is known to cause mouse mammary tumors. MMTV-ErbB2 transgenic mice develop mammary tumors with a latency of about 5-6 months along with the development of lung metastasis. One of the characteristics of MMTV-ErbB2 mouse mammary tumors is the presence of predominantly luminal epithelial cell types. Notch signalling is known to drive luminal cell differentiation from mouse mammary stem cells. Therefore Applicants hypothesized that the activation of the Notch pathway in MMTV-ErbB2 mammary tumors may contribute towards tumorigenesis in part by favouring luminal epithelial cell differentiation. To this end, Applicants investigated the levels of Notch signalling activation in MMTV-ErbB2-IRES-Cre mammary tumors by measuring the levels of Hes1 by Western blotting. As shown in
FIG. 9A , MMTV-ErbB2 driven mammary tumors express very high levels of Hes1 protein compared to age matched normal mammary glands. To investigate the effect of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) on breast cancer development, MMTV-ErbB2 mammary tumors were harvested from FVB mice carrying the MMTV-ErbB2 transgene. A single cell suspension was prepared and 5×105 tumor cells were injected into an empty fat pad of a recipient FVB mouse. Once palpable tumors had developed, recipient mice were treated with either oil or 25 mg/kg of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) on alternate days until the end of Me experiment. The tumor volume was measured and recorded on regular intervals. Preliminary results showed that the treatment of tumor bearing recipient mice with 6-(4-Tert-Butylphenoxv)Pyridin-3-Amine (I3) caused significant tumor growth retardation when compared to mice treated with oil alone (FIG. 9B ). This data showed that 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) has the ability to slow down the growth of established breast cancer. - To further investigate the Notch inhibitory effect of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) in a relevant pathological condition, primary human TALL samples were profiled for the activation of Notch signalling. An accumulation of active form of Notch (NICD) was used as a biomarker for pathway activation. Several primary human TALL exhibited an accumulation of oncogenic NICD and treatment of these tumors with 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) leads to a downregulation of this protein. Moreover, the downregulation of NICD in these primary human TALL samples correlates with a proliferative arrest (data not shown). On the contrary, primary human TALL samples that do not show detectable levels of NICD, did not respond to 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) treatment (data not shown).
- These data indicates that an accumulation of NICD can be used as a biomarker for Notch pathway activation and predict treatment outcome using Notch inhibitor 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3).
- In order to enhance the Notch inhibitory activity as well as efficacy of parental 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) compound, different chemical derivatives of I3 were tested in DL4-N1 coculture assay. Screening of more than 40 different chemical derivatives of 6-(4-Tert-Butylphenoxy)Pyridin-3-Amine (I3) yielded following compounds for their ability to block Notch pathway activation in coculture assay (
FIG. 10 ). - I3-A). 6-(4-cyclohexylphenoxy)pyridin-3-amine
- I3-B) 6-(4-(tert-Pentyl)phenoxy)pyridin-3-amine (CAS # 1036533-91-1)
- I3-C) 4-(4-(tert-butyl)phenoxy)aniline (CAS # 56705-89-6)
- I3-D). 6-(4-Butylphenoxy)pyridin-3-amine
- I3-E). 4-(4-(tert-pentyl)phenoxy)aniline (CAS # 328032-81-1)
- I3-F). 4-(4-cyclohexylphenoxy)aniline (CAS # 70682-64-3)
- I3-G) 6-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)pyridin-3-amine
- I3-H). 6-(3-(tert-butyl)phenoxy)pyridin-3-amine (CAS # 1098366-43-8)
- I3-I). 4-(4-(tent-butyl)phenoxy)-3-fluoroaniline (CAS # 946785-77-9)
- I3-J). 4-(4-isopropylphenoxy)aniline
- I3-K). 6-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)pyridin-3-amine
- I3-L). 4-(4-cyclohexylphenoxy)-3-fluoroaniline
- I3-M). 3-fluoro-4-(4-(cert-pentyl)phenoxy)aniline
- I3-N). 6-(4-(2-methylpentan-2-yl)phenoxy)pyridin-3-amine
- I3-O). 4-(4-5r,7r)-adamantan-1-yl)phenoxy)aniline
- I3-P). 4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)-3-fluoroaniline
- As show) in
FIG. 10 , some of these derivatives (I3-A, I3-B, I3-C, I3-E, I3-G, I3-H, I3-M and I3-N) block Notch signalling to comparable levels to parental compound I3, while derivatives I3-F and I3-I appears to have enhanced activity. - 4-(2-methylpentan-2-yl)phenol
- 4-Butyrylphenol (1000 mg, 6.09 mmol, 1.00 eq was suspended in toluene (25 mL) and DCM (5mL) and cooled to 0° C. 2M Me3Al solution in toluene (7 mL, 14.01 mmol, 2.30 eq) was added dropwise whereby the starting material was dissolved. After stirring at room temperature for 15 h, the reaction mixture was again cooled to 0° C. and TMSOSO2CF3 (1.1 mL, 6.09 mmol, 1.00 eq) was added dropwise. After stirring at room temperature for 3 d, the reaction was quenched 1w pouring the mixture into ice-water. After acidification with 40% H3PO4, the product was extracted with ethyl acetate (3×) and the organic layers were washed with H3PO4-acidic sat. aq. NaCl solution. The solvent was removed under reduced pressure at 30° C. The resulting crude product was purified by flash column chromatography (SiO2; DCM/petrolether 1:1 to 2:1) to give the title compound as colourless oil (188 mg, with a purity of around 90% (by NMR), 095 mmol, 15% yield). Rf=0.60 (DCM/
MeOH 4%). HRMS (ESI) calcd. for C12H17O− [M−H]− 177.1279, found: 177.1284. 1H NMR (400 MHz, CDCl3) δ 7.24-7.18 (m, 2H, aromatic H), 6.82-6.76 (m, 2H, aromatic H), 5.12 (s, 1H, OH), 1.60-1.52 (m, 2H, C(CH3)2CH2CH2CH3), 1.27 (s, 6H, C(CH3)2CH2CH2CH3), 1.16-1.01 (m, 2H, C(CH3)2CH2CH2CH3), 0.83 (t, J=7.3 Hz, 3H, C(CH3)2CH2CH2CH3). 13C NMR (101 MHz, CDCl3) δ 153.03, 142.29, 127.11, 114.85, 47.35, 37.25, 29.23, 18.09, 14.90. - The respective nitropyridines or nitrobenzenes and the particular phenols were dissolved in DMF or DMSO. Anhydrous K2CO3 was added and the reaction mixture was stirred at room temperature, unless otherwise stated, until complete conversion. The reaction was then quenched by the addition of H2O and the product was extracted with EtOAc or Et2O. The organic layers were washed with 1 M aq. NaOH solution (1×) and afterwards with sat. aq. NaCl solution (1×). The solvent was removed to dryness under reduced pressure at 30° C. The residue was resolved in DCM and filtered through cotton to remove inorganic salts. The crude product was purified by flash column chromatography to afford the corresponding title compounds (I3-n, I3-nA to I3-nP).
- 2-(4-(tert-butyl)phenoxy)-5-nitropyridine, I3-n
- Following procedure A, 2-chloro-5-nitropyridine (501 mg, 3.16 mmol, 1.00 eq) and 4-tert-butylphenol (611 mg, 4.07 mmol, 1.29 eq) were dissolved in DMF (6.0 mL). Anhydrous K2CO3 (654 mg, 4.73 mmol, 1.50 eq) was added and the reaction mixture was stirred at room temperature for 14 h. After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:100 to 1:50) to afford the title compound as colourless solid (820 mg, 3.01 mmol, 95% yield). Rf=0.40 (EtOAc/PE 1:20). HRMS (ESI) calcd. for C15H17N2O3 + [M+H]+ 273.1234, found: 273.1229. 1H NMR (400 MHz, CDCl3) δ 9.06 (d, J=2.8 Hz, 1H, aromatic H), 8.46 (dd, J=9.1, 2.8 Hz, 1H, aromatic H), 7.53-7.42 (m, 2H, aromatic H), 7.17-7.05 (m, 2H, aromatic H), 7.01 (d, j=9.1 Hz, 1H, aromatic H), 1.35 (s, 9H, C(CH3)3). 13C NMR (101 MHz, CDCl3) δ 167.20, 150.49, 148.98, 145.26, 140.29, 134.95, 126.99, 120.84, 111.38, 34.72, 31.57.
- 2-(4-cyclohexylphenoxy)-5-nitropyridine I3-nA
- Following procedure A, 2-chloro-5-nitropyridine (300 mg, 1.89 mmol, 1.00 eq) and 4-cyclohexylphenol (417 mg, 2.37 mmol, 1.25 eq) were dissolved in DMSO (6 mL). Anhydrous K2CO3 (397 mg, 2.87 mmol, 1.52 eq) was added and the reaction mixture was stirred at room temperature for 27 h. After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:100 to 1:75) to afford the title compound as colourless solid (600 mg, 2.01 mmol, quant. yield). Rf=0.35 (EtOAc/PE 1:20). HRMS (ESI) calcd. for C17H19N2O3 + [M+H]+ 299.1390, found: 299.1392. 1H NMR (400 MHz, CDCl3) δ 9.06 (d, J=2.9 Hz, 1H, aromatic H), 8.46 (dd, J=9.1, 2.9 Hz, 1H, aromatic H), 7.31-7.22 (m, 2H, aromatic H), 7.07 (dd, J=8.7, 2.3 Hz, 2H, aromatic H), 7.00 (d, J=9.1 Hz, 1H, aromatic H), 2.58-2.51(m, 1H, cyclohexyl H), 2.01-1.64 (m, 5H, cyclohexyl H), 1.56-1.10 (m, 5H, cyclohexyl H). 13C NMR (101 MHz, CDCl3) δ 167.18, 150.71, 145.88, 145.17, 140.22, 134.89, 128.30, 121.12, 111.30, 44.08, 34.59, 26.95, 26.19.
- 5-nitro-2-(4-(tert-pentyl)phenoxy)pyridine, I3-nB
- Following procedure A, 2-chloro-5-nitropyridine (303 mg, 1.91 mmol, 1.00 eq) and 4-tert-pentylphenol (397 mg, 2.42 mmol 1.27 eq) were dissolved in DMSO (6 mL). Anhydrous K2CO3 (403 mg, 2.92 mmol, 1.53 eq) was added and the reaction mixture was stirred at room temperature for 7 h. After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:100) to afford the title compound as colourless solid (530 mg, 1.85 mmol, 97% yield). Rf=0.31 (EtOAc/PE 1:20). HRMS (ESI) calcd. for C16H19N2O3 + [M+H]+ 287.1390, found: 287.1381. 1H NMR (400 MHz, CDCl3) δ 9.07-9.05 (m, 1H, aromatic H), 8.45 (dd, J=9.4, 2.4 Hz, 1H, aromatic H), 7.40 (d, J=8.6 Hz, 2H, aromatic H), 7.09 (d, J=8.6 Hz, 2H, aromatic H), 6.99 (d, J=9.2 Hz, 1H, aromatic H), 1.67 (q, J=7.4 Hz, 2H, Ar—C(CH3)2CH2CH3), 1.31 (s, 6H, Ar—C(CH3)2CH2CH3), 0.73 (t, J=7.4 Hz, 3H, Ar—C(CH3)2CH2CH3). 13C NMR (101 MHz, CDCl3) δ 167.17, 150.46, 147.34, 145.20, 140.27, 134.90, 127.56, 120.72, 111.28, 37.89, 37.06, 28.55, 9.26.
- 1-(tert-butyl)-4-(4-nitrophenoxy)benzene, I3-nC
- Following procedure A, 4-fluoronitrobenzene (500 mg, 3.54 mmol, 1.00 eq) and 4-tert-butylphenol (671 mg, 4.46 mmol, 1.26 eq) were dissolved in DMF (6.0 mL). Anhydrous K2CO3 (857 mg, 6.20 mmol, 1.75 eq) was added and the reaction mixture was stirred at room temperature for 52 h. After extraction with EtOAc, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:100) to afford the title compound as pale yellow solid (860 mg, 3.17 mmol, 89% yield). Rf=0.72 (EtOAc/PE 1:9). HRMS (ESI) calcd. for C16H18NO3 + [M+H]+ 272.1281, found: 272.1272. 1H NMR (400 MHz, CDCl3) δ 8.24-8.16 (m, 2H, aromatic H), 7.49-7.39 (m, 2H, aromatic H), 7.06-6.97 (m, 4H, aromatic H), 1.35 (s, 9H, C(CH3)3). 13C NMR (101 MHz, CDCl3) δ 163.82, 152.29, 148.59, 142.54, 127.27, 126.03, 120.15, 116.98, 34.67, 31.58.
- 2-(4-butylphenoxy)-5-nitropyridine, I3-nD
- Following procedure A, 2-chloro-5-nitropyridine (103 mg, 0.65 mmol, 1.00 eq) and 4-butylphenol (126 mg, 0.84 mmol, 1.29 eq) were dissolved in DMF (2.5 mL). Anhydrous K2CO3 (143 mg, 1.04 mmol, 1.59 eq) was added and the reaction mixture was stirred at room temperature for 6 h. After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:100) to afford the title compound as colourless solid (190 mg, 0.70 mmol, quant. yield). Rf=0.33 (EtOAc/PE 1:20). HRMS (ESI) calcd. for C15N17N2O3 + [M+H]+ 273.1234, found: 273.1226. 1H NMR (400 MHz, CDCl3) δ 9.05 (dd, J=2.9, 0.6 Hz, 1H, aromatic H), 8.46 (dd, J=9.1, 2.8 Hz, 1H, aromatic H), 7.32-7.21 (m, 2H, aromatic H), 7.11-7.02 (m, 2H, aromatic H), 7.00 (dd, J=9.0, 0.6 Hz, 1H, aromatic H), 2.69-2.60 (m, 2H, Ar—CH2CH2CH2CH3), 1.70-1.57 (m, 2H, Ar—CH2CH2CH2CH3), 1.39 (dq, J=14.6, 7.3 Hz, 2H, Ar—CH2CH2CH2CH3), 0.95 (t, J=7.3 Hz, 3H, Ar—CH2CH2CH2CH3). 13C NMR (101 MHz, CDCl3) δ 167.27, 150.75, 145.22, 140.86, 140.30, 134.92, 129.91, 121.22, 111.32, 35.21, 33.67, 22.51, 14.08.
- 1-nitro-4-(4-(tert-pentyl)phenoxy)benzene, I3-nE
- Following procedure A, 4-fluoronitrobenzene (318 mg, 2.25 mmol, 1.00 eq) and 4-tert-pentylphenol (460 mg, 2.28 mmol, 1.24 eq) were dissolved in DMSO (6 mL). Anhydrous K2CO3 (465 mg, 3.37 mmol, 1.49 eq) was added and the reaction mixture was stirred at room temperature for 2 h. After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:100) to afford the title compound as colourless solid (533 mg, 1.87 mmol, 83% yield), Rf=0.70 (EtOAc/PE 1:20). HRMS (ESI) calcd. for C17H20NO+ [M+H]+ 285.1365, found: 285.1359. 1H NMR (400 MHz, CDCl3) δ 8.25-8.14 (m, 2H, aromatic H), 7.44-7.32 (m, 2H, aromatic H), 7.06-6.96 (m, 4H, aromatic H), 1.66 (q, J=7.4 Hz, 2H, Ar—C(CH3)2CH2CH3), 1.31 (s, 6H, Ar—C(CH3)2CH2CH3), 0.71 (t, J=7.4 Hz, 3H, Ar—C(CH3)2CH2CH3). 13C NMR (101 MHz, CDCl3) δ 163.81, 152.24, 146.94, 142.56, 127.91, 126.01, 120.06, 116.99, 37.89, 37.06, 28.63, 9.27.
- 1-cyclohexyl-4-(4-nitrophenoxy)benzene, I3-nF
- Following procedure A, 4-fluoronitrobenzene (325 mg, 2.30 mmol, 1.00 eq) and 4-cyclohexylphenol (519 mg, 2.94 mmol, 1.28 eq) were dissolved in DMSO (6 mL). Anhydrous K2CO3 (513 mg, 3.72 mmol, 1.61 eq) was added and the reaction mixture was stirred at room temperature for 48 h. After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:100 to 1:50) to afford the title compound as pale yellow solid (640 mg, 2.15 mmol, 93% yield). Rf=0.55 (EtOAc/PE 1:20). HRMS (ESI) calcd. for C18H20NO3 + [M+H]+ 298.1438, found: 298.1442. 1H NMR (400 MHz, CDCl3) δ 8.31-8.11 (m, 2H, aromatic H), 7.26 (d, J=2.3 Hz, 2H, aromatic H), 7.13-6.92 (m, 4H, aromatic H), 2.57-2.50 (m, 1H, cyclohexyl H), 2.09-1.67 (m, 5H, cyclohexyl H), 1.59-1.18 (m, 5H, cyclohexyl H). 13C NMR (101 MHz, CDCl3) δ 163.89, 152.61, 145.8, 142.57, 128.66, 126.04, 120.49, 116.99, 44.14, 34.72, 26.99, 26.23.
- 2-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)-5-nitropyridine, I3-nG
- Following procedure A, 2-chloro-5-nitropyridine (300 mg, 1.89 mmol, 1.00 eq) and 4-adamantylphenol (546 mg, 2.39 mmol, 1.26 eq) were dissolved in DMSO (6 mL). Anhydrous K2CO3 (662 mg, 4.79 mmol, 2.53 eq) was added and the reaction mixture was stirred at room temperature for 42 h. After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:100 to 1:50) to afford the title compound as colourless solid (664 mg, 1.89 mmol, quant. Rf=0.36 (EtOAc/PE 1:20). HRMS (ESI) calcd. for C21H23N2O3 + [M+H]+ 351.1703, found: 351.1701. 1H NMR (400 MHz, CDCl3) δ 9.06 (d, J=2.8 Hz. 1H, aromatic H), 8.45 (dd, J=9.1, 2.8 Hz, 1H, aromatic H), 7.52-7.39 (m, 2H, aromatic H), 7.16-7.06 (m, 2H, aromatic H), 7.00 (d, J=9.1 Hz, 1H, aromatic H), 2.13-2.10 (m, 3H, adamantyl H), 1.94 (d, J=3.0 Hz, 5H, adamantyl H), 1.87-1.70 (m, 5H, adamantyl H). 13C NMR (101 MHz, CDCl3) δ 167.19, 150.51, 149.18, 145.20, 140.26, 134.89, 126.53, 120.83, 111.32, 43.35, 36.82, 36.18, 29.02.
- 2-(3-(tert-butyl)phenoxy)-5-nitropyridine, I3-nH
- Following procedure A, 2-chloro-5-nitropyridine (300 mg, 1.89 mmol, 1.00 eq) and 3-tert-butylphenol (358 mg, 2.38 mmol, 1.26 eq) were dissolved in DMSO (6 mL). Anhydrous K2CO3 (420 mg, 3.04 mmol, 1.60 eq) was added and the reaction mixture was stirred at room temperature for 70 h. After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:100) to afford the title compound as colourless solid (512 mg, 1.88 mmol, 99% yield). Rf=0.37 (EtOAcIPE 1:20). HRMS (ESI) calcd. for C15H17N2O3 + [M+H]+ 273.1234, found: 273.1232. 1H NMR (400 MHz, CDCl3) δ 9.08-9.04 (m, 2H, aromatic H), 8.47 (dd, J=9.1, 2.8 Hz, 1H, aromatic H), 7.39 (t, J=7.9 Hz, 1H, aromatic H), 7.33 (ddd, J=7.9, 1.8, 1.21 Hz, 1H, aromatic H), 7.17 (t, J=2.1 Hz, 1H, aromatic H), 7.01 (dd, J=9.1, 0.5 Hz, 1H, aromatic H), 6.98 (ddd, J=7.9, 2.4, 1.2 Hz, 1H, aromatic H) 1.34 (s, 9H, C(CH3)3). 13C NMR (101 MHz, CDCl3) δ 167.21. 153.88, 152.76, 145.26, 140.31, 134.93, 129.50, 123.17, 118.62, 118.47, 111.28, 35.02, 31.36.
- 1-(4-(tert-butyl)phenoxy)-2-fluoro-4-nitrobenzene, I3-nI
- Following procedure A, 3,4-difluoronitrobenzene (401 mg, 2.52 mmol, 1.00 eq) and 4-tert-butylphenol (477 mg, 3.18 mmol, 1.26 eq) were dissolved in DMSO (6 mL). Anhydrous K2CO3 (522 mg, 3.78 mmol, 1.50 eq) was added and the reaction mixture was stirred at room temperature for 19 h. After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:50) to afford the title compound as colourless oil (722 mg, 2.52 mmol, 99% yield). Rf=0.54 (EtOAc/PE 1:20). HRMS (ESI) calcd. for C16H17FNO3 + [M+H]+ 290.1187, found: 290.1194. 1H NMR (400 MHz, CDCl3) δ 8.07 (dd, J=10.3, 2.71 Hz, 1H, aromatic H), 7.96 (ddd, J=9.1, 2.7, 1.5 Hz, 1H, aromatic H), 7.49-7.38 (m, 2H, aromatic H), 7.09-6.99 (m, 2H, aromatic H), 6.96 (dd, I=9.1, 8.0 Hz, 1H, aromatic H), 1.35 (s, 9H, C(CH3)3). 13C NMR (101 MHz, CDCl3) δ 153.35, 152.23, 151.93, 151.82, 150.84, 148.70, 142.40, 142.33, 127.29, 120.68, 120.64, 119.38, 117.73, 117.71, 113.28, 113.05, 34.65, 31.54.
- 1-(4-cyclohexylphenoxy)-2-fluoro-4-nitrobenzene, I3-nJ
- Following procedure A, 3,4-difluoronitrobenzene (509 mg, 3.20 mmol, 1.00 eq) and 4-cyclohexylphenol (691 mg, 3.93 mmol, 1.23 eq) were dissolved in DMSO (6 mL). Anhydrous K2CO3 (664 mg, 4.81 mmol, 1.50 eq) was added and the reaction mixture was stirred at room temperature for 23 h. After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:50)to afford the title compound as pale yellow solid (1002 mg, 3.18 mmol, 99% yield). Rf=0.51 (EtOAc/PE 1:20). HRMS (ESI) calcd. for C18H19FNO3 + [M+]+ 316.1343, found: 316.1348. 1H NMR (400 MHz, CDCl3) δ 8.09 (dd, J=10.3, 2.7 Hz, 1H, aromatic H), 7.97 (ddd, J=9.1, 2.7, 1.4 Hz, 1H, aromatic H), 7.33-7.22 (m, 2H, aromatic H), 7.08-6.99 (m, 2H, aromatic H), 6.96 (dd, J=9.1, 8.0 Hz, 1H, aromatic H), 2.58-251 (m, 1H, cyclohexyl H), 1.98-1.73 (m, 5H, cyclohexyl H), 1.52-1.20 (m, 5H, cyclohexyl H 13C NMR (101 MHz, CDCl3) δ 153.35, 152.51, 152.01, 151.90, 150.84, 145.68, 142.39, 142.32, 128.67, 120.70, 120.66, 119.73, 117.70, 117.68, 113.30, 113.08, 44.09, 34.69, 26.97, 26.21.
- 2-fluoro-4-nitro-1-(4-(tert-pentyl)phenoxy)benzene, I3-nK
- Following procedure A, 3,4-difluoronitrobenzene (502 mg, 3.16 mmol, 1.00 eq) and 4-tert-pentylphenol (693 mg, 4.22 mmol, 1.34 eq) were dissolved in DMSO (6 mL). Anhydrous K2CO3 (656 mg, 4.75 mmol, 1.50 eq) was added and the reaction mixture was stiffed at room temperature for 22 h. After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:50) to afford the title compound as pale yellow oil (943 mg, 3.11 mmol, 99% yield). Rf=0.61 (EtOAc/PE 1:20). HRMS (ESI) calcd. for C17H19NO3 + [M+H]+ 304.1343, found: 304.1332 1H NMR (400 MHz, CDCl3) δ 8.08 (dd, J=10.3, 2.7 Hz, 1H, aromatic H), 7.96 (ddd, J =9.1, 2.7, 1.5 Hz, 1H aromatic H), 7.42-7.35 (m, 2H, aromatic H), 7.07-6.99 (m, 2H, aromatic H), 6.95 (dd, J=9.1, 8.0 Hz, 1H, aromatic H), 1.66 (q, J=7.4 Hz, 2H, Ar—C(CH3)2CH2CH3), 1.31 (s, 6H, Ar—C(CH3)2CH2CH3), 0.71 (t, J=7.4 Hz, 3H, Ar—C(CH3)2CH2CH3). 13C, NMR (101 MHz, CDCl3) δ 153.40, 152.19, 151.98, 151.87, 150.88, 147.11, 127.97, 120.71, 120.68, 119.34, 117.73, 117.71, 113.11, 37.92, 37.08, 28.64.
- 2-(4-(2-methylpentan-2-yl)phenoxy)-5-nitropyridine, I3-nL
- Following procedure A, 4-(2-methylpentan-2-yl)phenol (52 mg, 0.29 mmol, 1.00 eq) and 2-chloro-5-nitropyridine (57 mg, 0.36 mmol, 1.23 eq) were dissolved in DMSO (6 mL). Anhydrous K2CO3 (66 mg, 0.48 mmol, 1.65 eq) was added and the reaction mixture was stirred at room temperature for 27 h. After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:50) to afford the title compound as colourless solid (86 mg, 0.29 mmol, 98% yield). Rf=0.50 (EtOAc/PE 1:10). HRMS (ESI) calcd. for C17H21N2O3 + [M+H]+ 301.1547, found: 301.1545. 1H NMR (400 MHz. CDCl3) δ 9.07 (d, J=2.7 Hz, 1H, aromatic H), 8.46 (dd, J=9.1, 2.8 Hz. 1H, aromatic H), 7.45-7.35 (m, 2H, aromatic H), 7.14-7.05 (m, 2H, aromatic H), 6.99 (dd, J=9.0, 0.6 Hz, 1H, aromatic H), 1.65-1.54 (m, 2H, C(CH3)2CH2CH2CH3), 1.32 (s, 6H, C(CH3)2CH2CH2CH3), 1.19-1.05 (m, 2H, C(CH3)2CH2CH2CH3), 0.84 (t, J=7.3 Hz, 3H, C(CH3)2CH2CH2CH3). 13C NMR (101 MHz, CDCl3) δ 167.17, 150.43, 147.69, 145.21, 140.26, 134.90, 127.44, 120.72, 111.29, 47.27, 37.74, 29.07, 18.08, 14.87.
- (3r,5r,7r)-1-(4-(4-nitrophenoxy)phenyl)adamantane, I3-nM
- Following procedure A, 4-fluoronitrobenzene (303 mg, 2.15 mmol, 1.00 eq) and 4-adamantylphenol (600 mg, 2.63 mmol, 1.22 eq) were dissolved in DMSO (6 mL). Anhydrous K2CO3 (450 mg, 3.26 mmol, 1.52 eq) was added and the reaction mixture was stirred at room temperature for 20 h. After extraction with Et2O, the crude product was purified by flash column. chromatography (SiO2; EtOAc/petrolether 1:100 to 1:50) to afford the title compound as pale yellow solid (736 mg, 2.11 mmol, 98% yield). Rf=0.73 (EtOAc/PE 1:10). HRMS (ESI) calcd. for C22H24NO3 + [M+H]+ 350.1751, found: 350.1760. 1H NMR (400 MHz, CDCl3) δ 8.27 8.10 (m, 2H, aromatic H), 7.46-7.35 (m, 2H, aromatic H), 7.08-6.95 (m, 4H, aromatic H), 2.13-2.10 (m, 3H, adamantyl H), 1.93 (d, J=2.9 Hz, 6H, adamantyl H), 1.88-1.70 (m, 6H, adamantyl H). 13C NMR (101 MHz, CDCl3) δ 163.85, 152.30, 148.86, 142.53, 126.86, 126.85, 126.03, 120.18, 117.00, 43.40, 36.82, 36.17, 29.03.
- (3r,5r,7r)-1-(4-(2-fluoro-4-nitrophenoxy)phenyl)adamantane, I3-nN
- Following procedure A, 3,4-difluoronitrobenzene (303 mg, 1.90 mmol, 1.00 eq) and 4-adamantylphenol (533 mg, 2.34 mmol, 1.23 eq) were dissolved in DMSO (6 mL). Anhydrous K2CO3 (395 mg, 2.86 mmol, 1.50 eq) was added and the reaction mixture was stirred at room temperature for 4 h. After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:100) to afford the title compound as colourless solid (703 mg, 1.91 mmol, quant. yield). Rf=0.69 (EtOAc/PE 1:10). HRMS (APPI) calcd. for C22H22FNO+ [M]+367.1584, found: 367.1581. 1H NMR (400 MHz, CDCl3) δ 8.08 (dd, J=10.3, 2.7 Hz, 1H, aromatic H), 7.96 (ddd, J=9.1, 2.7, 1.5 Hz, 1H, aromatic H), 7.46-7.36 (m, 2H, aromatic H), 7.06-7.00 (m, 2H, aromatic H), 6.95 (dd, J=9.1, 8.0 Hz, 1H, aromatic H), 2.17-2.07 (m, 3H, adamantyl H), 1.92 (d, J=2.9 Hz, 5H, adamantyl H), 1.87-1.71 (m, 5H, adamantyl H). 13C NMR (101 MHz, CDCl3) δ 153.36, 153.35, 152.24, 152.21, 151.99, 151.88, 150.85, 150.83, 148.98, 126.89, 120.70, 120.66, 119.44, 119.42, 117.72, 117.70, 113.30, 113.07, 43.38, 36.81, 36.17, 29.02.
- 2-(4-isopropylphenoxy)-5-nitropyridine, I3-nO
- Following procedure A, 2-chloro-5-nitropyridine (303 mg, 1.91 mmol, 1.00 eq) and 4-iso-propylphenol (331 mg, 2.43 mmol, 1.27 eq) were dissolved in DMF (6.0 mL). Anhydrous K2CO3 (398 mg, 2.88 mmol, 1.51 eq) was added and the reaction mixture was stirred at room temperature for 24 h. After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:100) to afford the title compound as pale yellow solid (490 mg, 1.90 mmol, 99% yield). Rf =040 (EtOAc/PE 1:20). HRMS (ESI) calcd. for C14H15N2O3 + [M+H]+ 259.1077, found: 259.1072. 1 NMR (400 MHz. CDCl3) δ 9.04 (d, J=3.4 Hz, 1H, aromatic H), 8.44 (dd, J=9.1, 2.8 Hz, 1H, aromatic H), 7.37-7.28 (m, 2H, aromatic H), 7.12-7.06 (m, 2H, aromatic H), 7.03-6.97 (m, 1H, aromatic H), 2.96 (hept, J=6.9 Hz, 1H, CH(CH3)2), 1.30 (d, J=7.0 Hz, 6H, CH(CH3)2). 13C NMR (101 MHz, CDCl3) δ 167.08, 150.67, 146.49, 145.02, 140.18, 134.81, 127.84, 121.11, 111.24, 33.62, 24.03.
- 5-nitro-2-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)pyridine, I3-nP
- Following procedure A, 2-Chloro-5-nitropyridine (303 mg, 1.91 mmol, 1.00 eq) and 4-tert-octylphenol (495 mg, 2.40 mmol, 1.25 eq) were dissolved in DMSO (5 mL). Anhydrous K2CO3 (426 mg, 3.08 mmol, 1.61 eq) was added and the reaction mixture was stirred at 40° C. for 28 h, After extraction with Et2O, the crude product was purified by flash column chromatography (SiO2; EtOAc/petrolether 1:50) to afford the title compound as colourless solid (598 mg, 1.82 mmol, 95% yield). Rf=0.65 (EtOAc/PE 1:10). HRMS (ESI) calcd. for C19H25N2O3 + [M+H]+ 329.1860, found: 329.1854. 1H NMR (400 MHz, CDCl3) 9.07 (d, J=2.8 Hz, 1H, aromatic H), 8.45 (dd, 9.1, 2.8 Hz, 1H, aromatic H), 7.52-7.40 (m, 2H, aromatic H), 7.14-7.03 (m, 2H, aromatic H), 6.97 (d, J=9.1 Hz, 1H, aromatic H), 1.76 (s, 2H, Ar—C(CH3)2CH2C(CH3)3), 1.40 (s, 6H, Ar—C(CH3)2CH2C(CH3)3), 0.75 (s, 9H, Ar—C(CH3)2CH2C(CH3)3). 13C NMR (101 MHz, CDCl3) δ 167.24, 150.49, 148.12, 145.30, 140.29, 134.92, 127.78, 120.57, 111.15, 57.28, 38.63, 32.55, 31.93, 31.62.
- (general Procedure B:
- The respective nitro derivatives (I3-n, I3-nA to I3-nP) were first dissolved in MeOH or toluene, or directly added to a suspension of catalytic amounts of Pd (10%) on activated carbon powder in MeOH. The flask was purged with H2 (6×) and the reaction mixture was stirred at room temperature until complete conversion. The reaction mixture was then filtered through Celite. The solvent was removed under reduced pressure at 30° C. and the crude product was purified by flash column chromatography to give the corresponding title compounds (I3, I3-A to I3-P).
- 6-(4-(tert-butyl)phenoxy)pyridin-3-amine, I3
- Following procedure B, I3-n (300 mg, 1.10 mmol, 1.00 eq) was added to a suspension of Pd (10%) on activated carbon powder (82 mg, 0.08 mmol Pd, 0.07 eq) in MeOH (15 mL). The flask was purged with H2 (6×) and the reaction mixture was stirred at room temperature for 2 h. The crude product was purified by flash column chromatography (SiO2; DCM/
MeOH 1%) to give the title compound as pale beige solid (250 mg, 1.03 mmol, 94% yield). Rf=0.40 (DCM/MeOH 4%). HRMS (ESI) calcd. for C15H19N2O+ [M+H]+ 243.1492, found: 243.1487. 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J=3.0 Hz, 1H, aromatic H). 7.39-7.31 (m, 2H, aromatic H), 7.03 (dd, J=8.6, 3.0 Hz, 1H, aromatic H), 7.00-6.93 (m, 2H, aromatic H), 6.72 (d, J=8.6 Hz, 1H, aromatic H), 3.48 (s, 1H, NH2), 1.31 (s, 9H, C(CH3)3). 13C NMR (101 MHz, CDCl3) δ 156.62, 153.28, 146.33, 138.82, 134.06, 126.86, 126.47, 119.24, 112.36, 34.33, 31.52. - 6-(4-cyclohexylphenoxy)pyridin-3-amine, I3-A
- Following procedure B, I3-nA (201 mg, 0.67 mmol, 1.00 eq) was added to a suspension of Pd (10%) on activated carbon powder (47 mg, 0.04 mmol Pd, 0.07 eq) in MeOH (15 mL). The flask was purged with H2 (6×) and the reaction mixture was stirred at room temperature for 5 h. The crude product was purified by flash column chromatography (SiO2; DCM/
MeOH 1%) to give the title compound as beige solid (190 mg, 0.71 mmol, quant. yield). Rf=0.36 (DCM/MeOH 4%). HRMS (ESI) calcd. for C17H21N2O+ [M+H]+ 269.1.648, found: 269.1643. 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J=2.9 Hz, 1H, aromatic H), 7.22-7.13 (m, 2H, aromatic H), 7.04 (dd, J=8.6, 3.01 Hz, 1H, aromatic H), 7.01-6.92 (m, 2H, aromatic H), 6.73 (dd, J=8.8, 0.7 Hz, 1H, aromatic H), 3.36 (s, 2H, NH2), 2.51-2.44 (m, 1H, cyclohexyl H), 1.97-1.67 (m, cyclohexyl H), 1.49-1.15 (m, 5H, cyclohexyl H). 13C NMR (101 MHz, CDCl3) δ 156.88, 153.61, 143.47, 138.67, 134.21, 127.92, 126.96, 119.68, 112.38, 43.99, 34.68, 27.01, 26.25. - 6-(4-(tert-pentyl)phenoxy)pyridin-3-amine, I3-B
- Following procedure B, I3-nB (200 mg, 0.70 mmol, 1.00 eq) was added to a suspension of Pd (10%) on activated carbon powder (52 mg, 0.05 mmol Pd, 0.07 eq) in MeOH (15 mL). The flask was purged with H2 (6×) and the reaction mixture was stirred at room temperature for 3 h. The crude product was purified by flash column chromatography (SiO2; DCM/MeOH 0.5%) to give the title compound as beige solid (107 mg, 0.42 mmol, 60% yield). Rf=0.41 (DCM/
MeOH 4%). HRMS (ESI) calcd. for C16H21N2O+ [M+H]+ 257.1648, found: 257.1648. 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J=2.9 Hz, 1H, aromatic H), 7.34-7.23 (m, 2H, aromatic H), 7.06 (dd, J=8.6, 3.0 Hz, 1H, aromatic H), 7.02-6.94 (m, 2H, aromatic H), 6.73 (d, J=8.6 Hz, 1H, aromatic H), 3.35 (s, 2H, NH2), 1.62 (q, J=7.4 Hz, 2H, Ar—C(CH3)2CH2CH3), 1.27 (s, 6H, Ar—C(CH3)2CH2CH3), 0.70 (t, J=7.4 Hz, 3H, Ar—C(CH3)2CH2CH3). 13C NMR (101 MHz, CDCl3) δ 156.80, 153.36, 144.75, 138.72, 134.30, 127.19, 126.97, 119.13, 112.51, 37.63, 37.04, 28.64, 9.26. - 4-(1-(tert-butyl)phenoxy)aniline, I3-C
- Following procedure B, I3-nC (300 mg, 1.11 mmol, 1.00 eq) was added to a suspension of Pd (10%) on activated carbon powder (59 mg, 0.06 mmol Pd, 0.05 eq) in MeOH (15 mL). The flask was purged with H2 (6×) and the reaction mixture was stirred at room temperature for 3.5 h. The crude product was purified by flash column chromatography (SiO2; ethyl acetate/petrolether 1:100 to 1:10) to give the title compound as dark yellow oil (244 mg, 1.01 mmol, 91% yield). Rf=0.78 (DCM/
MeOH 4%). HRMS (ESI) calcd. for C16H20NO+ [M+H] 242.1539, found: 242.1530. 1H NMR (400 MHz, CDCl3) δ 7.33-7.27 (m, 2H, aromatic H), 6.91-6.84 (m, 4H, aromatic H), 6.72-6.66 (m, 2H, aromatic H), 3.49 (s, 2H, NH2), 1.31 (s, 9H, C(CH3)3). 13C NMR (101 MHz, CDCl3) δ 156.55, 149.24, 145.05, 142.30, 126.45, 121.08, 116.90, 116.49, 34.33, 31.66. - 6-(4-butylphenoxy)pyridin-3-amine, I3-D
- Following procedure B, I3-nD (170 mg, 0.62 mmol, 1.00 eq) was added to a suspension of Pd (10%) on activated carbon powder (53 mg, 0.05 mmol Pd, 0.08 eq) in MeOH (15 mL). The flask was purged with H2 (6×) and the reaction mixture was stirred at room temperature for 1.5 h. The crude product was purified by flash column chromatography (SiO2; DCM/
MeOH 1%) to give the title compound as brown oil (133 mg, 0.55 mmol, 88% yield). Rf=0.38 (DCM/MeOH 4%). HRMS (ESI) calcd. for C15H19N2O+ [M+H]+ 243.1492, found: 243.1485, 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J=3.1 Hz, 1H, aromatic H), 7.20-7.09 (m, 2H, aromatic H), 7.03 (dd, J=8.6, 3.0 Hz. 1H, aromatic H), 7.00-6.91 (m, 2H, aromatic H), 6.72 (d, J=8.6 Hz, 1H, aromatic H), 3.36 (s, 2H, NH2), 2.67-2.51 (m, 2H, Ar—CH2CH2CH2CH3), 1.66-1.52 (m, 2H, Ar—CH2CH2CH2CH3), 1.41-1.31 (m, 2H, Ar—CH2CH2CH2CH3), 0.93 (t, J=7.3 Hz, 3H, Ar—CH2CH2CH2CH3). 13C NMR (101 MHz, CDCl3) δ 156.83, 153.55, 138.75, 138.26, 134.12, 129.48, 126.90, 119.74, 112.28, 35.02, 33.74, 22.40, 14.02. - 4-(4-(tert-pentyl)phenoxy)aniline I3-E
- Following procedure B, I3-nE (313 mg, 1.10 mmol, 1.00 eq) was dissolved in MeOH (10 mL) and added to a suspension of Pd (10%) on activated carbon powder (52 mg, 0.05 mmol Pd, 0.04 eq) in MeOH (5 mL). The flask was purged with H2 (6×) and the reaction mixture was stirred at room temperature for 3 h. The crude product was purified by filtration through a thin SiO2 layer (DCM/
MeOH 4%) to give the title compound as beige oil (293 mg, 1.15 mmol, quant. yield). Rf=0.09 (EtOAc/PE 1:20). HRMS (ESI) calcd. for C17H22N2O+ [M+H]+ 256.1696, found: 256.1692. 1H NMR (400 MHz, CDCl3) δ7.29-7.19 (m, 2H, aromatic. H), 6.98-6.81 (m, 4H, aromatic H), 6.76-6.61 (m, 2H, aromatic H), 3.47 (s, 2H, NH2), 1.63 (q, J=7.4 Hz, 2H, Ar—C(CH3)2CH2CH3), 1.28 (s, 6H, Ar—C(CH3)2CH2CH3), 0.71 (t, J=7.4 Hz, 3H, Ar—C(CH3)2CH2CH3). 13C NMR (101 MHz, CDCl3) δ 156.45, 149.08, 143.29, 142.55, 127.08, 121.04, 116.79, 116.33, 37.50, 37.06, 28.69, 9.27. - 4-(4-cyclohexylphenoxy)aniline, I3-F
- Following procedure B, I3-nF (352 mg, 1.18 mmol, 1.00 eq) was dissolved in toluene (5 mL) and added to a suspension of Pd (10%) on activated carbon powder (38 mg, 0.04 mmol Pd, 0.03 eq) in MeOH (10 mL). The flask was purged with H2 (6×) and the reaction mixture was stirred at room temperature for 2 h. The crude product was purified by flash column chromatography (SiO2; DCM) to give the title compound as beige solid (315 mg, 1.18 mmol, quant. yield). Rf=0.86 (DCM/
MeOH 4%). HRMS (ESI) calcd. for C18H22NO+ [M+H]+ 268.1696, found: 268.1692. 1H NMR (400 MHz, CDCl3) δ 7.17-7.07 (m, 2H, aromatic H), 6.94-6.82 (m, 4H, aromatic H), 6.72-6.62 (m, 2H, aromatic H), 3.49 (s, 2H, NH2), 2.51-2.44 (m, 1H, cyclohexyl H), 1.98-1.68 (m, 5H, cyclohexyl H), 1,46-1.21 (m, 5H, cyclohexyl H). 13C NMR (101 MHz, CDCl3) δ 156.87, 149.13, 142.53, 142.05, 127.81, 121.02, 117.22, 116.33, 43.90, 34.79, 27.05, 26.27. - 6-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)pyridin-3-amine, I3-G
- Following procedure B, I3-nG (278 mg, 0.79 mmol, 1.00 eq) was dissolved in toluene (10 mL) and added to a suspension of Pd (10%) on activated carbon powder (56 mg, 0.05 mmol Pd, 0.07 eq) in MeOH (10 mL). The flask was purged with H2 (3×) and the reaction mixture was stirred at room temperature for 3 h. The crude product was purified by flash column chromatography (SiO2; DCM/
MeOH 0% to 1%) to give the title compound as colourless solid (176 mg, 0.55 mmol, 69% yield). Rf=0.43 (DCM/MeOH 4%). FIRMS (ESI) calcd. for C21H25N2O+ [M+H]+ 321.1961, found: 321.1959. 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J=3.0 Hz, 1H, aromatic H), 7.37-7.29 (m, 2H, aromatic H), 7.08-6.96 (m, 3H, aromatic H), 6.74 (d, J=8.6 Hz, 1H, aromatic H), 3.40 (s, 2H, NH2), 2.12-2.09 (m, 3H, adamantyl H), 1.93 (dd, J=9.7, 3.0 Hz, 5H, adamantyl H), 1.86-1.70 (m, 5H, adamantyl H). 13C, NMR (101 MHz, CDCl3) δ 156.73, 153.37, 151.35, 146.65, 138.76, 134.15, 128.14, 126.86, 126.06, 125.54, 124.88, 119.29, 112.40, 43.36, 43.22, 36.87, 36.84, 35.87, 29.02. - 6-(3-(tert-butyl)phenoxy)pyridin-3-amine, I3-H
- Following procedure B, I3-nH (362 mg, 1.33 mmol, 1.00 eq) was dissolved in MeOH (10 mL) and added to a suspension of Pd (10%) on activated carbon powder (44 mg, 0.04 mmol Pd, 0.03 eq) in MeOH (5 mL). The flask was purged with H2 (5×) and the reaction mixture was stirred at room temperature for 2 h. The crude product was purified by flash column chromatography (SiO2; DCM/
MeOH 0% to 1%) to give the title compound as pale brown oil (303 mg, 1.25 mmol, 94% yield). Rf=0.44 (DCM/MeOH 4%). HRMS (ESI) calcd. for C15H19N2O+ [M+H]+ 243.1492, found: 243.1493. 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J=3.0 Hz, 1H, aromatic H), 7.48-7.40 (m, 1H, aromatic H), 7.32 (ddd, 7.8, 1.9, 1.0 Hz, 1H, aromatic H), 7.29-7.27 (m, 1H, aromatic H), 7.24 (d, J=3.0 Hz, 1H, aromatic H), 7.01 (ddd, j=8.0, 2.4, 1.0 Hz, 1H, aromatic H), 6.92 (dd, J=8.6, 0.7 Hz, 1H, aromatic H), 3.40 (s, 2H, NH2) 1.48 (s, 9H, C(CH3)3). 13C NMR (101 MHz, CDCl3) δ 156.81, 155.65, 153.31, 138.69, 134.40, 129.10, 126.99, 120.85, 117.23, 116.69, 112.54, 34.89, 31.41. - 4-(4-(tert-butyl)phenoxy)-3-fluoroaniline, I3-I
- Following procedure B, I3-nI (501 mg, 1.73 mmol, 1.00 eq) was dissolved in MeOH (13 mL) and added to a suspension of Pd (10%) on activated carbon powder (56 mg, 0.05 mmol Pd, 0.03 eq) in MeOH (2 mL). The flask was purged with H2 (5×) and the reaction mixture was stirred at room temperature for 1.5 h. The crude product was purified bye flash column chromatography (SiO2; DCM) to give the title compound as colourless solid (455 mg, 1.75 mmol, quant. yield). Rf=0.76 (DCM/
MeOH 1%). HRMS (ESI) calcd. for C16H19FNO+ [M+H]+ 260.1445, found; 260.1442. 1H NMR (400 MHz, CDCl3) δ 7.37-7.29 (m, 2H, aromatic H), 6.94 (t, J=8.8 Hz, 1H, aromatic H), 6.91-6.85 (m, 2H, aromatic H), 6.52 (dd, J=12.0, 2.7 Hz, 1H, aromatic H), 6.42 (ddd, J=8.6, 2.7, 1.3 Hz, 1H, aromatic H), 3.61. (s, 2H, NH2), 1.33 (s, 9H, C(CH3)3), 13C NMR (101 MHz, CDCl3) δ 156.58, 156.44, 154.12, 145.02, 144.42, 144.33, 134.83, 134.71, 126.41, 123.92, 123.90, 115.43, 110.97, 110.93, 103.93, 103.72, 34.25, 31.59. - 4-(4-cyclohexylphenoxy)-3-fluoroaniline, I3-J
- Following procedure B, I3-nJ (550 mg, 1.74 mmol, 1.00 eq) was dissolved in MeOH (12 mL) and added to a suspension of Pd (10%) on activated carbon powder (46 mg, 0.04 mmol Pd, 0.03 eq) in MeOH (3 mL). The flask was purged with H2 (6×) and the reaction mixture was stirred at room temperature for 2 h. The crude product was purified by flash column chromatography (SiO2; DCM/petrolether 1:1 to 2:1) to give the title compound as pale rose solid (489 mg, 1.71 mmol, 98% yield). Rf=0.81 (DCM/
MeOH 4%), HRMS (ESI) calcd. for C18H21FNO+ [M+H]+ 286.1602, found: 286.1613. 1H NMR (400 MHz, CDCl3) δ 7.19?7.10 (m, 2H, aromatic H), 6.93 (t, J=8.8 Hz, 1H, aromatic H), 6.90-6.83 (m, 2H, aromatic H), 6.51 (dd, J=12.1, 2.7 Hz, 1H, aromatic H), 6.41 (ddd, J=8.6, 2.7, 1.2 Hz, 1H, aromatic H), 3.66 (s, 2H, NH2), 2.52-2.45 (m, 1H, cyclohexyl H), 1.96-1.72 (m, 5H, cyclohexyl H), 1.53-1.18 (m, 5H, cyclohexyl H). 13C NMR (101 MHz, CDCl3) δ 156.74, 156.55, 154.09, 144.39, 144.30, 142.04, 134.86, 134.74, 127.79, 123.89, 115.76, 110.93, 110.90, 103.90, 103.69, 43.80, 34.72, 26.99, 26.22. - 3-fluoro-4-(4-(tert-pentyl)phenoxy)aniline, I3-K
- Following procedure B, I3-nK (497 mg, 1.64 mmol, 1.00 eq) was dissolved in MeOH (13 mL) and added to a suspension of Pd (10%) on activated carbon powder (28 mg, 0.03 mmol Pd, 0.02 eq) in MeOH (2 mL). The flask was purged with H2 (6×) and the reaction mixture was stirred at room temperature for 1.5 h. The crude product was purified by flash column chromatography (SiO2; ethyl acetate/petrolether 1:10 to 1:7.5) to give the title compound as orange oil (463 mg, 1.69 mmol, quant. yield). Rf=0.28 (EtOAc/petrolether 1:5). HRMS (ESI) calcd. for C17H21FNO+ [M+H]+ 274.1602, found: 274.1599, 1H NMR (400 MHz, CDCl3) δ 7.26-7.17 (m, 2H, aromatic H), 6.92 (t, J=8.8 Hz, 1H, aromatic H), 6.89-6.80 (m, 2H, aromatic H), 6.51 (dd, J=12.0, 2.7 Hz, 1H, aromatic H), 6.42 (ddd, J=8.7, 2.7, 1.2 Hz, 1H, aromatic H), 3.65 (s, 2H, NH2), 1.61 (q, J=7.4 Hz, 2H, Ar—C(CH3)2CH2CH3), 1.26 (s, 6H, Ar—C(CH3)2CH2CH3), 0.69 (t, J=7.4 Hz, 3H, Ar—C(CH3)2CH2CH3). 13C NMR (101 MHz, CDCl3) δ 156.61, 156.37, 154.15, 144.34, 144.25, 143.34, 134.98, 134.86, 123.95, 123.92, 115.41, 110.98, 110.95, 104.00, 103.78, 37.07, 28.68, 9.26.
- 6-(4-(2-methylpentan-2-yl)phenoxy)pyridin-3-amine, I3-L
- Following procedure B, I3-nL (50 mg, 0.17 mmol, 1.00 eq) was dissolved in MeOH (12 mL) and added to a suspension of Pd (10%) on activated carbon powder (31 mg, 0.03 mmol Pd, 0.17 eq) in MeOH (3 mL). The flask was purged with H2 (6×) and the reaction mixture was stirred at room temperature for 1.5 h. The crude product was purified by flash column chromatography (SiO2; DCM/
MeOH 1%) to give the title compound as pale orange oil (39 mg, 0.14 mmol, 87% yield). Rf=0.41 (DCM/MeOH 4%). HRMS (ESI) calcd. for C17H23N2O+ [M+H]+ 271.1805, found: 271.1796. 1H NMR. (400 MHz, CDCl3) δ 7.73 (d, J=2.9 Hz, 1H, aromatic H), 7.32-7.26 (m, 2H, aromatic H), 7.07 (dd, J=8.6, 3.0 Hz, 1H, aromatic H), 7.01-6.94 (m, 2H, aromatic H), 6.74 (d, J=8.6 Hz, 1H, aromatic H), 3.35 (s, 2H, NH2), 1.61-1.51 (m, 2H, C(CH3)2CH2CH2CH3), 1.27 (s, 6H, C(CH3)2CH2CH2CH3), 1.16-1.01 (m, 2H, C(CH3)2CH2CH2CH3), 0.82 (t, J=7.3 Hz, 3H, C(CH3)2CH2CH2CH3). 13C NMR (101 MHz, CDCl3) δ 156.82, 153.32, 145.10, 138.67, 134.32, 128.12, 127.09, 126.99, 119.62, 119.13, 112.53, 47.31, 37.49, 29.17, 18.08, 14.90. - 4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)aniline, I3-M
- Following procedure B, I3-nM (615 mg, 1.76 mmol, 1.00 eq) was dissolved in toluene (15 mL) and added to a suspension of Pd (10%) on activated carbon powder (126 mg, 0.12 mmol Pd, 0.07 eq) in MeOH (10 mL). The flask was purged with H2 (6×) and the reaction mixture was stirred at room temperature for 19 h. The crude product was purified by flash column chromatography (SiO2; DCM) to give the title compound as beige solid (538 mg, 1.68 mmol, 96% yield). Rf =0.39 (DCM/
MeOH 1%). HRMS (ESI) calcd, for C22H26NO+ [M+H]+ 320.2009, found: 320.2006. 1H NMR (400 MHz, CDCl3) δ 7.32-7.25 (m, 2H, aromatic H), 6.93-6.86 (m, 4H, aromatic H), 6.72-6.65 (m, 2H, aromatic H), 3.56 (s, 2H, NH2), 2.14-2.06 (m, 3H, adamantyl H), 1.90 (d, J=2.9 Hz, 5H, adamantyl H), 1.84-1.71 (m, 5H, adamantyl H). 13C NMR (101 MHz, CDCl3) δ 156.59, 149.02, 145.32, 142.51, 125.98, 121.10, 116.84, 116.34, 43.45, 36.88, 35.78, 29.07. - 4-(4-((3r,5r,7r)-adamantan-1-yl)phenoxy)-3-fluoroaniline, I3-N
- Following procedure B, I3-nN (570 mg, 1.55 mmol, 1.00 eq) was dissolved in toluene (10 mL) and added to a suspension of Pd (10%) on activated carbon powder (143 mg, 0.13 mmol Pd, 0.09 eq) in MeOH (10 mL). The flask was purged with H2 (6×) and the reaction mixture was stirred at room temperature for 7 h. The crude product was purified by flash column chromatography (SiO2; DCM) to give the title compound as colourless solid (510 mg, 1.51 mmol, 97% yield). Rf=0.67 (DCM/
MeOH 1%). HRMS (ESI) calcd. for C22H25FNO+ [M+H]+ 338.1915, found: 338.1916. 1H NMR (400 MHz, CDCl3) δ7.32-7.23 (m, 2H, aromatic H), 6.92 (t, J=8.8 Hz, 1H, aromatic H), 6.89-6.81 (m, 2H, aromatic H), 6.51 (dd, J=12.0, 2.7 Hz, 1H, aromatic H), 6.41 (ddd, J=8.7, 2.7, 1.2 Hz, 1H, aromatic H), 3.64 (s, 2H, NH2), 2.11-2.07 (m, 3H, adamantyl H), 1.89 (d, J=2.9 Hz, 5H, adamantyl H), 1.83-1.70 (m, 5H, adamantyl H). 13C NMR (101 MHz, CDCl3) δ 156.60, 156.47, 154.15, 145.37, 144.33, 144.24, 134.91, 134.79, 125.98, 123.97, 123.95, 115.47, 110.98, 110.95, 103.98, 103.76, 43.43, 36.86, 35.76, 29.06. - 6-(4-isopropylphenoxy)pyridin-3-amine, I3-O
- Following procedure B, I3-nO (202 mg, 0.78 mmol, 1.00 eq) was added to a suspension of Pd (10%) on activated carbon powder (76 mg, 0.07 mmol Pd, 0.09 eq) in MeOH (15 mL). The flask was purged with H2 (6×) and the reaction mixture was stirred at room temperature for 1 h. The crude product was purified by flash column chromatography (SiO2; DCM/
MeOH 1%) to give the title compound as beige solid (150 mg, 0.66 mmol 84% yield). Rf=0.42 (DCM/MeOH 4%). HRMS (ESI) calcd. for C14H17N2O+ [M+H]+ 229.1335, found: 229.1326. 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J=2.9 Hz, 1H, aromatic H), 7.24-7.14 (m, 2H, aromatic P), 7.05 (dd, J=8.6, 3.0 Hz, 1H, aromatic H), 7.01-6.93 (m, 2H, aromatic H), 6.73 (d, J=8.6 Hz, 1H, aromatic H), 3.33 (s, 2H, NH2), 2.89 (hept, J=6.9 Hz, 1H, CH(CH3)2), 1.24 (d, J=7.0 Hz, 6H, CH(CH3)2). 13C NMR (101 MHz, CDCl3) δ 156.88, 153.59, 144.19, 138.68, 134.19, 127.55, 126.97, 119.76, 112.35, 77.48, 77.16, 76.84, 33.57, 24.20. - 6-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)pyridin-3-amine, I3-P
- Following procedure B, I3-nP (283 mg, 0.86 mmol, 1.00 eq) was dissolved in toluene (4 mL) and added to a suspension of Pd (10%) on activated carbon powder (78 mg, 0.07 mmol Pd 0.09 eq) MeOH (15 mL). The flask was purged with H2 (5×) and the reaction mixture was stirred at room temperature for 2 h. The crude product was purified by flash column chromatography (SiO2; DCM/
MeOH 2%) to give the title compound as colourless solid (235 mg, 0.79 mmol, 91% yield). Rf=0.49 (DCM/MeOH 4%). HRMS (ESI) calcd. for C19N27N2O+ 299.2118, found: 299.2112. 1H NMR (400 MHz, CDCl3) δ 7.73 (dd, J=3.0, 0.7 Hz, 1H, aromatic H), 7.37-7.29 (m, 2H, aromatic H), 7.06 (dd, J=8.6, 3.0 Hz, 1H, aromatic H), 6.99-6.93 (m, 2H, aromatic H), 6.71 (dd, J=8.6, 0.7 Hz, 1H, aromatic H), 3.10 (s, 2H, NH2), 1.72 (s, 2H, Ar—C(CH3)2CH2C(CH3)3), 1.36 (s, 6H, Ar—C(CH3)2CH2C(CH3)3), 0.73 (s, 9H, Ar—C(CH3)2CH2C(CH3)3). 13C NMR (101 MHz, CDCl3) δ 156.87, 153.39, 145.48, 138.70, 134.39, 127.37, 126.94, 118.96, 112.41, 57.20, 38.36, 32.50, 31.93, 31.68.
Claims (17)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/354,521 US20210382038A1 (en) | 2011-12-21 | 2021-06-22 | Method for identifying modulators of notch signaling |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11010130.0 | 2011-12-21 | ||
EP11010130.0A EP2606884A1 (en) | 2011-12-21 | 2011-12-21 | Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
PCT/IB2012/057622 WO2013093885A1 (en) | 2011-12-21 | 2012-12-21 | Inhibitors of notch signalling pathway and use thereof in treatment of cancers |
US201414366917A | 2014-06-19 | 2014-06-19 | |
US15/017,986 US10274481B2 (en) | 2011-12-21 | 2016-02-08 | Method for identifying modulators of notch signaling |
US16/363,336 US11085918B2 (en) | 2011-12-21 | 2019-03-25 | Method for identifying modulators of notch signaling |
US17/354,521 US20210382038A1 (en) | 2011-12-21 | 2021-06-22 | Method for identifying modulators of notch signaling |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/363,336 Continuation US11085918B2 (en) | 2011-12-21 | 2019-03-25 | Method for identifying modulators of notch signaling |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210382038A1 true US20210382038A1 (en) | 2021-12-09 |
Family
ID=47722321
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/366,917 Active US9296682B2 (en) | 2011-12-21 | 2012-12-21 | Inhibitors of notch signalling pathway and use thereof in treatment of cancers |
US15/017,986 Active US10274481B2 (en) | 2011-12-21 | 2016-02-08 | Method for identifying modulators of notch signaling |
US15/921,560 Active US10054581B1 (en) | 2011-12-21 | 2018-03-14 | Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
US16/363,336 Active US11085918B2 (en) | 2011-12-21 | 2019-03-25 | Method for identifying modulators of notch signaling |
US17/354,521 Pending US20210382038A1 (en) | 2011-12-21 | 2021-06-22 | Method for identifying modulators of notch signaling |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/366,917 Active US9296682B2 (en) | 2011-12-21 | 2012-12-21 | Inhibitors of notch signalling pathway and use thereof in treatment of cancers |
US15/017,986 Active US10274481B2 (en) | 2011-12-21 | 2016-02-08 | Method for identifying modulators of notch signaling |
US15/921,560 Active US10054581B1 (en) | 2011-12-21 | 2018-03-14 | Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
US16/363,336 Active US11085918B2 (en) | 2011-12-21 | 2019-03-25 | Method for identifying modulators of notch signaling |
Country Status (26)
Country | Link |
---|---|
US (5) | US9296682B2 (en) |
EP (3) | EP2606884A1 (en) |
JP (4) | JP6373760B2 (en) |
CN (3) | CN107434779B (en) |
AU (1) | AU2012356033B2 (en) |
BR (1) | BR112014015105B1 (en) |
CA (1) | CA2859740C (en) |
CY (1) | CY1119964T1 (en) |
DK (1) | DK2793884T3 (en) |
ES (1) | ES2660782T3 (en) |
HK (1) | HK1203396A1 (en) |
HR (1) | HRP20180348T1 (en) |
HU (1) | HUE036583T2 (en) |
IL (1) | IL233285A0 (en) |
LT (1) | LT2793884T (en) |
MX (1) | MX355632B (en) |
NO (1) | NO2793884T3 (en) |
PL (1) | PL2793884T3 (en) |
PT (1) | PT2793884T (en) |
RS (1) | RS56907B1 (en) |
RU (1) | RU2631611C2 (en) |
SG (2) | SG11201403418VA (en) |
SI (1) | SI2793884T1 (en) |
TR (1) | TR201802117T4 (en) |
WO (1) | WO2013093885A1 (en) |
ZA (1) | ZA201404965B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2606884A1 (en) | 2011-12-21 | 2013-06-26 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Inhibitors of notch signaling pathway and use thereof in treatment of cancers |
US10626372B1 (en) | 2015-01-26 | 2020-04-21 | Fate Therapeutics, Inc. | Methods and compositions for inducing hematopoietic cell differentiation |
US10501413B2 (en) | 2015-03-23 | 2019-12-10 | University Of Miami | Inhibitors of the Notch transcriptional activation complex and methods for use of the same |
EP3371314B1 (en) | 2015-11-04 | 2023-07-05 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
JP7534070B2 (en) | 2015-11-04 | 2024-08-14 | フェイト セラピューティクス,インコーポレイテッド | Methods and compositions for inducing hematopoietic cell differentiation - Patents.com |
US11318167B2 (en) | 2015-12-11 | 2022-05-03 | The Johns Hopkins University | Isolation of fusion-competent myoblasts and therapeutic applications thereof related to muscular dystrophy |
CN105541703A (en) * | 2016-01-27 | 2016-05-04 | 吉林大学 | Triamine monomer containing pyridine structure and preparation method thereof |
WO2017158190A1 (en) | 2016-03-17 | 2017-09-21 | Ecole polytechnique fédérale de Lausanne (EPFL) | Enhancers of notch signaling and their use in the treatment of cancers and malignancies medicable by upregulation of notch |
CN108884060B (en) | 2016-04-12 | 2022-08-09 | 株式会社Lg化学 | Compound and organic electronic element comprising same |
IT201600132360A1 (en) | 2016-12-29 | 2018-06-29 | Univ Degli Studi Roma La Sapienza | NOTCH INHIBITORS FOR USE IN THE TREATMENT OF ACUTE TELLER LYMPHOBLASTIC CELLS T |
EP3585485A2 (en) | 2017-02-24 | 2020-01-01 | Xeniopro GmbH | Aromatic compounds which enhance notch signaling, for use in therapy |
WO2018154118A2 (en) * | 2017-02-24 | 2018-08-30 | Reinmueller Viktoria | Novel aromatic compounds |
EP3462349A1 (en) * | 2017-10-02 | 2019-04-03 | Koninklijke Philips N.V. | Assessment of notch cellular signaling pathway activity using mathematical modelling of target gene expression |
CA3102129A1 (en) * | 2018-06-21 | 2019-12-26 | Cellestia Biotech Ag | Process for making amino diaryl ethers and amino diaryl ethers hydrochloride salts |
EP3860562A1 (en) | 2018-10-02 | 2021-08-11 | Frequency Therapeutics, Inc. | Pharmaceutical compositions comprising otic therapeutic agents and related methods |
US20220175776A1 (en) | 2019-04-08 | 2022-06-09 | Frequency Therapeutics, Inc. | Combination of chir99021 and valproic acid for treating hearing loss |
EA202192394A1 (en) | 2019-04-10 | 2022-01-24 | Селлестия Биотек Аг | NOTCH PATHWAY INHIBITORS AND THEIR USE FOR CANCER TREATMENT |
CN114007696A (en) * | 2019-04-10 | 2022-02-01 | 塞莱斯蒂亚生物技术股份公司 | Compounds for treating oncovirus-induced cancer and methods of use thereof |
CN111153817B (en) * | 2020-01-20 | 2021-02-02 | 四川大学 | phenoxy-N-phenylaniline derivatives and application thereof |
EP4129283A4 (en) * | 2020-03-31 | 2024-04-24 | Natural Medicine Institute of Zhejiang Yangshengtang Co., Ltd. | Pharmaceutical combination and use thereof |
EP4153575A4 (en) * | 2020-05-21 | 2024-07-17 | Stemsynergy Therapeutics Inc | Notch inhibitors and uses thereof |
EP4213845A1 (en) | 2020-09-16 | 2023-07-26 | Cellestia Biotech AG | New use of inhibitors of the notch signalling pathway |
EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
WO2022122667A1 (en) | 2020-12-07 | 2022-06-16 | Cellestia Biotech Ag | Pharmaceutical combinations for treating cancer |
CN117794536A (en) | 2021-06-02 | 2024-03-29 | 塞莱斯蒂亚生物技术股份公司 | Compounds for use in methods of treating autoimmune and inflammatory diseases |
WO2023079132A1 (en) | 2021-11-08 | 2023-05-11 | Cellestia Biotech Ag | Pharmaceutical combinations for treating cancer |
EP4223292A1 (en) | 2022-02-07 | 2023-08-09 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
WO2024012414A1 (en) * | 2022-07-11 | 2024-01-18 | Westlake University | Use of a fbxo42 specific inhibitor in treating notch signaling-dependent disease |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9296682B2 (en) * | 2011-12-21 | 2016-03-29 | Ecole Polytechnique Federale De Lausanne (Epfl) | Inhibitors of notch signalling pathway and use thereof in treatment of cancers |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8430252D0 (en) | 1984-11-30 | 1985-01-09 | Beecham Group Plc | Compounds |
US4816373A (en) * | 1986-01-31 | 1989-03-28 | Mitsubishi Paper Mills, Ltd. | Method of producing images |
US4959377A (en) * | 1989-06-29 | 1990-09-25 | Hoechst-Roussel Pharmaceuticals Inc. | Phenoxypyridinamine compounds which are use as a dermatological composition |
WO1993025225A1 (en) * | 1992-06-17 | 1993-12-23 | University Of Massachusetts Medical Center | Liposomal formulations for administering to cancer patients |
US5935924A (en) | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
US6214966B1 (en) | 1996-09-26 | 2001-04-10 | Shearwater Corporation | Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution |
US6692919B1 (en) * | 1997-07-23 | 2004-02-17 | Yale University | Activated forms of notch and methods based thereon |
WO2000042012A1 (en) | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
US7351834B1 (en) * | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
CA2369595C (en) | 1999-04-23 | 2010-10-05 | Alza Corporation | Conjugate having a cleavable linkage for use in a liposome |
JP2001089412A (en) * | 1999-09-22 | 2001-04-03 | Otsuka Pharmaceut Co Ltd | Benzene derivative or its pharmaceutically acceptable salt |
DE60233261D1 (en) * | 2001-12-14 | 2009-09-17 | Exelixis Inc | INHIBITORS OF HUMAN ADAM-10 |
WO2003095448A1 (en) * | 2002-05-06 | 2003-11-20 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
JP2006513260A (en) * | 2002-08-03 | 2006-04-20 | ロランティス リミテッド | Complexes of Notch signaling pathway regulators and their use in drug therapy |
WO2005014524A2 (en) * | 2003-08-07 | 2005-02-17 | Wisconsin Alumni Research Foundation | Amino thiol compounds and compositions for use in conjunction with cancer therapy |
US20050214250A1 (en) | 2003-11-06 | 2005-09-29 | Harris J M | Method of preparing carboxylic acid functionalized polymers |
WO2006052128A1 (en) * | 2004-11-10 | 2006-05-18 | Hubrecht Laboratorium | Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation |
GB0518232D0 (en) * | 2005-09-07 | 2005-10-19 | Merck Sharp & Dohme | New methods |
PE20090321A1 (en) * | 2007-06-04 | 2009-04-20 | Genentech Inc | ANTI-NOTCH1 NRR ANTIBODIES, METHOD OF PREPARATION AND PHARMACEUTICAL COMPOSITION |
WO2009146875A1 (en) | 2008-06-03 | 2009-12-10 | Fresenius Medical Care Deutschland Gmbh | Pharmaceutical compositions comprising gamma secretase modulators |
US8436025B2 (en) * | 2008-09-19 | 2013-05-07 | CompleGen Partners, Inc. | Compounds and methods for PKC theta inhibition |
US20100292193A1 (en) * | 2009-04-10 | 2010-11-18 | The Regents Of The University Of California | Radioprotective drugs |
-
2011
- 2011-12-21 EP EP11010130.0A patent/EP2606884A1/en not_active Withdrawn
-
2012
- 2012-12-21 LT LTEP12824809.3T patent/LT2793884T/en unknown
- 2012-12-21 RS RS20180212A patent/RS56907B1/en unknown
- 2012-12-21 BR BR112014015105-9A patent/BR112014015105B1/en active IP Right Grant
- 2012-12-21 PL PL12824809T patent/PL2793884T3/en unknown
- 2012-12-21 CN CN201710300003.0A patent/CN107434779B/en active Active
- 2012-12-21 CA CA2859740A patent/CA2859740C/en active Active
- 2012-12-21 NO NO12824809A patent/NO2793884T3/no unknown
- 2012-12-21 DK DK12824809.3T patent/DK2793884T3/en active
- 2012-12-21 JP JP2014548321A patent/JP6373760B2/en active Active
- 2012-12-21 EP EP17203495.1A patent/EP3332783A1/en active Pending
- 2012-12-21 ES ES12824809.3T patent/ES2660782T3/en active Active
- 2012-12-21 EP EP12824809.3A patent/EP2793884B1/en active Active
- 2012-12-21 CN CN202110711788.7A patent/CN113616648A/en active Pending
- 2012-12-21 CN CN201280070333.0A patent/CN104136027B/en active Active
- 2012-12-21 US US14/366,917 patent/US9296682B2/en active Active
- 2012-12-21 RU RU2014127753A patent/RU2631611C2/en active
- 2012-12-21 WO PCT/IB2012/057622 patent/WO2013093885A1/en active Application Filing
- 2012-12-21 MX MX2014007544A patent/MX355632B/en active IP Right Grant
- 2012-12-21 TR TR2018/02117T patent/TR201802117T4/en unknown
- 2012-12-21 SI SI201231225T patent/SI2793884T1/en unknown
- 2012-12-21 AU AU2012356033A patent/AU2012356033B2/en active Active
- 2012-12-21 PT PT128248093T patent/PT2793884T/en unknown
- 2012-12-21 SG SG11201403418VA patent/SG11201403418VA/en unknown
- 2012-12-21 SG SG10201605984RA patent/SG10201605984RA/en unknown
- 2012-12-21 HU HUE12824809A patent/HUE036583T2/en unknown
-
2014
- 2014-06-19 IL IL233285A patent/IL233285A0/en active IP Right Grant
- 2014-07-07 ZA ZA2014/04965A patent/ZA201404965B/en unknown
-
2015
- 2015-04-28 HK HK15104071.7A patent/HK1203396A1/en unknown
-
2016
- 2016-02-08 US US15/017,986 patent/US10274481B2/en active Active
-
2018
- 2018-02-22 CY CY20181100210T patent/CY1119964T1/en unknown
- 2018-02-27 HR HRP20180348TT patent/HRP20180348T1/en unknown
- 2018-03-14 US US15/921,560 patent/US10054581B1/en active Active
- 2018-07-18 JP JP2018134937A patent/JP2018172433A/en active Pending
-
2019
- 2019-03-25 US US16/363,336 patent/US11085918B2/en active Active
-
2020
- 2020-04-10 JP JP2020071001A patent/JP6887701B2/en active Active
-
2021
- 2021-05-12 JP JP2021080716A patent/JP2021120399A/en active Pending
- 2021-06-22 US US17/354,521 patent/US20210382038A1/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9296682B2 (en) * | 2011-12-21 | 2016-03-29 | Ecole Polytechnique Federale De Lausanne (Epfl) | Inhibitors of notch signalling pathway and use thereof in treatment of cancers |
Non-Patent Citations (1)
Title |
---|
Brown et al., Bioisosteres in Medicinal Chemistry, Published Online 3 August 2012, Wiley-VCH, First Edition, pp. 1-237, DOI:10.1002/9783527654307 (Year: 2012) * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210382038A1 (en) | Method for identifying modulators of notch signaling | |
US20190270707A1 (en) | Inhibitors of prmt5 and methods of their use | |
JP6952097B2 (en) | NAT10 modulator for treating or preventing laminopathy, aging and cancer | |
ES2750309T3 (en) | Novel arylamide derivatives that have antiandrogenic properties | |
KR20170070140A (en) | Method for treating cancer | |
EA009478B1 (en) | Non-nucleoside reverse transcriptase inhibitors | |
KR20220021462A (en) | Inhibitors of the Notch signaling pathway and their use in the treatment of cancer | |
KR100984951B1 (en) | Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments | |
NZ627559B2 (en) | Inhibitors of notch signalling pathway and use thereof in treatment of cancers | |
ES2978446T3 (en) | Biphenyl compounds as SOCE modulators, compositions and uses thereof | |
Zhu et al. | Design, synthesis, and biological evaluation of novel spirocyclic compounds as potential anti-glioblastoma agents | |
JP2024517473A (en) | Compounds and methods for modulating YAP/TEAD and their applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL), SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RADTKE, FREDDY;LEHAL, RAJWINDER;REINMULLER, VIKTORIA;AND OTHERS;REEL/FRAME:058633/0311 Effective date: 20140716 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |